Factor XI Antibodies and Methods of Use

Human monoclonal antibodies targeting FXI and FXIa provide a safer antithrombotic solution by inhibiting coagulation pathways, effectively reducing thromboembolic risks without increasing bleeding complications.

JP7587550B2Active Publication Date: 2024-11-20NOVARTIS AG
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2022079828
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-05-25
Filing Date
2022-05-13
Publication Date
2024-11-20
Estimated Expiration
2036-06-24

AI Technical Summary

Technical Problem

Current anticoagulant therapies for conditions like atrial fibrillation are effective in preventing thromboembolic events but carry a high risk of bleeding complications, highlighting a need for safer treatments that can reduce thrombosis without increasing bleeding risk.

Method used

Development of human monoclonal antibodies that bind to coagulation factor XI (FXI) and its activated form (FXIa) with high affinity, inhibiting their activity to prevent blood clot formation without promoting bleeding, thereby reducing thromboembolic risks.

Benefits of technology

The antibodies effectively inhibit the coagulation pathway, reducing the risk of thrombosis in conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism while minimizing the risk of bleeding, thus offering a safer antithrombotic treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587550000019
    Figure 0007587550000019
  • Figure 0007587550000020
    Figure 0007587550000020
  • Figure 0007587550000021
    Figure 0007587550000021
Patent Text Reader

Abstract

It offers a safer treatment with comparable efficacy to existing treatments, but with reduced bleeding risk, which may reduce the thromboembolic complications of AF, including stroke, systemic embolism, cognitive decline, and mortality. The present invention provides monoclonal antibodies and antigen-binding fragments thereof that bind to human factor XI and activated factor XI ("factor XIa"), as well as pharmaceutical compositions and methods of treatment comprising the same.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application is filed on 20 U.S. Provisional Application No. 62 / 184,955, filed June 26, 2015; and Benefit of U.S. Provisional Application No. 62 / 341,568, filed May 25, 2016 claims.

[0002] This application has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The AS filed on June 23, 2016 contains a sequence listing incorporated herein. The CII copy is named "PAT056955-WO-PCT_SL.txt" and is 45,685 bytes long. It is Isu.

[0003] background Thrombosis is classified into inherited risk factors known as thrombophilia or hypercoagulable states, and acquired risk factors. This refers to the formation of a blood clot inside a blood vessel following the combination of hazardous factors. Increased platelet reactivity and activation of clotting factors are some of the fundamental features of thrombosis. Thrombosis can occur in both the venous and arterial circulation and may occur in the deep venous This can result in deep vein thrombosis (DVT), pulmonary embolism, and stroke. When a thrombus occurs in the artery, ischemia occurs downstream, leading to acute coronary syndrome (ACS), ischemic stroke, and other conditions. Clot formation within the venous system can result in hemorrhagic stroke, acute limb ischemia, and / or acute myocardial infarction. Typically, this leads to thrombosis, pulmonary embolism, and chronic thromboembolic pulmonary hypertension. Blood may also form in the left atrial appendage of patients with atrial fibrillation (AF) and become dislodged. The resulting thrombus can lead to potentially serious complications, namely thromboembolic stroke and systemic embolism. Thrombosis may result. Low molecular weight heparins (LMWHs), thrombin inhibitors All currently available antithrombotic agents, including factor Xa (FXa) inhibitors, It is associated with a significant risk of bleeding (Weitz JI (2010) Thromb. Haemost. 103, 62). The development of antithrombotic agents that do not affect the , is strongly desired.

[0004] Current anticoagulants are either injected or taken orally. Injectable anticoagulant LMWH It is widely used and has a therapeutic profile superior to that of previously applied unfractionated heparin. Over the past few decades, the most commonly used oral anticoagulants have been: The reason was warfarin. Warfarin has a narrow therapeutic window and therefore is a drug that is not effective in preventing coagulation. They require frequent monitoring for adverse drug reactions and exhibit a variety of drug-drug interactions. Orally available direct FXa and thrombin inhibitors enter the anticoagulant market, The scope of application is increasing.

[0005] LMWH, FXa inhibitors, and thrombin inhibitors all have been shown to be effective in preventing intravenous Prevention of thromboembolic disease, treatment of spontaneous DVT and pulmonary embolism, and treatment of atrial fibrillation However, these anticoagulants also have the potential to reduce the risk of stroke, which is caused by the older drug, Bleeding complications generally comparable to those observed with leucovorin and unfractionated heparin In the ADVANCE-2 clinical trial, the FXa inhibitor apixaban ( Eliquis) to evaluate the efficacy of the LMWH enoxaparin in patients undergoing total knee arthroplasty Acute apixaban therapy was compared with enoki mushroom in preventing venous thromboembolic disease. Although more effective than saparin, both agents were associated with a significant risk of bleeding. Patient-related bleeding occurred in 4% of patients receiving apixaban and 4% of patients receiving enoxaparin. This occurred in 5% of patients treated with 100 mg / kg / day (Lassen, MR, et al. (2009) N. Engl. J. Med. 361, 594).

[0006] The RE-LY trial evaluated the direct thrombin inhibitor dabigatran (Prada xa) was compared with warfarin in patients with atrial fibrillation and risk of stroke. (Connolly, SJ, et al. (2009) N. Engl. J. Med. 361, 1139). The therapy was associated with a significant reduction in the risk of stroke or systemic embolism. The complications occurred in 3.1% of patients receiving 150 mg dabigatran daily and 3.1% of patients receiving 150 mg dabigatran daily. This occurred in 3.4% of patients receiving rofecoxib (p=0.31).

[0007] Atrial fibrillation (AF) remains the most common cardiac arrhythmia in clinical practice. AF accounts for approximately one third of all hospitalizations for rhythm disorders. It is estimated to affect more than 2.3 million patients in the United States and approximately 2.0 million in the United States. This number continues to grow rapidly due to the growing proportion of the aging population. It is estimated that AF affects approximately 5% of people and 10% of people over the age of 80. However, the prevalence of AF is increasing beyond that explained by age alone. Hypertension, congestive heart failure, left ventricular hypertrophy, coronary artery disease, and diabetes, as well as obstructive sleep AF risk factors such as obstructive apnea are also on the rise. The number of individuals affected by AF is increasing. In fact, the number of cases is expected to increase two to three times in Westerners over the next 30 years (Kannel and Benjamin (2008) Med Clin North Am. 2008; 92:17-40; Bunch, et al. (2012) JI nnovations of Card Rhythm Manag 2012; 3: 855-63).

[0008] The main risk of AF is a 4-5-fold increase in embolic stroke. The risk of stroke increases sharply with age, rising to 23.5% in those aged 80-89. AF is associated with a doubling of mortality in both sexes (Kannel and Benjamin Min 2008). AF is also independently associated with cognitive decline and all forms of dementia. (Marzona, et al. (2012) CMAJ 2012; 184: 329-36; Geita et al 2013; Bunch et al. al 2012).

[0009] Most patients with AF require approximately 10 years of therapy in their lifetime to prevent cardioembolic stroke and systemic embolism. The CHA2DS2-VASc risk score has been validated. It has been shown to predict thromboembolic risk in patients with atrial fibrillation and to identify patients who would benefit from anticoagulant therapy. It is a widely used stratification tool to identify individuals with pulmonary embolism (LIP 2011; Camm, et al. (2011) 12) Eur Heart J 2012; 33: 2719-2747) Accumulating evidence suggests that CHA2DS2-VASc Scores such as CHADS2 and other criteria can be used to identify patients who will develop stroke and thromboembolism. At least as accurate, or perhaps better than these, and with AF It is crucial to identify patients who are at truly low risk. It is estimated that 85-90% of patients with AF will require anticoagulant therapy.

[0010] Efficacy of vitamin K antagonists (VKAs) in reducing stroke and systemic embolism A meta-analysis of six studies evaluating the effect of schizophrenia on stroke risk was A highly significant reduction was observed (relative reduction in risk of stroke was 67%). All-cause mortality was significantly reduced with dose-adjusted VKAs versus controls (26%) (Hart, Pearce, and Aguilar (2007) Ann Intern Med 2007; 146:857-867). A midrange INR target is associated with the best benefit-risk ratio. (Hylek et al (2003) N Engl J Med; 349:1019-1026), international and national guidelines It has been widely adopted in the guidelines.

[0011] In recent years, new oral anticoagulants (NOAs), also called direct oral anticoagulants (DOACs), have been developed. C) have been approved and introduced into clinical practice. These drugs have been shown to reduce the incidence of thromboembolic disease. It is at least as effective as, or better than, warfarin in reducing (Connolly, et al. (2009) N Engl J Med; 361:1139-51; Connolly, et al. (2011) N Engl J Med; 364:806-17; Patel, et al. (2011) N Engl J Med 2011; 365:883-91). NOACs also reduce the most serious complications of warfarin: hemorrhagic stroke and cranial It was also associated with a significant reduction in internal bleeding. Major bleeding events were associated with good warfarin therapy and In addition, NOACs were less effective than warfarin. It is associated with the potential for serious drug-drug interactions and should not be used without routine monitoring. This is expected to facilitate their use in routine medical practice.

[0012] Despite recent improvements, the risk of bleeding associated with anticoagulant use remains high. For example, the annual incidence of major bleeding and clinically relevant non-major bleeding is 14. 9% and in the ROCKET study, the majority of patients treated with rivaroxaban The annual incidence of major bleeding events was 3.6% (Patel et al 2011). The risk of major bleeding in patients with a HAS Bled risk score of ≥3 The annual incidence was >5% (Gallego, et al. (2012) Carc Arrhythm Electrophysiol. ; 5:312-318). Major bleeding is a particularly debilitating clinical outcome, e.g., in the ROCKE In the T study, when major bleeding occurred, the all-cause mortality rate was 20% in the rivaroxaban group. The incidence of major bleeding events was 26.1% in the thrombolytic group and 2.4% in the thrombolytic group. in 4.7% and 5% of patients in the rivaroxaban and warfarin groups, respectively. Stroke and systemic embolism occurred in 4% of patients (Piccini, et al. (2014) Eur Heart J; 35 Hospitalization, transfusion of blood products, and utilization of blood resources also contributed to the occurrence of hemorrhage. The risk of bleeding was also significantly affected by the lack of anticoagulation in eligible patients. This is also the main reason. The Euro Heart Survey on Arterial Diagnosis and Treatment (EHDT) includes data from hospitalized patients with AF. In the pulmonary fibrillation study, 67% of eligible patients were discharged with oral anticoagulant therapy. They were simply given a coagulant (Nieuwlaat, et al (2005) Eur Heart J;26, 2422-243 4).

[0013] Therefore, it is a promising treatment with efficacy comparable to existing treatments, but with reduced bleeding tendency, stroke, and total hemorrhage. May reduce thromboembolic complications of AF, including systemic embolism, cognitive decline, and mortality Therefore, there is a large unmet medical need for safer treatments.

[0014] overview The present invention relates to human coagulation factor XI and XIa (activated factor XI) (hereinafter, Thus, the monoclonal antibodies that bind to FXI (also referred to as "FXI", "FXIa", and similar terms) Patent application title: CLONAL ANTIBODY, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND TREATMENT METHOD COMPRISING THE ADMINISTRATION OF SAME Thrombosis or thromboembolic diseases / disorders (e.g., thrombotic stroke, atrial fibrillation, atrial fibrillation, Prevention of stroke in pulmonary fibrillation (SPAF), deep vein thrombosis, venous thromboembolism, pulmonary embolism, Acute coronary syndrome (ACS), ischemic stroke, acute limb ischemia, chronic thromboembolic pulmonary hypertension It is effective in preventing and treating chronic obstructive pulmonary disease (COPD, systemic embolism) but does not carry the risk of bleeding. Development of antithrombotic agents that pose little or no risk of bleeding would be a promising solution. A large unmet medical need would be met.

[0015] In specific embodiments, the antibodies provided herein (e.g., human monoclonal antibodies, The human FXIa and FXIr antibodies (humanized monoclonal antibodies) It binds with similar high affinity to the catalytic domain (CD) of FXIa and is involved in the inactive Induce protease domain conformation.

[0016] As described herein, isolated anti-FXI antibodies and / or anti-FXIa antibodies, e.g. The full length IgG with two binding sites described herein may bind to FXI and / or FXI a, equilibrium dissociation constant (K D For example, the The isolated antibody has a specific binding affinity to human FXI and / or FXIa of 100 pM or less, 50 pM or less , 45 pM or less, 40 pM or less, 35 pM or less, 20 pM or less, or 10 pM or less K D More specifically, the isolated antibodies described herein may also bind to human FXI. and / or FXIa can be detected by surface plasmon resonance (SPR), e.g., BIACORE ( 34 pM or less as measured by the Equilibrium Titration Assay (SE K below 4 pM measured by D It is also possible to combine with FXI and / or FXIa in the cells were measured by BIACORE™ assays. K ≤ 53 pM measured by SET or ≤ 4 pM measured by SET D You can also combine them with In a specific embodiment, the isolated antibodies described herein (e.g., NOV1401 ) in human FXI and FXIa, e.g., by equilibrium titration assay (SET). The concentrations measured are approximately 5 pM (e.g., 4.7 pM) and 2 pM (e.g., 1. 3pM or less apparent K D In a specific embodiment, the nucleotides described herein are Anti-FXI / FXIa antibodies were used to bind to FXI / FXIa in cynomolgus monkeys using SET (e.g., 12.5 (±6.6) pM for FXIa as measured by and an apparent K of approximately 5.0 (±0.7) pM. D In a specific embodiment, the The anti-FXI / FXIa antibodies described herein are derived from rabbit FXI and / or FXIa antibodies. , with a K of approximately 20(±2)nM D In a specific embodiment, the antibodies described herein bind to FXI / FXIa antibodies are specific for human, cynomolgus monkey, and rabbit FXI and / or FXIa. It binds to XIa but does not specifically bind to mouse or rat FXI.

[0017] The isolated anti-FXI antigen-binding fragment and / or the anti-FXIa antigen-binding fragment described herein Synthetic fragments, such as Fab fragments and other fragments that contain a single binding site, can be used to bind FXI. and / or FXIa with an equilibrium dissociation constant (K D ) to join them together. For example, As described herein, the isolated antigen-binding fragments bind to human FXI and / or FXIa. , 10nM or less, 5nM or less, 1nM or less, 500pM or less, 305pM or less, 62pM More specifically, the isolated antigen-binding fragments described herein may bind with a KD of It also binds to human FXI and / or FXIa with a KD of 305 pM or less. is also possible.

[0018] The present invention relates to isolated antibodies or antibodies that bind to human, rabbit, and cynomolgus monkey FXIa. The present invention also relates to antigen-binding fragments of the catalytic domain of FXI and / or FXIa. The present invention relates to an isolated antibody or antigen-binding fragment thereof that binds to a surface of the antibody, specifically, to the active site region. Also relates to.

[0019] The present invention also relates to antibodies that bind to FXI and / or FXIa and are described in Table 1 ( For example, an isolated antibody or its antigen-binding domain that further competes for binding to NOV1401 The present invention also relates to the antibodies and / or antigen-binding fragments thereof described herein. "Competition" refers to the ability of both antibodies (or binding fragments) to bind to the same or overlapping FXI domains. Binding to an epitope and / or an FXIa epitope (e.g., The present invention means a method for determining the binding affinity of a serotonin molecule by a competitive binding assay using any of the methods described above. As used herein, an antibody or antigen-binding fragment thereof refers to a competing antibody or antigen-binding fragment thereof. The fragment may have the same FXI epitope and / or FXI antigen-binding fragment as the antibody or antigen-binding fragment of the present invention. XIa epitope or overlapping FXI and / or FXIa epitopes The FXI and / or FXIa antibodies of the present invention are not intended to bind to any particular pitope. or does not "compete" with an antigen-binding fragment (e.g., NOV1401 or NOV1090). As used herein, a competing antibody or antigen-binding fragment thereof is an antibody or antigen-binding fragment of the present invention. sterically blocking (e.g., competing) the antigen-binding fragment or antigen-binding fragment from binding to its target. Antibodies bind to nearby, non-overlapping FXI and / or FXIa epitopes and physically prevents the antibody or antigen-binding fragment of the invention from binding to its target. and / or (ii) different, non-overlapping FXI epitopes and / or F The present invention relates to a method for binding to the XIa epitope and / or FXIa protein. The FXI and / or FXIa antibodies or antigen-binding fragments of the invention are The conformational change is such that it can no longer bind in the form that occurs in the absence of the conformational change. The antibody does not include a competing antibody or antigen-binding fragment thereof that induces an alteration in the protein.

[0020] In one embodiment, an antibody that binds to FXI and / or FXIa and is described in Table 1. The isolated antibodies or antigen-binding fragments thereof that further compete for binding with the antibodies of Table 1. In another embodiment, FXI and and / or binds to FXIa and further competes for binding with the antibodies listed in Table 1 The isolated antibody or antigen-binding fragment thereof binds to all of the epitopes to which the antibody in Table 1 binds. To combine.

[0021] In one embodiment, the isolated antibody or antigen-binding fragment thereof binds to active FXI (FXIa). When it binds to the active FXI (FXIa) catalytic domain, it binds to FXIa and its cofactors. In another embodiment, the conformation of the The isolated antibody or antigen-binding fragment thereof comprises the four N-terminal amino acids of the inactive conformation. Residues in loops 145, 188, and 220 of the This induces further changes that shift and / or become irregular.

[0022] In one embodiment, the isolated antibody or antigen-binding fragment thereof is an antibody that binds to FXI (e.g., human FXI). ), but upon binding to FXI, the FXI catalytic domain binds to loops 145, 188, and 220 are regular in the active conformation as well as in the structure of the FXIa catalytic domain. This prevents the taking of any action.

[0023] In one embodiment, the isolated antibody or antigen-binding fragment thereof binds to FXI but not to FXI. Upon binding to NF-κB, the FXI catalytic domain binds to four residues at the N-terminus, loop 145, 188, and and 220 are in the active conformation, which is regular as in the structure of the FXIa catalytic domain. This prevents theft of personal information.

[0024] In one embodiment, the isolated antibody or antigen-binding fragment thereof binds to FXI but not to FXI. Upon binding to FXIa, it induces a conformational change in the zymogen structure that allows it to bind to FXIa. The inhibitory FXI conformation closely related to that observed when By further conferring a conformational shift, the FXI catalytic domain is able to assume an active conformation. This prevents the taking of

[0025] In one embodiment, the isolated antibody or antigen-binding fragment thereof is FXI and / or FXI a but binds to FXI and / or FXIa and FXI and / or FXI When the antibody:antigen complex is formed with the catalytic domain of a, loops 145, 188, and 2 20 compared to the uncomplexed structure of the catalytic domain of active factor XI (FXIa). This causes a shift and / or loss of orientation compared to the original.

[0026] In one embodiment, the isolated antibody or antigen-binding fragment thereof is FXI and / or FXI a but binds to FXI and / or FXIa and FXI and / or FXI When the catalytic domain of a forms an antibody-antigen complex, the four amino-terminal residues, loop 145 , 188, and 220 of the catalytic domain of active factor XI (FXIa) complexed with This causes a shift and / or loss of orientation compared to the unmodified structure.

[0027] In one embodiment, the isolated antibody or antigen-binding fragment thereof binds to active FXI (FXIa). It binds to the FXI (FXIa) catalytic domain and changes its conformation to that of loop 145. , 188, and 220 are shifted and / or dislocated relative to the active conformation. This causes the enzyme to change to an inactive conformation in which tropism is lost.

[0028] In one embodiment, the isolated antibody or antigen-binding fragment thereof binds to FXI but does not bind to thymo Induce a conformational change in the cytoplasmic structure that, upon binding to FXIa, The inhibitory FXI conformation closely related to the observed inhibitory FXI conformation This prevents the catalytic domain from adopting an active conformation by providing Stop.

[0029] The present invention also relates to antibodies that bind to the same epitope as the antibodies described in Table 1 (e.g., NOV1401). The present invention further relates to an isolated antibody or antigen-binding fragment thereof that binds to the polypeptide.

[0030] The binding affinity of the isolated antibodies and antigen-binding fragments described herein is determined by lysis average The amount of acetylene can be determined by equilibrium titration (SET). The SET method is known in the art. Alternatively, the isolated antibodies or fragments described herein can be used in The binding affinity of the fragment can be determined, for example, by surface profiling in a BIACORE™ assay. This can be determined by plasmon resonance measurements. ) Methods for kinetic assays are known and are described in further detail below.

[0031] The isolated anti-FXI and / or isolated FXIa antibodies and anti The original binding fragments were used to isolate factor IX (also known as FIX), factor X ( FX), and / or thrombin, directly or indirectly, and / or or platelet receptor binding, thereby inhibiting the intrinsic coagulation pathway and / or Alternatively, activation of the common coagulation pathway can be prevented.

[0032] The isolated anti-FXI and / or isolated FXIa antibodies and anti The original binding fragments were used to isolate factor IX (also known as FIX), factor X ( FX) and / or thrombin, directly or indirectly, at concentrations of 100 nM or less , 50nM or less, 35nM or less, 25nM or less, 10nM or less, or 5.2nM or less I C 50 More specifically, the isolated antibodies or The antigen-binding fragments thereof include those that bind to factor IX (also known as FIX), factor X ( FX) and / or thrombin, directly or indirectly, at concentrations of 100 nM or less , 50nM or less, 35nM or less, 25nM or less, 10nM or less, or 5.2nM or less I C 50 More specifically, the isolated antibodies or antigens thereof described herein may be inhibited by The binding fragments include those for factor IX (also known as FIX), factor X (FX), and and / or thrombin, direct or indirect activation, at 100 nM or less, 50 nM or less IC less than or equal to 35nM, less than or equal to 25nM, less than or equal to 20nM, or less than or equal to 18nM 50 Blocked by More specifically, the isolated antibodies or antigen-binding fragments thereof described herein may , factor IX (also known as FIX), factor X (FX), and / or Direct or indirect activation of thrombin was controlled by 100 nM or less, 50 nM or less, 35 nM or less, IC of ≤ M, ≤ 25 nM, ≤ 10 nM, or ≤ 5 nM 50 It can be hindered by In certain embodiments, the anti-FXI / FXIa antibody or its antigen-binding fragment thereof described herein is The fragment inhibits FXIa-mediated activation of its natural substrate, FIX, at concentrations below 2 nM. For example, an IC of 1.8 nM 50 and inhibits.

[0033] Isolated anti-FXI and / or anti-FXIa antibodies, or antigen-binding fragments thereof Inhibition of FXI and / or FXIa-mediated activation of FIX using fragments, e.g. Inhibits the intrinsic and / or common coagulation pathways through Therefore, isolated anti-FXI / FXIa antibodies, or The antigen-binding fragments of these antibodies can be used to prevent blood clotting or the spread of blood clotting. The present invention relates to a method for treating FIX-related disorders, comprising: , preventing or treating coagulation disorders such as deep vein thrombosis and stroke (e.g., ischemic stroke); or can be used to improve

[0034] In a specific embodiment, anti-FXI and / or anti-FXIa antibodies, or antibodies thereof The antigen-binding fragment of is determined, for example, by the aPTT assay described in the Examples section. It increases the clotting time (i.e., the time it takes for a clot to start forming) of human plasma in a concentration-dependent manner. In a specific embodiment, the aPTT can be increased. In the range of 10 nM to 20 nM, for example, about 14 nM or At a total anti-FXI antibody (e.g., NOV1401) concentration of 15 nM, compared to baseline In certain embodiments, anti-FXI and / or anti-FXIa antibodies, or These antigen-binding fragments can be determined, for example, by the aPTT assay described in the Examples section. As shown in Fig. 1, the IC50 ranges from 5 nM to 20 nM, e.g., about 13 nM, in a concentration-dependent manner. , it is possible to prolong the clotting time of human plasma.

[0035] In specific embodiments, the anti-FXI antibodies and / or anti-FXI The aPTT antibodies, or antigen-binding fragments thereof, can be used, for example, as described in the Examples section. For example, at least 1.1-fold, 1.2-fold, 1.0-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 1.1-fold, 1.2-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9 ... .3x, 1.4x, 1.5x, 1.6x, 1.7x, 1.8x, 1.9x, or 2x, It is possible to extend the clotting time of human plasma (i.e., the time it takes for a clot to begin to form). In specific embodiments, the anti-FXI and / or anti-F antibodies described herein XIa antibodies, or antigen-binding fragments thereof, can be used, for example, in the aPTT assay described in the Examples section. At least 1.4-fold, 1.5-fold, 1.6-fold, or 1.0-fold as determined by assay. It can extend the clotting time (i.e., the time it takes for a clot to start forming) of human plasma by seven times. It is possible.

[0036] In specific embodiments, the anti-FXI and / or anti-FXIa antibodies described herein The antibody, or an antigen-binding fragment thereof, inhibits the expression of IFN-γ in the presence of very low concentrations of tissue factor (TF). We investigated the effect of FXIa inhibition on the thrombin → FXIa feed-forward loop. The amount of thrombin in human plasma is measured by thrombin generation assay (TGA). In certain embodiments, the antibodies described herein can be used to reduce the expression of IL-1 in a concentration-dependent manner. Anti-FXI and / or anti-FXIa antibodies, or antigen-binding fragments thereof, are isolated from human blood. In plasma thrombin generation assay (TGA), the range is 10 nM to 30 nM, e.g. , IC of about 20 nM or 24 nM 50 value and a residual thrombin concentration of about 159 nM. It is possible to reduce the amount of thrombin.

[0037] In a specific embodiment of the present invention, the catalytic domain of human FXI and / or FXIa is The terminal elimination half-life (t 1 / 2 ) for about 1 Incubate for 4 to 15 days. 1-3 and LCDR1-3), or an antigen-binding In a specific embodiment, such an anti-FXI / FXIa antibody has a polypeptide fragment of about It exhibits absolute subcutaneous (sc) bioavailability of 61-66%.

[0038] In a specific embodiment, the present invention provides a method for the preparation of a method for the preparation of a human FXI antibody that specifically binds to human FXI and / or FXIa. The antibodies or antigen-binding fragments thereof provided herein (e.g., NOV1401, Table 1 The antibodies described in have the following characteristics: (i) For example, apparent Ks of about 1-2 pM and 4-5 pM, respectively D So, human F specifically binds to the catalytic domains (CD) of XI and FXIa; (ii) Coagulation assessed by activated partial thromboplastin time (aPTT) assay Prolonging blood time; (iii) F by activated factor XII (FXIIa) and thrombin, respectively Inhibiting thrombin generation in human plasma through inhibition of XI activation; (iv) Antithrombotic and anticoagulant activities were observed in FXI- / - mice reconstituted with human FXI. Demonstrating coagulant activity; (v) For example, in cynomolgus monkeys, free FXI (FXI f ) levels or or prolonging the reduction; (vi) For example, the terminal elimination half-life of a whole antibody in cynomolgus monkeys is about 14 to 15 days. Between; (vii) specifically binds to human and monkey FXI and / or FXIa; does not specifically bind to mouse or rat FXI and / or FXIa; And (viii) The following residues in human FXI (numbered according to Swissprot): Pro 410, Arg413, Leu415, Cys416, His431, Cys432, T yr434, Gly435, Glu437, Tyr472~Glu476, Tyr521 ~Lys527, Arg548, His552, Ser575, Ser594~Glu5 97, and one or more of Arg602 to Arg604 (e.g., two, three , 4, 5, 6, or 7 or more) or in part or in whole Contact One or more of (e.g., two, or three, or four, or five, or 6, 7, or all of the above.

[0039] The isolated anti-FXI antibody and / or isolated FXIa antibody described herein, or The antigen-binding fragment of the present invention may be a monoclonal antibody, a human or humanized antibody, a chimeric antibody, a single chain antibody, or a combination thereof. an antibody, a Fab fragment, an Fv fragment, an F(ab')2 fragment, or an scFv fragment, and / or It may be of an IgG isotype (e.g., IgG1, such as human IgG1). In embodiments, the anti-FXI and / or anti-FXIa antibodies described herein are recombinant. In specific embodiments, the anti-FXI antibodies and / or antibodies described herein are human antibodies. Alternatively, the anti-FXIa antibody is a human IgG1 / lambda (λ) antibody. The anti-FXI and / or anti-FXIa antibodies described herein inhibit effector F that have been engineered to reduce the likelihood of functioning (e.g., ADCC and / or CDC) c domain, e.g., a human Fc domain comprising a D265A substitution and / or a P329A substitution It is a human IgG1 / lambda (λ) antibody containing

[0040] The isolated anti-FXI antibody and / or isolated FXIa antibody or The antigen-binding fragments of these also include those in which the amino acid sequence is a human VH germline sequence or a human VL germline sequence. The frameworks were replaced with antibody frameworks derived from each of the cell lineage sequences. It may include.

[0041] Another embodiment of the invention is a Fab having the complete heavy and light chain sequences of the Fabs set forth in Table 1. More specifically, the present invention relates to an isolated antibody or an antigen-binding fragment thereof. The synthetic fragment can have the heavy and light chain sequences of NOV1090 and NOV1401.

[0042] Further aspects of the invention include the heavy and light chain variable domains of the Fabs listed in Table 1. More specifically, the isolated antibody or antigen-binding fragment thereof comprises an isolated antibody having the sequence The antigen-binding fragments are composed of the heavy and light chain variable domains of NOV1090 and NOV1401. It may have a main sequence.

[0043] Further aspects of the invention include the Kabat CDR, the IMGT CDR, the Chothia CDR, The heavy chain variable domain CDRs, or combination CDRs, of the antibodies listed in Table 1 R (i.e., HCDR1, HCDR2, and HCDR3) sequences and a light chain variable domain and an isolated CDR (i.e., LCDR1, LCDR2, and LCDR3) sequence. More specifically, the present invention includes an isolated antibody or antigen-binding fragment thereof. The fragment may be a Kabat CDR, an IMGT CDR, a Chothia CDR, or a combination thereof. For example, the CDRs of NOV1090 and NOV1401 are shown in Table 1. CDR1 sequence, HCDR2 sequence, HCDR3 sequence, LCDR1 sequence, LCDR2 sequence, and and LCDR3 sequences.

[0044] The present invention also provides a nucleic acid sequence comprising a heavy chain CDR1 selected from the group consisting of SEQ ID NO: 3 and 23, SEQ ID NO: Heavy chain CDR2 selected from the group consisting of SEQ ID NOs: 4 and 24, and SEQ ID NOs: 5 and 25 and a heavy chain CDR3 selected from the group consisting of human FXI and / or human FXI The present invention also relates to an isolated antibody or antigen-binding fragment thereof that binds to a. The isolated antibody or antigen-binding fragment thereof is selected from the group consisting of SEQ ID NOs: 13 and 33. a light chain CDR1 selected from the group consisting of SEQ ID NOs: 14 and 34; and a light chain CDR3 selected from the group consisting of SEQ ID NOs: 15 and 35.

[0045] The present invention also provides a nucleic acid sequence comprising a light chain CDR1, sequence selected from the group consisting of SEQ ID NOs: 13 and 33. A light chain CDR2 selected from the group consisting of SEQ ID NO: 14 and 34, and a light chain CDR3 selected from the group consisting of SEQ ID NO: 15 and and 35, Also disclosed is an isolated antibody or antigen-binding fragment thereof that binds to FXIa.

[0046] The present invention also provides isolated antibodies or antigen binding sites thereof that bind to FXI and / or FXIa. a synthetic fragment comprising HCDR1, HCDR2, and HCDR3, and LCDR1, and LCDR2, and LCDR3, and HCDR1, HCDR2, and HCDR3 are SEQ ID NO: 3, 4, and 5, and LCDR1, LCDR2, and LCDR3 are SEQ ID NO: 1 3, 14, and 15, or HCDR1, HCDR2, and HCDR3 are SEQ ID NOs: 23, 24, and 25, and LCDR1, LCDR2, LCDR3 are represented by the sequence The present invention also relates to an isolated antibody or antigen-binding fragment thereof comprising numbers 33, 34, and 35.

[0047] The present invention also provides an isolated antibody or antigen-binding fragment thereof that binds FXI and / or FXIa. a heterologous fragment comprising HCDR1, HCDR2, and HCDR3, and LCDR1, L CDR2, and LCDR3, and HCDR1, HCDR2, and HCDR3 are LCDR1, LCDR2, LCDR3 comprising SEQ ID NOs: 47, 37, and 15, respectively, or an antigen-binding fragment thereof. This also applies to one side.

[0048] The present invention also provides an isolated antibody or antigen-binding fragment thereof that binds FXI and / or FXIa. a heterologous fragment comprising HCDR1, HCDR2, and HCDR3, and LCDR1, L CDR2, and LCDR3, and HCDR1, HCDR2, and HCDR3 are and comprising SEQ ID NOs: 46, 4, and 5, respectively, and LCDR1, LCDR2, and LCDR3 are The isolated antibodies or antigen-binding fragments thereof include SEQ ID NOs: 33, 14, and 15, respectively. Also relates to.

[0049] The present invention also relates to the variable heavy chains of SEQ ID NOs: 9 and 29 as defined by Chothia. HCDR1, HCDR2, and HCDR3, and the variable light sequences of SEQ ID NOs: 19 and 39 The present invention also relates to an antibody or antigen-binding fragment having the LCDR1, LCDR2, and LCDR3 of the LCDR1, LCDR2, and LCDR3 chains. In another embodiment of the invention, the antibody or antigen-binding fragment is HCDR1, HCDR2, and HCDR3 of the heavy chain variable domain sequences of SEQ ID NOs: 9 and 29 DR3, and LCDR1, LCDR2, LCDR3, and LCDR4 of the light chain variable domain sequences of SEQ ID NOs: 19 and 39 R2, and LCDR3.

[0050] The present invention also relates to the HCD of the variable heavy chain of SEQ ID NO: 9 and SEQ ID NO: 29 as defined by IMGT. R1, HCDR2, and HCDR3, and the L of the variable light chain of SEQ ID NOs: 19 and 39 Also disclosed is an antibody or antigen-binding fragment having CDR1, LCDR2, and LCDR3. In another embodiment of the invention, the antibody or antigen-binding fragment is HCDR1, HCDR2, and HCDR3, and LCDR1, L of the light chain variable domain sequences of SEQ ID NOs: 19 and 39 It may have a CDR2, and an LCDR3.

[0051] In one embodiment of the invention, the isolated antibody or antigen-binding fragment thereof is selected from SEQ ID NOs: 9 and 29. The isolated antibody or antigen-binding fragment comprises a heavy chain variable domain sequence selected from the group consisting of: In addition, the heavy chain variable domain and the light chain variable domain may further comprise a light chain variable domain sequence. In combination with the light chain variable domain, it forms the antigen-binding site for FXIa. In particular, the light chain variable domain sequence may be selected from SEQ ID NOs: 19 and 39, wherein the isolated antibody or antigen-binding fragment thereof binds to FXI and / or FXIa. To combine.

[0052] The present invention also provides a light chain variable domain sequence selected from the group consisting of SEQ ID NOs: 19 and 39. An isolated antibody or antigen thereof that comprises a sequence and binds to human FXI and / or human FXIa. The isolated antibody or antigen-binding fragment further comprises a heavy chain variable domain sequence. In this case, the light chain variable domain and the heavy chain variable domain can be combined. In addition, it forms an antigen-binding site for FXI and / or FXIa.

[0053] In particular, an isolated antibody or antigen-binding fragment thereof that binds to FXI and / or FXIa heavy and light chains comprising the sequences of SEQ ID NOs: 9 and 19; or 19 and 39, respectively; The polypeptide may have a chain variable domain.

[0054] The present invention further relates to a method for the preparation of a nucleic acid sequence comprising: Overlaps with 0%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity The present invention also relates to an isolated antibody or antigen-binding fragment thereof comprising a chain variable domain, wherein the antibody In one embodiment, the isolated antibody or its antigen binds to FXI and / or FXIa. The binding fragment also has at least one sequence selected from the group consisting of SEQ ID NOs: 19 and 39. having 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity In a further aspect of the invention, the isolated antibody or antigen-binding fragment comprises , HCDR1, HCDR2, HCD, as defined by Kabat and listed in Table 1 R3, LCDR1, LCDR2, and LCDR3. The isolated antibody or antigen-binding fragment may be defined by Chothia, IMGT, or a combination. The HCDR1, HCDR2, HCDR3, LCDR1, and LCDR2 are listed in Table 1. R2, and LCDR3.

[0055] The present invention also relates to a method for the preparation of a nucleic acid sequence comprising: 0%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity The present invention also relates to an isolated antibody or antigen-binding fragment thereof having a chain variable domain, The body binds to FXI and / or FXIa.

[0056] In another aspect of the invention, an isolated antibody or antibody which binds FXI and / or FXIa is The antigen-binding fragment of may have a heavy chain comprising the sequence of SEQ ID NO: 11 or 31. The isolated antibody may In addition, in combination with the heavy chain, it binds to human FXI and / or human FXIa. In particular, the light chain may comprise a sequence comprising SEQ ID NO: 21 or 41. In particular, isolated antibodies or their antibodies that bind to FXI and / or FXIa may be used. The original binding fragments include the sequences of SEQ ID NOs: 11 and 21; or 31 and 41, respectively. The antibody may have heavy and light chains comprising

[0057] The present invention still further comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11 or 31. The present invention also relates to an isolated antibody or antigen-binding fragment thereof comprising a heavy chain having 90% sequence identity with the In one embodiment, the antibody binds to FXI and / or FXIa. The isolated antibody or antigen-binding fragment thereof may also be selected from the group consisting of SEQ ID NO: 21 or 41. At least 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the sequence The light chain also includes a light chain having sequence identity to the above sequence.

[0058] The present invention still further comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 21 or 41. The sequences share 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity with each other. The present invention also relates to an isolated antibody or antigen-binding fragment thereof comprising a light chain that binds to F Binds to XI and / or FXIa.

[0059] The present invention also provides compositions comprising the isolated antibodies or antigen-binding fragments thereof described herein. The present invention also relates to an antibody composition in combination with a pharma- ceutically acceptable carrier. In particular, the present invention relates to antibodies of Table 1, such as antibodies NOV1090 and NOV1401. The present invention further includes pharmaceutical compositions comprising the isolated antibodies of Table 1 or antigen-binding fragments thereof. The present invention also relates to pharmaceutical compositions comprising a combination of two or more of the antibodies or antigen-binding fragments thereof. .

[0060] The present invention also provides a method for the preparation of a polypeptide encoding a variable heavy chain having a sequence selected from SEQ ID NOs: 9 and 29. In particular, the nucleic acid is selected from the group consisting of SEQ ID NOs: 10 and 30. At least 80%, 85%, 90%, 95%, 97%, 98%, or 99% identical to the sequence being examined % sequence identity. In a further aspect of the invention, the sequence has SEQ ID NO: 10 or 30 It is.

[0061] The present invention also provides a nucleic acid encoding a variable light chain having a sequence selected from SEQ ID NOs: 20 and 40. In particular, the nucleic acid is selected from the group consisting of SEQ ID NO: 20 and 40. The sequence selected has at least 80%, 85%, 90%, 95%, 97%, 98%, or 99% In a further embodiment of the invention, the sequence has SEQ ID NO: 20 and SEQ ID NO: 4. The value is 0.

[0062] The present invention also relates to a method for the preparation of a nucleic acid sequence comprising: 0% sequence identity It also relates to isolated nucleic acids.

[0063] The present invention also relates to vectors comprising one or more of the nucleic acid molecules described herein. Also relates to.

[0064] The present invention also relates to a recombinant DNA sequence encoding the heavy chain of the above-described antibody, and and a second recombinant DNA sequence encoding the light chain of the antibody, In this case, the DNA sequence is operably linked to a promoter and is expressed in the host cell. It is contemplated that the antibody may be a human monoclonal antibody. It is also contemplated that the host cell is a non-human mammalian cell.

[0065] The present invention also relates to a method for determining the expression of FXI and / or FXIa, and / or the expression of intrinsic coagulation pathway. A method for reducing activation of the coagulation pathway and / or common coagulation pathway, comprising administering to cells an effective amount of contacting the subject with a composition comprising an isolated antibody or antigen-binding fragment thereof described herein; The present invention also relates to a method including the steps of:

[0066] The present invention also relates to a method for inhibiting binding of FXI and / or FXIa to FIX. The cells are treated with an effective amount of an isolated antibody or antigen-binding fragment thereof described herein. The present invention also relates to a method comprising contacting a subject with a composition comprising the steps of:

[0067] It is contemplated that the cell is a human cell. It is further contemplated that the cell is in a subject. In one embodiment, it is contemplated that the cell is a platelet. The subject may be a human. It is still further contemplated that:

[0068] The present invention is also directed to a method of treating, ameliorating, or preventing a thromboembolic disorder in a subject. and administering to the subject an effective amount of a composition comprising an antibody or antigen-binding fragment thereof described herein. In one aspect, the thromboembolic disorder is a thrombus disorder. Sexual disorders (e.g., thrombosis, thrombotic stroke, atrial fibrillation, prevention of stroke in atrial fibrillation (S PAF, deep vein thrombosis, venous thromboembolism, and pulmonary embolism. It is also contemplated that.

[0069] Any of the foregoing isolated antibodies or antigen-binding fragments thereof may be referred to as monoclonal antibodies. or an antigen-binding fragment thereof.

[0070] Non-limiting embodiments of the present disclosure are described in the following aspects: 1. An isolated anti-FXI antibody that binds within the catalytic domain of FXI and / or FXIa; and and / or an isolated anti-FXIa antibody or fragment thereof. 2. Isolated antibodies that bind to one or more epitopes of anti-FXI and / or FXIa or a fragment thereof, wherein the epitope is Pro410, Arg413, Leu415, Cys416, His431, Cys432, Tyr434, Gly435, Glu43 7, Tyr472, Lys473, Met474, Ala475, Glu476, Tyr 521, Arg522, Lys523, Leu524, Arg525, Asp526, L ys527, Arg548, His552, Ser575, Ser594, Trp595 , Gly596, Glu597, Arg602, Glu603, and Arg604 An isolated antibody or fragment thereof comprising two or more amino acid residues thereof. 3. The epitope is Pro410, Arg413, Leu415, Cys416, His 431, Cys432, Tyr434, Gly435, Glu437, Tyr472, L ys473, Met474, Ala475, Glu476, Tyr521, Arg522 , Lys523, Leu524, Arg525, Asp526, Lys527, Arg5 48, His552, Ser575, Ser594, Trp595, Gly596, Gl At least four of the following amino acids: u597, Arg602, Glu603, and Arg604 The isolated antibody or fragment of embodiment 2, comprising an acid residue. 4. The epitope is Pro410, Arg413, Leu415, Cys416, His 431, Cys432, Tyr434, Gly435, Glu437, Tyr472, L ys473, Met474, Ala475, Glu476, Tyr521, Arg522 , Lys523, Leu524, Arg525, Asp526, Lys527, Arg5 48, His552, Ser575, Ser594, Trp595, Gly596, Gl Six or more of the following amino acids: u597, Arg602, Glu603, and Arg604 The isolated antibody or fragment of embodiment 2, comprising an acid residue. 5. The epitope is Pro410, Arg413, Leu415, Cys416, His 431, Cys432, Tyr434, Gly435, Glu437, Tyr472, L ys473, Met474, Ala475, Glu476, Tyr521, Arg522 , Lys523, Leu524, Arg525, Asp526, Lys527, Arg5 48, His552, Ser575, Ser594, Trp595, Gly596, Gl Eight or more of the following amino acids: u597, Arg602, Glu603, and Arg604 The isolated antibody or fragment of embodiment 2, comprising an acid residue. 6. The epitope is Pro410, Arg413, Leu415, Cys416, His 431, Cys432, Tyr434, Gly435, Glu437, Tyr472, L ys473, Met474, Ala475, Glu476, Tyr521, Arg522 , Lys523, Leu524, Arg525, Asp526, Lys527, Arg5 48, His552, Ser575, Ser594, Trp595, Gly596, Gl The monoclonal antibody of embodiment 2, comprising residues u597, Arg602, Glu603, and Arg604. Antibodies or fragments. 7. The epitope is composed of the amino acid residues Pro410, Arg413, and Lys527, and the amino acid residues Le u415, Cys416, His431, Cys432, Tyr434, Gly435, Glu437, Tyr472, Lys473, Met474, Ala475, Glu47 6, Tyr521, Arg522, Lys523, Leu524, Arg525, Asp 526, Arg548, His552, Ser575, Ser594, Trp595, G Of ly596, Glu597, Arg602, Glu603, and Arg604 and one or more amino acid residues. 8. The epitope is composed of the amino acid residues Pro410, Arg413, and Lys527, and Le u415, Cys416, His431, Cys432, Tyr434, Gly435, Glu437, Tyr472, Lys473, Met474, Ala475, Glu47 6, Tyr521, Arg522, Lys523, Leu524, Arg525, Asp 526, Arg548, His552, Ser575, Ser594, Trp595, G Of ly596, Glu597, Arg602, Glu603, and Arg604 The isolated antibody or fragment of embodiment 2, comprising four or more amino acid residues. 9. The epitope is composed of the amino acid residues Pro410, Arg413, and Lys527, and Le u415, Cys416, His431, Cys432, Tyr434, Gly435, Glu437, Tyr472, Lys473, Met474, Ala475, Glu47 6, Tyr521, Arg522, Lys523, Leu524, Arg525, Asp 526, Arg548, His552, Ser575, Ser594, Trp595, G Of ly596, Glu597, Arg602, Glu603, and Arg604 and 6 or more amino acid residues. 10. Isolated anti-FXI antibodies that bind within the catalytic domain of FXI and / or FXIa and / or isolated anti-FXIa antibodies or fragments thereof, XIa to one or more of factor IX, factor XIIa, and thrombin An isolated antibody or fragment that blocks binding. 11. FXI and / or FXIa, factor IX, factor XIIa, or thrombopoietin 11. The method of claim 10, wherein the antibody blocks binding to one or more of the clotting factors, Isolated antibody or fragment. 12. Binding of one or more of FIX, FXI, and FXIa to platelet receptors The isolated antibody or fragment of embodiment 1, which blocks binding of 13. An isolated antibody or a method according to embodiment 1, which prevents activation of the intrinsic coagulation pathway or the common coagulation pathway. piece. 14. Human FXI protein and / or human FXIa protein, BIACORE ≤ 34 nM as measured by the (TM) assay or by the equilibrium titration assay in solution (S K below 4 pM measured by ET) D An isolated antibody or fragment thereof that binds at 15. At least 90% identity to at least one of the CDRs listed in Table 1. 2. The isolated antibody or fragment of embodiment 1, comprising at least one complementarity determining region having the same identity as the antibody or fragment of embodiment 1. 16. The isolated antibody or fragment of embodiment 1, comprising CDR1, CDR2, and CDR3 of Table 1. . 17. An isolated variant of the antibody or fragment of embodiment 1, wherein the antibody or fragment is selected from the group consisting of C, D, E, E, F, H ... DR1, CDR2, and CDR3, and the variant is CDR1, CDR2, or CDR3. An isolated mutant with at least one to four amino acid changes in one of R3 . 18. The monoclonal antibody of embodiment 1, comprising a heavy chain CDR3 selected from the group consisting of SEQ ID NOs: 5 and 25. Antibodies or fragments. 20. A VH selected from the group consisting of SEQ ID NO: 9 and 29, or 90% thereto and an amino acid sequence having an identity to SEQ ID NO: 19 and 39. 2. The method of claim 1, comprising administering to the patient a VL sequence as set forth in claim 1, or an amino acid sequence having 90% identity thereto. Antibodies or fragments. 21. A VH selected from the group consisting of SEQ ID NO: 9 and 29, or 95% thereof and an amino acid sequence having an identity to SEQ ID NO: 19 and 39. 2. The method of claim 1, comprising administering to the patient a VL sequence as set forth in claim 1, or an amino acid sequence having 95% identity thereto. Antibodies or fragments. 22. A VH selected from the group consisting of SEQ ID NO: 9 and 29, or 97% thereof and an amino acid sequence having an identity to SEQ ID NO: 19 and 39. 2. The method of claim 1, comprising administering to the patient a VL sequence as set forth in claim 1, or an amino acid sequence having 97% identity thereto. Antibodies or fragments. 23. The monoclonal antibody of embodiment 1, comprising a variable heavy chain sequence selected from the group consisting of SEQ ID NOs: 9 and 29. Antibodies or fragments. 24. The antibody of embodiment 1, comprising a variable light chain sequence selected from the group consisting of SEQ ID NOs: 19 and 39. Isolated antibody or fragment. 25. A variable heavy chain selected from the group consisting of SEQ ID NO: 9 and 29; and SEQ ID NO: 19 and 39. The isolated antibody or fragment of embodiment 1, comprising a variable light chain sequence selected from the group consisting of: . 26. An antibody or fragment comprising the variable heavy chain sequence of SEQ ID NO: 9 and the variable light chain sequence of SEQ ID NO: 19. and an antibody or fragment comprising the variable heavy chain sequence of SEQ ID NO:29 and the variable light chain sequence of SEQ ID NO:39. 2. The isolated antibody or fragment of embodiment 1, selected from the group consisting of: 27. CDR1 of the heavy chain variable region selected from the group consisting of SEQ ID NO: 46; CDR2 selected from the group consisting of: CDR3 selected from the group consisting of SEQ ID NO: 33 a light chain variable region CDR1 selected from the group consisting of SEQ ID NO: 14; and a CDR3 selected from the group consisting of SEQ ID NO: 15. Antibodies or fragments. 28. CDR1 of the heavy chain variable region selected from the group consisting of SEQ ID NO: 3 and 23; SEQ ID NO: CDR2 selected from the group consisting of: 4 and 24; CDR3 selected from the group consisting of: 5 and 25 CDR3 of the light chain variable region selected from the group consisting of SEQ ID NOs: 13 and 33 1; CDR2 selected from the group consisting of SEQ ID NO:14 and 34; and SEQ ID NO:15 2. The isolated antibody or fragment of embodiment 1, comprising a CDR3 selected from the group consisting of: 29. CDR1 of the heavy chain variable region selected from the group consisting of SEQ ID NO: 6 and 26; SEQ ID NO: CDR2 selected from the group consisting of CDR numbers 7 and 27; CDR3 selected from the group consisting of CDR numbers 8 and 28 CDR3 of the light chain variable region selected from the group consisting of SEQ ID NOs: 16 and 36 1; CDR2 selected from the group consisting of SEQ ID NO: 17 and 37; and SEQ ID NO: 18 2. The isolated antibody or fragment of embodiment 1, comprising a CDR3 selected from the group consisting of: 30. CDR1 of the heavy chain variable region of SEQ ID NO: 3; CDR2 of the heavy chain variable region of SEQ ID NO: 4; CDR3 of the heavy chain variable region of sequence number 5; CDR1 of the light chain variable region of sequence number 13; 14; and CDR3 of the light chain variable region of SEQ ID NO: 15, The isolated antibody or fragment of embodiment 1. 31. CDR1 of the heavy chain variable region of SEQ ID NO: 23; CDR2 of the heavy chain variable region of SEQ ID NO: 24 25; CDR1 of the light chain variable region of SEQ ID NO: 33; CDR2 of the light chain variable region of sequence number 34; and CDR3 of the light chain variable region of sequence number 35 The isolated antibody or fragment of embodiment 1, comprising 32. CDR1 of the heavy chain variable region of SEQ ID NO: 6; CDR2 of the heavy chain variable region of SEQ ID NO: 7; CDR3 of the heavy chain variable region of sequence number 8; CDR1 of the light chain variable region of sequence number 16; 17; and CDR3 of the light chain variable region of SEQ ID NO: 18, The isolated antibody or fragment of embodiment 1. 33. CDR1 of the heavy chain variable region of SEQ ID NO: 26; CDR2 of the heavy chain variable region of SEQ ID NO: 27 28; CDR1 of the light chain variable region of SEQ ID NO: 36; CDR2 of the light chain variable region of sequence number 37; and CDR3 of the light chain variable region of sequence number 38 The isolated antibody or fragment of embodiment 1, comprising 34. A pharmaceutical composition comprising an antibody or fragment thereof according to any one of the above embodiments and a pharma- ceutical acceptable carrier. Composition. 35. An embodiment that binds to the same epitope as the isolated antibody or fragment of any of the preceding embodiments. An isolated antibody or fragment thereof. 36. Binding to human FXI protein and / or human FXIa protein: An isolated antibody or fragment of embodiment 1 that competes with the isolated antibody or fragment of any of the preceding embodiments. Piece. 37. The isolated antibody of embodiment 1, selected from the group consisting of NOV1090 and NOV1401. Body or fragment. 38. A method for treating a thromboembolic disorder comprising administering to a subject an effective amount of a compound according to any one of the preceding embodiments. Administering a pharmaceutical composition comprising the antibody or fragment to a subject suffering from a thromboembolic disorder. The method includes the steps: 39. The subject has one or more of the following: ischemic stroke and deep vein thrombosis associated with atrial fibrillation The method of embodiment 38, wherein the patient is multiplexed. 40. The method of embodiment 38, wherein the subject is suffering from an ischemic stroke associated with atrial fibrillation. 41. A method for treating a thromboembolic disorder, comprising administering to a subject an effective amount of a compound according to any one of the preceding embodiments. A pharmaceutical composition comprising the antibody or fragment is administered to a patient suffering from a thromboembolic disorder in combination with statin therapy. administering to an affected subject. 42. A medicament comprising an antibody according to any of the preceding aspects. 43. A nucleic acid encoding one or more of the antibodies according to any of the preceding embodiments. 44. A vector comprising a nucleic acid according to embodiment 43. 45. A host cell comprising the vector according to embodiment 44. 46. ​​Upon binding to the active FXI (FXIa) catalytic domain, FXIa is The four residues at the N-terminus, loops 145, 188, and 220, are responsible for the active conformation. Inactive conformations that are shifted and / or disordered compared to the inactive conformation The isolated antibody or fragment of embodiment 1, wherein the antibody or fragment is modified to a polypeptide. Upon binding to FXI, the FXI catalytic domain binds to loops 145, 188, and 22. 0 adopts an active conformation that is as regular as in the structure of the FXIa catalytic domain The isolated antibody or fragment of embodiment 1, which prevents 48. Upon binding to FXI, the FXI catalytic domain binds to four residues at the N-terminus, loop 145, and , 188, and 220 are regular in the structure of the FXIa catalytic domain. 2. The isolated antibody or fragment of embodiment 1, wherein the antibody or fragment is prevented from assuming a conformation. 49. Upon binding to FXI, it induces a conformational change within the zymogen structure, resulting in the formation of FX Inhibition closely correlates with the inhibitory FXI conformation observed when bound to Ia By further providing the catalytic FXI conformation, the FXI catalytic domain The isolated antibody or fragment of embodiment 1, which is prevented from adopting a conformation. 50. Binds to FXI and / or FXIa and is a catalytic receptor for FXI and / or FXIa Upon forming an antibody:antigen complex, the active sites of loops 145, 188, and 220 are Compared to the uncomplexed structure of the catalytic domain of human factor XI (FXIa). The isolated antibody or fragment of embodiment 1, which causes a shift in and / or loss of orientation. 51. Binds to FXI and / or FXIa and is a catalytic domain of FXI and / or FXIa When the antibody:antigen complex is formed, the four amino acid residues at the N-terminus, the loop 145, and the loop 188 , and 220 uncomplexed portions of the catalytic domain of active factor XI (FXIa). The isolated structure of embodiment 1, which causes a shift and / or loss of orientation compared to the original structure. Antibody or fragment. 52. Binds to active FXI (FXIa) and mediates its coactivation with the FXI (FXIa) catalytic domain. The conformation of the ribosome is similar to that of the ribosome, with loops 145, 188, and 220 in the active conformation. to an inactive conformation that is shifted and / or disoriented relative to the The isolated antibody or fragment of embodiment 1,

[0071] definition Unless otherwise defined, all technical and scientific terms used herein are defined by the It has the same meaning as commonly understood by a person skilled in the art to which the invention pertains.

[0072] The terms "FXI protein," "FXI antigen," and "FXI" are used interchangeably. It is used to refer to the factor XI protein in different species. Factor XI is a limited protein. When converted to an active serine protease by protein cleavage, it mediates the intrinsic pathway of blood coagulation. The zymogen that participates in the catalysis is a glycoprotein that exists in human plasma at a concentration of 25-30 nM. The protein is mammalian plasma coagulation factor XI.

[0073] The terms "FXIa protein," "FXIa antigen," and "FXIa" are used interchangeably. It is commonly used to refer to the activated form of FXI protein in different species. Factor XI mediates thrombin through the contact phase of blood clotting, or on the platelet surface. Upon activation, it is converted to its active form, coagulation factor Xla (FXIa). Upon activation of factor XI, an internal peptide bond is broken in each of the two chains, forming disulfide bonds. Serine, which consists of two heavy chains and two light chains held together by peptide bonds This results in the production of activated factor Xla, a protease. The enzyme FXIa converts coagulation factor IX to IXa, which then converts coagulation factor X to IXa. Activates coagulation factor II (Xa), which then activates thrombin (Xa). For example, human FXI has the sequence shown in Table 1 (SEQ ID NO:1) and and literature (Mandle RJ Jr, et al. (1979) Blood; 54(4):850; NCBI Reference Sequence :AAA51985).

[0074] In the context of the present invention, the terms "FXI" and "FXIa" (and the like) refer to naturally occurring FXI. Mutants and variants of the I protein and the FXIa protein, respectively, The amino acid sequence of the natural primary structure (amino acid sequence) described in the above report and This includes mutants and variants having substantially the same amino acid sequence.

[0075] The terms "catalytic domain", "serine protease catalytic domain" and the terms used herein A similar term used in is the number of amino acids counted from Glu1 at the N-terminus of the mature circulating protein. This also refers to the amino acids Ile370 to Val607 at the C-terminus of FXI. As used herein, the term "active site" may also be used to refer to groups 388 to 625. The term refers to a catalytic site that contains the amino acids His413, Asp462, and Se557. This refers to the three catalytic residues (Bane and Gailani (2014) Drug Disc. 19(9)).

[0076] The term "about" in reference to a number x means, for example, x±10%.

[0077] As used herein, the term "antibody" refers to whole antibodies and any antigen-binding fragments (including "Antibody" refers to a single chain or a single chain of an antibody, i.e., an "antigen-binding portion" thereof. It contains at least two heavy (H) chains and two light (L) chains interconnected by bond bonds. Each heavy chain is a glycoprotein. The heavy chain constant region is made up of three domains: CH1, CH2, and C Each light chain comprises a light chain variable region (abbreviated herein as VL) and a light chain constant region (H3). The light chain constant region contains one domain, CL. The VH and VL domains The complementarity determining regions are interspersed with more conserved regions called framework regions (FR). Each VH and VD can be further subdivided into regions of hypervariability called CDRs. Each VL has three CDRs and CDRs arranged in the following order from amino terminus to carboxy terminus: and four FRs: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The somatic constant regions of immunoglobulins are responsible for the expression of various antigens in various cells of the host tissue or immune system (e.g., Fc. It mediates binding to factors including the first component of the classical complement system (Clq) and the first component of the classical complement system (Vector cells). Ugh.

[0078] As used herein, the term "antigen-binding portion" or "antigen-binding fragment" of an antibody The term refers to a compound that retains the ability to specifically bind to a given antigen (e.g., factor XIa (FXIa)). The term refers to one or more fragments of an intact antibody that bind to the antigen. This function can be fulfilled by a fragment of an antibody, which is an active site of the antibody. Examples of binding fragments encompassed within the term are Fab fragments, VL domains, VH domains, C Monovalent fragment consisting of the L domain and the CH1 domain; disulfide bond in the hinge region F(ab)2 fragment, a bivalent fragment containing two Fab fragments linked by a bridge; an Fd fragment consisting of the main and CH1 domains; Fv fragments consisting of a VH domain and a VL domain; deoxyribonucleic acid (dAb) fragments (Ward et al., 1989 Nature 341:544-546); and isolated complementarity determinations. Contains the CDR region.

[0079] In addition, the two domains of the Fv fragment, the VL domain and the VH domain, are They are encoded by genes, but can be synthesized using recombinant methods to produce them as a single protein chain. The peptides can be attached by artificial peptide linkers that allow the synthesis of The VL and VH regions can then be paired to form a monovalent molecule known as a single chain Fv (scFv). See, e.g., Bird et al., 1988 Science 242:423-426; and Huston et al., 1988 Proc. Natl. Acad. Sci. 85:5879-5883). Such single chain antibodies are These antibody fragments contain one or more antigen-binding portions or fragments. The fragments are obtained using conventional techniques known to those skilled in the art, and have the same utility as intact antibodies. are screened for.

[0080] Antigen-binding fragments also include single domain antibodies, maxibodies, minibodies, intrabody antibodies, antibody, diabody, triabody, tetrabody, v-NAR, and bis-scFv (See, e.g., Hollinger and Hudson, 2005, Nature Biotechnology, 23, 9, 1126-1136) The antigen-binding portion of an antibody can also be incorporated into a type III fibroblast. Fibronectin (Fn3) and other polypeptides (fibronectin polypeptide monobody) (see U.S. Patent No. 6,703,199, which describes a method for It can be grafted.

[0081] The antigen-binding fragment forms a pair of antigen-binding regions in combination with a complementary light chain polypeptide. , and assembled into a single chain molecule containing a pair of tandem Fv segments (VH-CH1-VH-CH1). (Zapata et al., 1995 Protein Eng. 8(10):1057-1062; and U.S. Pat. No. 5,313,316. No. 5,641,870).

[0082] As used herein, the term "affinity" refers to the affinity of an antigen to a single antigenic site. It refers to the strength of the interaction between the body and the antigen. Within each antigenic site, the variable regions of the antibody "arms" The region interacts with antigens at multiple sites through weak non-covalent forces, and the interaction The larger the affinity, the stronger the affinity. The term "high affinity" as used herein for the b fragment generally refers to a -9 K below M D (For example, 10 -10 K below M D , 10 -11 K below M D , 10 - 12 K below MD , 10 -13 K below M D , 10 -14 K below M D etc.) The term refers to an antigen-binding fragment or an antigen-binding fragment thereof.

[0083] The term "amino acid" includes naturally occurring and synthetic amino acids, as well as naturally occurring It also refers to amino acid analogs and amino acid mimetics that function in a manner similar to the amino acids in the naturally occurring The amino acids in the genome are those encoded by the genetic code, as well as those that are later modified. O-phosphoryl acids, e.g., hydroxyproline, γ-carboxyglutamic acid, and O-phosphoryl Amino acid analogs are compounds that have the same basic chemical structure as naturally occurring amino acids. Hydrogen, carboxyl groups, amino groups, and R groups, e.g., homoserine, norleucine , methionine sulfoxide, methionine methylsulfonium bonded to the alpha carbon Such analogs refer to compounds that have modified R groups (e.g., norleucine) or modified They have a peptide backbone but retain the same basic chemical structure as naturally occurring amino acids. An acid mimetic is a compound that has a structure that is different from the general chemical structure of an amino acid, but is similar to the naturally occurring amino acid. Refers to chemical compounds that function in a similar manner to acids.

[0084] As used herein, the term "binding specificity" refers to a molecule that reacts with only one antigenic determinant. Refers to the capacity of an individual antigen-binding site.

[0085] The antibody (e.g., FXI-binding antibody and / or FXIa-binding antibody) is “specifically The phrase "bind (or selectively)" refers to a heterogeneous population of proteins and other biological materials. Cognate antigens in the host (e.g., FXI and / or FXIa in humans or cynomolgus As used herein, the term refers to a binding reaction that determines the presence of FXI and / or FXIa in a given antibody. The phrases "antibody that recognizes an antigen" and "antibody specific for an antigen" are used interchangeably with "antibody specific for an antigen." The term "antibody that binds to" is used interchangeably with the term "antibody that binds to."

[0086] The term "mediates FXI and / or FXIa" refers to FXI and / or FXIa. XIa is a member of the family of factors IX (also known as FIX), X (FX), and and / or by directly or indirectly activating thrombin; and / or By binding to platelet receptors, it mediates the intrinsic and / or common coagulation pathways. This refers to the fact that

[0087] The term "hemostasis" refers to the primary mechanism for stopping blood flow at the site of injury and in wound healing. These represent the major mechanisms for restoring vascular patency during healing. In physical thrombosis, there are three mechanisms: primary arrest, which refers to the interaction of activated platelets with the vessel wall; At the same time, blood fibrin formation and a process called fibrinolysis are activated.

[0088] Terms such as "clotting and the coagulation cascade" and "cascade model of coagulation" are used to describe wound healing. Protein-based systems used to stabilize blood clots that form to seal the The coagulation pathway is a proteolytic cascade. Each enzyme in the pathway is present in plasma. Upon activation, it undergoes proteolytic cleavage to release the active factor from the precursor molecule. It exists as a zymogen (in an inactive form). The coagulation cascade regulates the activation process. The pathway functions as a series of positive and negative feedback loops that control the Thrombin, which can convert soluble fibrinogen into fibrin, which forms blood clots. The purpose of the present invention is to produce

[0089] The process of thrombin generation consists of three phases: the intrinsic pathway, and the activated clotting factor FXa (activated clotting factor). The extrinsic pathway, an alternative pathway for generating activated factor X, and thrombin (Hoffman MM a nd Monroe DM (2005) Curr Hematol Rep. 4:391 -396; Johne J, et al. (2006) Biol Chem. 387:173-178).

[0090] Platelet aggregation occurs when a blood vessel breaks and substances that normally do not come into direct contact with the bloodstream aggregate. These substances (mainly collagen and von Willebrand factor) The endothelial cells (e.g., erythrocytes) allow platelets to adhere to the fractured surface. When platelets are stimulated, they release chemicals that attract more platelets to the damaged area, a process known as platelet aggregation. These two processes are the initial response to stop bleeding.

[0091] As used herein, the term "thromboembolic disorder" or similar terms refers to a condition characterized by an intrinsic coagulation pathway. The coagulation pathway and / or the common coagulation pathway are abnormally activated or not naturally inactivated. The term "condition" refers to any number of conditions or diseases that are not treated or managed properly (e.g., without any therapeutic measures). These conditions include , thrombotic stroke, atrial fibrillation, prevention of stroke in atrial fibrillation (SPAF), deep vein thrombosis These include, but are not limited to, pulmonary embolism, venous thromboembolism, and pulmonary embolism. Catheter-related conditions in which the catheter becomes thrombosed (e.g., Hickman catheters in cancer patients) This includes patients with pulmonary bypass, extracorporeal membrane oxygenation (ECMO), where the tubing can cause blood clots. Ugh.

[0092] As used herein, the term "thromboembolic" or similar terms also refer to the anti- Using FXI Ab and / or anti-FXIa Ab or their antigen-binding fragments The following can be prevented or treated: Paroxysmal atrial fibrillation or flutter, persistent atrial fibrillation or flutter, or suspected or confirmed cardiac arrhythmias, such as permanent atrial fibrillation or permanent atrial flutter Thromboembolism in subjects who have been A subpopulation of subjects with stroke prevention in atrial fibrillation (SPAF) Subjects with AF undergoing percutaneous coronary intervention (PCI); Treatment of acute venous thromboembolic events (VTE) in patients at high risk for bleeding, and and prevention of long-term secondary VTE; In secondary prevention after a transient ischemic attack (TIA) or non-disability-inducing stroke For the prevention of cerebral and cardiovascular events, as well as thromboembolic events in heart failure with sinus rhythm cerebral and cardiovascular events in; - Left atrium clot formation and thrombosis in subjects undergoing cardiac defibrillation for cardiac arrhythmias Thrombosis; · Thrombosis before, during, and after ablation procedures for cardiac arrhythmias; Venous thrombosis, which can be deep vein thrombosis or superficial vein thrombosis in the legs or upper extremities. thrombosis of the abdominal and thoracic veins, venous sinus thrombosis and jugular vein thrombosis including but not limited to treatment and secondary prevention; Thrombosis on any artificial surfaces within a vein, such as catheters or pacemaker leads; Pulmonary embolism in patients with or without venous thrombosis; ·Chronic Thromboembolic Pulmonary Hypertension (CTEPH); Arterial thrombosis on ruptured atherosclerotic plaques, on prostheses or catheters in arteries Thrombosis in the thrombosis of the ventricles and in apparently normal arteries, which may be associated with acute coronary syndrome. group, ST elevation myocardial infarction, non-ST elevation myocardial infarction, unstable angina, stent thrombosis, arterial Thrombosis of any artificial surface in the system, and in subjects with or without pulmonary hypertension including but not limited to pulmonary artery thrombosis; Thrombosis and thrombosis in patients undergoing percutaneous coronary intervention (PCI) Embolism; Cardioembolic and cryptogenic stroke; Thrombosis in patients with invasive and non-invasive cancer malignancies; Thrombosis across the indwelling catheter; Thrombosis and thromboembolism in critically ill patients; Cardiac thrombosis and thromboembolism, which are cardiothrombosis after myocardial infarction, Conditions such as aneurysms, myocardial fibrosis, cardiac hypertrophy and dysfunction, myocarditis, and artificial surfaces within the heart. including, but not limited to, cardiothrombotic events associated with pulmonary embolism; · Thromboembolism in patients with valvular heart disease, with or without atrial fibrillation; · Thromboembolism involving mechanical or biological prostheses for heart valves; - After cardiac repair surgery for simple or complex cardiac anomalies, natural or artificial cardiac pads thromboembolism in patients with arterial or venous conduits; Knee replacement, hip replacement, and orthopedic, thoracic or abdominal surgery venous thrombosis and thromboembolism after; Following neurosurgery, including intracranial and spinal interventions arterial or venous thrombosis; Factor V Leiden, Mutation of Prothrombin, Antithrombin III, Prothrombin Factor C deficiency and protein S deficiency, factor XIII mutations, familial fibrinogen deficiency Plasminogenemia, congenital plasminogen deficiency, elevated factor XI levels, sickle cell disease, Antiphospholipid syndrome, autoimmune diseases, chronic intestinal diseases, nephrotic syndrome, hemolytic uremia, bone marrow Proliferative disorders, disseminated intravascular coagulation, paroxysmal nocturnal hemoglobinuria, and heparin-induced hematopoietic disorders congenital or acquired thrombophilia, including but not limited to thrombocytopenia; Thrombosis and thromboembolism in chronic kidney disease; and - Thrombosis and pulmonary embolism in patients undergoing hemodialysis and extracorporeal membrane oxygenation Thromboembolism It may also refer to any number of.

[0093] The term "chimeric antibody" refers to an antibody that (a) combines an antigen-binding site (variable region) with a class, effector, or both. Different classes, effector functions, and / or species, or different classes, effector functions, and and / or species-altered constant regions, or entirely different constant regions that confer new properties to the chimeric antibody. The nucleotides can be defined to link to various molecules, such as enzymes, toxins, hormones, growth factors, drugs, etc. An antibody molecule in which a constant region or a portion thereof has been modified, replaced, or exchanged; or (b) modifying a variable region or a portion thereof to have a different or altered antigen specificity; The term refers to an antibody molecule in which a modified, replaced or exchanged variable region has been engineered. For example, mouse antibodies have their constant regions replaced with constant regions derived from human immunoglobulins. The chirality can be improved by replacing the constant region with a human constant region. The Ra antibody has been shown to recognize the antigen while reducing its antigenicity in humans compared to the original mouse antibody. It may retain its specificity in

[0094] The term "conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to a particular nucleic acid sequence, conservatively modified variants are those that have identical amino acids. A nucleic acid encoding an amino acid sequence or an essentially identical amino acid sequence, or When the sequence is not coded, it refers to essentially identical sequences. Due to the degeneracy of the genetic code, A large number of functionally identical nucleic acids encode any given protein. For example, The three glycerides GCA, GCC, GCG, and GCU all contain the amino acid alanine. Thus, alanine is encoded at every position specified by a codon. Codons can be converted to any of the corresponding codons listed without modifying the polypeptide. Such nucleic acid variations can be one type of conservatively modified variation. Any "silent mutation" that occurs during the course of any nucleic acid sequence encoding a polypeptide as described herein. The sequence also describes any possible silent variations of the nucleic acid. Each codon (AUG, which is usually a codon for methionine only, and It has been recognized that any codon in the sequence (except the codon TGG) can be modified to result in a functionally identical molecule. Thus, within each sequence described, the nucleic acid encoding the polypeptide Each silent mutation is implied.

[0095] In polypeptide sequences, "conservatively modified variants" refer to chemically similar amino acids. Individual substitutions, deletions, or deletions in a polypeptide sequence resulting in the replacement of the corresponding amino acid. Conservative substitutions, which represent functionally similar amino acids, are well known in the art. Such conservatively modified variants are well known in the art. This is in addition to, and does not exclude, homozygotes and alleles. There are eight groups: 1) alanine (A), glycine (G); 2) aspartic acid (D), glutamic acid (Glu); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (L). 5) isoleucine (I), leucine (L), methionine (M), valine (V) );6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W);7) Serine (S), threonine (T); and 8) cysteine ​​(C), methionine (M) are mutually Containing amino acids that are conservative substitutions for (see, e.g., Creighton, Proteins (1984) In some embodiments, the term "conservative sequence modifications" refers to modifications of the amino acids The binding characteristics of the antibody containing the sequence may not be significantly affected or altered. It is used to refer to an amino acid modification that is

[0096] The term "epitope" means a protein determinant capable of specific binding to an antibody. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains. They usually have specific three-dimensional structural characteristics as well as specific charge characteristics. Conformational and nonconformational epitopes are classified into two types: Competitive binding assays are distinguished by the fact that binding to the β-lactamase is lost in the presence of the β-lactamase but not to the β-lactamase. In the method, one antibody is fused to a second antibody by any of the methods well known to those of skill in the art. Two antibodies are said to "compete" if they are shown to bind to the same epitope.

[0097] As used herein, the term "human antibody" refers to a human antibody that is a human antibody having framework and CDR regions. Any of the above ranges are intended to include antibodies having variable regions derived from sequences of human origin. Furthermore, if the antibody contains a constant region, the constant region may also be such a human sequence, e.g. For example, a gene derived from a human germline sequence or a mutated version of a human germline sequence. The human antibodies of the invention may be modified by omitting amino acid residues that are not encoded by human sequences (e.g., In vitro mutagenesis was performed using random or site-directed mutagenesis. Mutations introduced into the genome or by somatic mutations in vivo Mutations) may be included.

[0098] The term "human monoclonal antibody" refers to an antibody displaying a single binding specificity. Both the framework and CDR regions have variable regions derived from human sequences. In one embodiment, a human monoclonal antibody refers to an antibody that is encoded by a human immunoglobulin gene. A library of vectors prepared using phage display technology for screening do.

[0099] A "humanized" antibody is an antibody that is less immunogenic in humans but retains the reactivity of a non-human antibody. This means, for example, that the non-human CDR regions are retained and the remainder of the antibody is The human counterparts (i.e., constant regions and framework portions of the variable regions) are replaced by those of the human counterparts. This can be achieved by, for example, Morrison et al., Proc. Natl. Acad. Sci. U SA, 81:6851-6855, 1984; Morrison and Oi, Adv. Immunol., 44:65-92, 1988; Verho eyen et al., Science, 239:1534~1536, 1988; Padlan, Molec. Immun., 28:489~498, 1991 and Padlan, Molec. Immun., 31:169-217, 1994. Examples include the Xoma technology disclosed in US 5,766,886. Not limited.

[0100] "Identical" or "identical" in the context of two or more nucleic acid or polypeptide sequences The term "percent" refers to two or more sequences or subsequences that are the same. using one of the sequence comparison algorithms below, or by manual alignment and compared for maximum correspondence across a visually measured comparison area or designated region; A specified percentage of amino acid residues or nucleotides in two sequences when sequenced If the tid is the same (i.e., it spans the specified area, or if it is not specified, , 60% identity across the entire sequence, optionally 65%, 70%, 75%, 80%, Two sequences are considered to be "substantially identical" if they share 85%, 90%, 95%, or 99% identity. Optionally, identity is at least about 50 nucleotides (or 10 amino acids). or more preferably, over a range of 100 to 500 or 1000 nucleotides (or 20, 50, or 200 amino acids or more) in length. It exists.

[0101] For sequence comparison, one sequence acts as a reference sequence, against which test sequences are compared. When using a sequence comparison algorithm, a test and a reference sequence are typically Enter the sequence into the computer, specify subsequence coordinates if necessary, and run the sequence algorithm program. Specify the program parameters. You can also use the default program parameters. Alternatively, alternative parameters can be specified. The sequence comparison algorithm then The percent sequence identity of the test sequence compared to the reference sequence is determined based on the program parameters. Calculate the points.

[0102] As used herein, a "comparison window" refers to a window in which, after optimal alignment of two sequences, the sequences are compared to one another. A reference sequence having the same number of consecutive positions can be compared, typically between 20 and 600, typically between about 50 and about 20 0, more usually a number of consecutive positions selected from the group consisting of about 100 to about 150. In the art, the term "comparison" includes a reference to a segment by any one of the following: Methods for sequence alignment are well known. An optimal sequence alignment for comparison is, for example, Sm The local homology algorithm by Ith and Waterman (1970) Adv. Appl. Math. 2:482c or by homology screening according to Needleman and Wunsch, J. Mol. Biol. 48:443, 1970. This can also be achieved by the sex alignment algorithm described in Pearson and Lipman, Proc. Nat'l Acad. Sci. USA 85:2444, 1988. A computerized implementation of the algorithm (Wisconsin Genetics Software) tware Package, Genetics Computer Group, 57 GAP, BESTFIT, 5 Science Dr., Madison, WI It can also be done by manual alignment and Visual inspection (e.g., Brent et al., Current Protocols in Molecular Biology, John Wiley & Sons , Inc. (see Ringbou, ed., 2003).

[0103] Suitable Algorithms for Determining Percent Sequence Identity and Percent Sequence Similarity Two examples are described in Altschul et al. (1977) Nuc. Acids Res. 25:3389-3402; and and Altschul et al. (1990) J. Mol. Biol. 215:403-410. The ST algorithm and the BLAST 2.0 algorithm were used to perform the BLAST analysis. The software for this is provided by the National Center for Biotechnology Information. This algorithm is published by the Department of Electrical and Electronics Information. When matching words of the same length in the database sequence, a threshold score T by identifying a short word length W in the query sequence that matches or satisfies This involves first identifying high-scoring sequence pairs (HSPs). Let T be the neighborhood word score threshold. These initial neighborhood word hits are then used to find the sequence of matches that contain the word 'localization'. Serves as a seed to initiate searches to find longer HSPs. The word hits are extended in either direction along each sequence for as far as the core can grow. The cumulative score is calculated based on the parameter M (the number of matching residues for a pair of matching residues) for nucleotide sequences. reward score; always >0) and N (penalty for mismatched residues) For amino acid sequences, the scoring matrix is The cumulative alignment score is calculated using the for the accumulation of one or more negative scoring residue alignments; , if the cumulative score falls below zero; or if either end of the sequence is reached stops the extension of the word hit in each direction. The W, T, and X used determine the sensitivity and speed of the alignment. The program (for nucleotide sequences) uses a word length (W) of 11, an expectation (E) of 10, ), M=5, N=-4 as defaults, and a comparison of both strands is performed. The BLASTP program for and 50 BLOSUM62 scoring matrices (Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915, 1989) Alignment (B), 10 periods Use the defaults of E, M=5, and N=-4 and perform a comparison of both strands.

[0104] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (e.g. See, e.g., Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5787, 1993. One measure of similarity provided by the BLAST algorithm is It is an indication of the probability that a match between two nucleotide or amino acid sequences will occur by chance. For example, the minimum total probability (P(N)) of a test nucleic acid being compared to a reference nucleic acid is The minimum sum probability when compared is less than about 0.2, and more preferably less than about 0.01. and most preferably, a nucleic acid is considered similar to a reference sequence if it has a repeat sequence identity of less than about 0.001. can be.

[0105] The percent identity between two amino acid sequences is also calculated using the PAM120 weighted residue table, ALIGN using a gap length penalty of 2 and a gap penalty of 4. The paper was incorporated into the program (version 2.0) by E. Meyers and W. Miller (Comput. It can also be determined using the algorithm by In addition, the percent identity between the two amino acid sequences is calculated using the Blossom 62 matrix. or PAM250 matrix, and 16, 14, 12, 10, 8, 6, or Uses gap weights of 1, 2, 3, 4, 5, or 6, and length weights of 1, 2, 3, 4, 5, or 6. the GCG software package (available on the internet at gcg.com) The GAP program was integrated into the genomic DNA by Needleman and Wunsch (J. Mol. Biol. 48:44 4-453, 1970) can also be used to determine the concentration of fluorine.

[0106] Other than the percentage of sequence identity mentioned above, the two nucleic acid sequences or polypeptides may have substantial Another indication of identity to the first nucleic acid is the sequence encoded by the first nucleic acid, as described below. The polypeptide immunologically binds to an antibody against a polypeptide encoded by a second nucleic acid. Thus, for example, if two peptides have only conservative substitutions, Thus, if different, the polypeptide is typically substantially identical to the second polypeptide. Another indication that two nucleic acid sequences are substantially identical is the The ability of two molecules or their complements to hybridize to one another under stringent conditions. Yet another indication that two nucleic acid sequences are substantially identical is that the same primer One advantage of this is that sequences can be amplified using

[0107] The term "isolated antibody" refers to an antibody that is substantially free of other antibodies having different antigenic specificities. (e.g., an isolated antibody that specifically binds FXI and / or FXIa is (substantially free of antibodies that specifically bind to antigens other than XI and / or FXIa) However, isolated antibodies that specifically bind FXI and / or FXIa may not be specific to other antigens. Additionally, an isolated antibody may have cross-reactivity against other intracellular substances and / or chemicals. It may be substantially free of the substance.

[0108] The term "isotype" refers to the antibody class ( For example, IgM, IgE, IgG, such as IgG1 or IgG4. Also included are modified versions of one of these classes, the modifications conferring Fc function. Modify, e.g., to enhance or reduce effector function or binding to Fc receptors. It is applied to the sea.

[0109] As used herein, "K assoc " or "K a " The term "antibody" refers to a specific antibody-antibody As used herein, "K" is intended to refer to the association rate of molecular interactions. di s " or "K d The term "antibody-antigen interaction" refers to the off-rate of a particular antibody-antigen interaction. As used herein, "K D The term "K d K a Ratio to (i.e. Chi, K d / K a ) and is expressed as a molar concentration (M) Antibody K D Values ​​can be determined using methods well established in the art. Antibody K D Methods for determining the concentration of The surface plasmon resonance is measured using a sensor system or by solution equilibrium titration (SE T) measuring the affinity in solution.

[0110] As used herein, a "monoclonal antibody" or a "monoclonal antibody composition" refers to a The term refers to a preparation of antibody molecules of single molecular composition. Each antibody displays a single binding specificity and affinity for a particular epitope.

[0111] As used herein, the term "nucleic acid" is used interchangeably with the term "polynucleotide." Deoxyribonucleotides or ribonucleotides and their single-stranded or The term "nucleic acid" refers to a polymer of the well-known nucleotides. Nucleic acids containing analogs or modified backbone residues or modified linkages, including synthetic, naturally occurring A native nucleic acid, or a non-naturally occurring nucleic acid, that has similar binding properties to the reference nucleic acid and is Examples of such analogs include, but are not limited to, nucleic acids that are metabolized in a manner similar to leutidine. Specifically, phosphorothioates, phosphoramidates, methylphosphonates, chiral methyl These include arylphosphonates, 2-O-methylribonucleotides, and peptide nucleic acids (PNAs).

[0112] Unless otherwise indicated, a particular nucleic acid sequence also refers to conservatively modified versions thereof. Variants (e.g., degenerate codon substitutions) and complementary sequences are implicitly and explicitly included. In particular, as detailed below, degenerate codon substitutions include: The third position of one or more selected (or all) codons may contain mixed bases and / or This can be achieved by creating a sequence in which the nucleotides are replaced with deoxyinosine or deoxyinosine residues. (Batzer et al., Nucleic Acid Res. 19:5081, 1991; Ohtsuka et al., J. Biol. Chem. 260:2605 ~2608, 1985; and Rossolini et al., Mol. Cell. Probes 8:91-98, 1994).

[0113] The term "operably linked" refers to two or more polynucleotides (e.g., DNA A) refers to the functional relationship between the segments. The term "operably linked" refers to the functional relationship between the segments. Typically, the term refers to the functional relationship of a regulatory sequence to a sequence to be transcribed. The promoter or enhancer sequence may be selected so that it is suitable for use in an appropriate host cell or other expression system. operably linked to a coding sequence when the coding sequence stimulates or modulates transcription of the coding sequence in the Generally, a promoter transcriptional regulatory sequence operably linked to the sequence to be transcribed. The enhancer is physically adjacent to the transcribed sequence, i.e., it is cis-acting. Some transcriptional regulatory sequences, such as transcription factors, are physically attached to the coding sequences whose transcription they enhance. They do not have to be adjacent or closely spaced.

[0114] As used herein, the term "optimized" refers to a nucleotide sequence that is optimized for expression in a production cell. Or the production organism, generally a eukaryotic cell, for example a Pichia cell, a Chinese ha Amino acids were synthesized using preferred codons in mouse ovary cells (CHO) or human cells. Optimized nucleotide sequence means that the nucleic acid sequence is encoded by a modified nucleotide sequence. is the amino acid sequence originally encoded by the starting nucleotide sequence, also known as the "parent" sequence. The nucleic acid sequence is engineered to be preserved entirely, or as much as possible. The sequences have been engineered to have codons that are preferred in mammalian cells. However, the present invention also provides optimized versions of these sequences in other eukaryotic or prokaryotic cells. The amino acid sequence encoded by the optimized nucleotide sequence is also contemplated. It is also said to be optimized.

[0115] As used herein, the terms "polypeptide" and "protein" refer to a polypeptide consisting of a single amino acid residue. The terms "polypeptide" and "protein" are used interchangeably to refer to a polymer. The term cyclic amine refers to an amino acid sequence in which one or more amino acid residues are replaced by an artificial chemical equivalent of the corresponding naturally occurring amino acid. In addition to amino acid polymers that are functional mimetics, naturally occurring amino acid polymers and non-naturally occurring amino acid polymers are also included. Unless otherwise indicated, the term "polypeptide" refers to any amino acid polymer that is A peptide sequence also implicitly encompasses conservatively modified variants thereof.

[0116] As used herein, the term "recombinant human antibody" refers to an antibody that is engineered to contain human immunoglobulin genes. Animals (e.g., mice) that are transgenic or transchromosomal for or expressing an antibody, human antibody, isolated from the hybridoma prepared thereby. The antibody, composition, etc. isolated from a host cell transformed in such a manner, e.g., a transfectoma. Antibodies isolated from recombinant combinatorial human antibody libraries, and human immunoglobulins Other DNA sequences involving splicing of all or part of the purine gene sequence to other DNA sequences Antibodies, such as antibodies prepared, expressed, created, or isolated by any means. prepared, expressed, created, or isolated by recombinant means, e.g., This includes all human antibodies. Such recombinant human antibodies include the framework regions and CDRs. The domains have variable regions derived from human germline immunoglobulin sequences, except that In certain embodiments, such recombinant human antibodies are prepared by in vitro mutagenesis. (or in animals transgenic for human Ig sequences, In vivo somatic mutagenesis (SMM) and thus the VH of the recombinant antibody can be The amino acid sequences of the VH and VL domains are derived from human germline VH and VL sequences. These arise from and are related to, but not limited to, the germline repertoire of human antibodies in vivo. This is a sequence that may not occur in nature.

[0117] The term "recombinant host cell" (or simply, "host cell") refers to a cell that contains a recombinant expression vector. Such terms are intended to refer only to particular target cells. It is understood that the term is not intended to refer to the individual cells, but also to the progeny of such cells. In subsequent generations, certain modifications occur due to mutations or environmental influences. Therefore, such progeny cells may not in fact be identical to the parent cell. are also included within the scope of the term "host cell" as used herein.

[0118] The term "subject" includes human and non-human animals. Non-human animals include non-human primates. (e.g., cynomolgus monkeys), sheep, rabbits, dogs, cows, chickens, amphibians, and reptiles. This includes all vertebrates (e.g., mammals and non-mammals), including insects. Except where otherwise noted, the terms "patient" and "subject" are used interchangeably herein. As used in the specification, "cyno" or "cynomolgus" The term "cynomolgus monkey" refers to the cynomolgus monkey (Macaca fascicularis )). In a specific embodiment, the patient or subject is a human.

[0119] In one embodiment, any disease or disorder (e.g., thromboembolic disorders) as used herein. "Treating" or the term "treatment" refers to the modification of a disease or disorder. Improve (i.e., slow the onset of the disease or at least one of its clinical symptoms) In another embodiment, the term "treating" refers to "treating "Treatment" or "treatment" includes parameters that may not be discernible by the patient. It refers to mitigating or improving at least one physical parameter. In this context, "treating" or "treatment" refers to treating a disease or disorder by physically modifying it. The objective of the study was to either regulate (e.g., stabilize discernible symptoms) or physiologically modulate (e.g., (e.g., stabilization of physical parameters) or modulating both physical and physiological In yet another embodiment, "treating" or "treatment" refers to a disease or refers to preventing or delaying the onset or development or progression of a disorder.

[0120] "Prevention" in the context of the indications described herein, including, for example, thromboembolic disorders For example, the thromboembolic disease progression described below in patients at risk of such progression. By "prevention of or slowing the deterioration of a parameter" is meant any effect that prevents or slows the deterioration of a parameter.

[0121] The term "vector" refers to a molecule capable of transporting another polynucleotide to which it has been linked. A vector is intended to refer to a polynucleotide molecule capable of being expressed in a mammalian cell. The term "protease" refers to a circular double-stranded DNA loop into which a DNA segment consisting of Another type of vector is a plasmid, which is a vector that incorporates additional DNA segments into the viral genome. Adeno-associated viral vectors (AAV or AAV2) that can be ligated into the Which viral vectors? Certain vectors (e.g., bacterial vectors with a bacterial origin of replication) vectors and mammalian episomal vectors) in the host cell into which they are introduced. Other vectors (e.g., non-mammalian episomal vectors) are capable of autonomous replication. When introduced into a host cell, it can integrate into the genome of the host cell, thereby Moreover, certain vectors replicate together with the main genome. Such vectors are capable of directing the expression of genes. Generally, recombinant DNA vectors are referred to as recombinant expression vectors (or simply, "expression vectors"). Expression vectors useful in Method A are often in the form of plasmids. As these are the most commonly used forms of vectors, the terms "plasmid" and " The terms "transfected vector" and "transfected vector" can be used interchangeably. However, the present invention contemplates any vector that provides an equivalent function. Viral vectors (e.g., replication-defective retroviruses, adenoviruses, and adenoviruses) that It is intended to include other forms of expression vectors, such as vectors associated with viruses. [Brief description of the drawings]

[0122] [Figure 1-1] 1A-1C show the effect of NOV1401 on FeCl3-induced thrombosis in FXI- / - mice reconstituted with human FXI protein. NOV1401 inhibited thrombosis in a dose-dependent manner. The antibody prolonged the aPTT to the same extent as in untreated FXI- / - mice. [Figure 1-2] (As stated above.) [Diagram 2] 2A-2B show the effect of multiple intravenous (A; N=2) or subcutaneous (sc) (B; N=2) doses of NOV1401 at 3 mg / kg, 10 mg / kg, and 30 mg / kg on aPTT (diamonds) and their relationship to total plasma NOV1401 levels (squares) in cynomolgus monkeys. A single dose of 3 mg / kg approximately doubled the aPTT, which was maintained over 5-6 weeks. All doses tested prolonged the aPTT to a similar extent, and the higher doses tested did not appear to increase the magnitude of aPTT prolongation observed with the 3 mg / kg dose. [Diagram 3]3A-3B show the effect of multiple iv (A; N=2) or sc (B; N=2) doses of NOV1401 at 3 mg / kg, 10 mg / kg, and 30 mg / kg on plasma free FXI (squares) and the relationship to aPTT (diamonds) in cynomolgus monkeys. A single dose of 3 mg / kg reduced free FXI by approximately 90% over a 5-6 week period. All doses tested reduced free FXI to a similar extent, and the higher doses tested did not appear to increase the magnitude of reduction in free FXI observed at the 3 mg / kg dose. [Figure 4] 4A-4B show the X-ray structure of the Fab of the NOV1401 antibody of the invention bound to FXI. FIG. 4A shows the X-ray structure of the NOV1401 Fab-FXI CD complex. The FXI catalytic domain is shown as a grey surface and the Fab is shown as a light grey (light chain) and dark grey (heavy chain) ribbon. FIG. 4B shows the X-ray structure of the NOV1401 Fab-FXI CD complex superimposed with the zymogen FXI. The FXI catalytic domain is shown as a grey ribbon. The variable domains of the Fab are shown as light grey (VL) and dark grey (VH) ribbons. The zymogen structure containing the four apple domains is superimposed as a dark grey ribbon at the bottom of the structure (PDB 2F83). The activation cleavage site (Ile370) is indicated. [Diagram 5] Figures 5A-5B show the conformational changes of FXIa upon binding of NOV1401 Fab. Figure 5A shows a perspective view of the active site of FXIa before binding of the Fab. FXIa is represented as a ribbon with a transparent surface. Cross sections of the structure that change conformation upon binding of the Fab are labeled (loop 145, loop 188, and loop 220). The S1 and S1 subpockets are indicated. Figure 5B shows the inactive conformation of FXI within the Fab complex. (Fab not shown). [Figure 6-1]6A-6C show composite response curves for anti-FXI / FXIa antibodies. FIG. 6A shows inhibition of factor XIa activity by NOV1401. Representative composite response curve for NOV1401, an antibody that inhibits the enzymatic activity of full-length human FXIa. The assay measures cleavage of a fluorescently labeled peptide as described in Example 3. Nonlinear curve fitting with a logistic fit model [y=A2+(A1-A2) / (1+(x / IC50)p), where y is the % inhibition at inhibitor concentration x, A1 is the minimum inhibition value, and A2 is the maximum inhibition value. The exponent p is the Hill coefficient] is used on this representative data set, resulting in an IC50 value of 160 pM. FIG. 6B shows a composite response curve for aPTT. Representative composite response curve for prolongation of clotting time by antibody NOV1401 in an aPTT assay using pooled human plasma. The assay measures clotting time after initiating the intrinsic clotting cascade in the presence of different concentrations of NOV1401 as described in Example 4. The black line represents the fit using a logistic nonlinear fitting model. The dotted line represents the baseline clotting time of pooled human plasma in the absence of NOV1401. The baseline clotting time is 32.3 seconds and is indicated in the graph by the gray dashed line. The gray dotted line indicates the antibody concentration at which the clotting time doubles compared to the baseline, i.e., 2×aPTT value, which is 14 nM. Figure 6C shows the TGA response curve. A representative composite response curve for the inhibition of thrombin generation by antibody NOV1401 in TGA with pooled human plasma is shown. The assay, as described in Example 4, measures the effect of different concentrations of NOV1401 on thrombin generation that can be induced by very low concentrations of tissue factor (TF) via the so-called thrombin → FXIa feed-forward loop. The black line represents the fit using a four-parameter dose-response curve model. The dotted line represents the residual thrombin concentration resulting from thrombin generation induced by small amounts of TF. An IC50 value of 24 nM and a residual thrombin concentration of 159 nM (dotted line) were calculated for this composite response curve. [Figure 6-2] (As stated above.) [Figure 7-1] 7A-7B show the effect of NOV1401 administered sc at 10 mg / kg (N=3) and 100 mg / kg (N=5) weekly for 13 weeks (14 doses) or iv at 50 mg / kg (N=3) weekly for 4 weeks (5 doses) on aPTT and FXI activity (FXI:C). FIG. 7A shows the effect on aPTT measured on days 2, 23, and 79 of the study. aPTT was increased 2.1-3 fold in all animals receiving NOV1401 and remained elevated throughout the dosing phase of the study. No dose-dependency was observed, and no gender-related differences were noted. FIG. 7B shows the effect on FXI:C measured on days 2, 23, and 79 of the study, plotted as a percent of plasma FXI activity. FXI:C decreased to levels between 5-12% in all animals receiving NOV1401 and remained at these levels throughout the dosing phase of the study. No dose-dependency was observed, and no sex-related differences were noted. [Figure 7-2] (As stated above.)

[0123] Detailed Description The present invention relates, in part, to antibody molecules that specifically bind to FXIa and inhibit its biological activity. The present invention is based on the discovery of the present invention, which provides full-length IgG format antibodies, as well as Fab fragments (e.g. For example, antibodies NOV1090 and NOV1401, as well as antigen-binding fragments thereof. do.

[0124] Thus, the present invention relates to FXI and / or FXIa (e.g., human, rabbit, and and an antibody that specifically binds to FXI and / or FXIa in cynomolgus monkeys, and a pharmaceutical composition Also provided are methods of making and using such antibodies and compositions.

[0125] Factor XI FXI is involved in both the intrinsic and extrinsic coagulation pathways, as well as in plasma-mediated It plays an important role in bridging the initiation and amplification phases of hemostasis. Both thrombin and FXI activate FXI, resulting in sustained thrombin generation and FXI may result in the inhibition of fibrinolysis and fibrinolysis in a tissue factor-rich environment after vascular injury. Although it plays a minor role in normal hemostasis, it is thought to play a key role in thrombosis. Severe factor XI deficiency is associated with a reduced incidence of ischemic stroke and venous thromboembolic events. (Salomon et al 2008; Salomon, et al. (2011) Thromb Haemost.; 105:269- 73) Bleeding episodes in subjects with severe factor XI deficiency are infrequent, mild, and It is often injury-induced, with increased fibrinolytic activity in the oral and nasal mucosa, and in the urinary tract. It is preferable for the affected tissue to be affected (Salomon et al. 2011). Hemorrhage in vital organs is , is extremely rare or not recognized.

[0126] Plasma coagulation is a sequential process in which coagulation factors in the blood interact and activate, ultimately resulting in Ultimately, this results in the production of fibrin and the formation of a blood clot. In the card model, the process of fibrin generation follows two distinct pathways: the intrinsic pathway and the It can be initiated by both the intrinsic and extrinsic pathways (Mackman, 2008).

[0127] In the extrinsic pathway, vascular injury induces the activation of extravascular tissue factor (TF) and factor VII (FVII). and activates factor X and prothrombin, Activated thrombin finally converts soluble fibrinogen into fibrinogen. The extrinsic pathway is central to hemostasis and has interactions with the clotting factors in this pathway. Interference results in a risk of bleeding.

[0128] In the intrinsic pathway, factor XII can sometimes be activated by a process called contact activation. The generation of activated factor XIIa is the result of the sequential activation of factors XI and IX. Factor IXa activates factor X, which leads to the extrinsic pathway and the intrinsic pathway. The two pathways merge at this stage (common pathway). Thrombin activation is initiated by thrombin catalyzing factor XI. This occurs via a feed-forward loop that activates the factor XII-independent This feedforward loop is boosted by amplifying its own production. Contributes to persistent thrombus growth but requires strong activation by extravascular tissue factor for clot formation Therefore, the intrinsic pathway plays a minimal role in hemostasis. There is virtually no involvement of blood (Gailani and Renne (2007) Arterioscler Thromb Vasc Biol 2007, 27(12):2507-13, Muller, Gailiani, and Renne 2011).

[0129] Preclinical studies to inhibit FXI or FXIa across a range of species using a variety of approaches FXI- / - mice are resistant to experimental venous thrombosis (Wa ng, et al. (2006) J Thromb Haemost; 4:1982-8) and arterial thrombosis (Wang, et al. (20 05) J Thromb Haemost; 3:695-702) is resistant to FXI. Treatment of mice with an activation-blocking antibody (Ab; 14E11) reduced the incidence of experimental thrombosis. (Cheng, et al. (2010) Blood, 116:3981-9), resulting in ischemic stroke. Reduced cerebral infarct size in a mouse model of cerebral infarction (Leung, et al. (2012) Transl Stroke Res 2012; 3:381-9). Anti-FXI blocks the binding and activation of FIX by FXIa. In baboons administered Ab, on collagen-coated vascular grafts, A reduction in platelet-rich thrombus growth was observed (Tucker, et al. (2009) Blood 2009; 113:93 6-44), and similar results were found with 14E11 in this model (Cheng 2010). No excessive bleeding was noted in any of these studies.

[0130] Mice (Zhang, et al. (2010) Blood 2010; 116:4684-92), cynomolgus monkeys (Younis, et al. (2012) Blood 2012; 119:2401-8), and baboons (Crosby, et al. (2013) Arteri In oscler Thromb Vasc Biol 2013; 33:1670-8), antisense oligonucleotides were used. Blocking FXI synthesis by thrombolytic therapy has been shown to have antithrombotic and anticoagulant effects without excessive bleeding. Furthermore, in rats (Schumacher, et al. (2007) Eur J Pharmacol 2007; 570:167-74) and rabbits (Wong, et al. (2011) J Thromb Thromboly sis 2011; 32:129-37) in venous and arterial thrombosis models, Blocking FXIa with an inhibitor produced a similar effect.

[0131] Patients with severe FXI deficiency rarely bleed spontaneously and have high fibrinolytic activity. The patient is only prone to mild trauma-induced bleeding, except in certain tissues. The nature of the disease will require population studies to characterize the thrombotic profile of these patients compared with the general population. In particular, such studies will necessitate the use of ischemic stroke in these patients. (Salomon 2008) and deep vein thrombosis (DVT) (Salomon, et al. (2011) Blood 200 8; 111: 4113-17) is reported to reduce the incidence of severe FXI. The number of ischemic strokes observed in 115 patients with deficiency (N=1) was The incidence rate was lower than expected in the general population (N=8.6) (p<0.003). The incidence of DVT in patients with severe FXI deficiency (N=0) was 10.1% compared with the control population. The number of cases was less than the expected number (N=4.7) for FXI (p<0.019). Individuals with a BEL above the 90th percentile had twice the risk of developing DVT (Meijer (2000) N Engl J Med. 2000; 342:696-701).

[0132] Recently, patients undergoing total knee arthroplasty, a procedure that predisposes to DVT, have been screened using FXI angiography. Patients were treated with either antisense or standard treatment (enoxaparin). g) a seven-fold reduction in the incidence of venous thrombosis and fewer bleeding events compared to standard care (non-significant) (Buller et al, (2014) N Engl J Med. 372(3):232-40. do i: 10.1056 / NEJMoa1405760. Epub 2014 Dec 7).

[0133] Taken together, the above studies strongly support FXI as a valid target for antithrombotic therapy.

[0134] FXIa antibodies and antigen-binding fragments The present invention provides antibodies that specifically bind to FXI and / or FXIa. In some embodiments, the present invention provides human, rabbit, and cynomolgus monkey FXI and / or The antibody of the present invention specifically binds to FXIa or FXIa. Human monoclonal antibodies and Fabs isolated as described herein include, but are not limited to, stomach.

[0135] The present invention relates to FXI and / or FXIa proteins (e.g., human, mouse, Antibodies that specifically bind to FXI and / or FXIa in herons and cynomolgus monkeys The antibody comprises a VH domain having the amino acid sequence of SEQ ID NO: 9 and SEQ ID NO: 29. The present invention also relates to a method for the production of antibodies that specifically bind to FXI protein and / or FXIa protein. and an antibody that binds to any one of the VH CDRs listed in Table 1 below. In particular, the present invention provides an antibody comprising a VH CDR having the sequence of and / or FXIa protein (e.g., human, rabbit, and cynomolgus monkey FXIa protein). XI and / or FXIa), which are listed in Table 1 below. One, two, three or more VH CDRs having any of the amino acid sequences of the VH CDRs Antibodies comprising (or, alternatively, consisting of) the CDRs are provided.

[0136] The present invention relates to an antibody that specifically binds to FXIa protein, comprising SEQ ID NO: 19 or The present invention also provides an antibody comprising a VL domain having an amino acid sequence of 39. protein and / or FXIa protein (e.g., human, rabbit, and cynomolgus An antibody that specifically binds to monkey FXI and / or FXIa, The present invention relates to a method for producing a VL CDR having an amino acid sequence of any one of the VL CDRs listed in the above. In particular, the present invention provides antibodies against FXIa proteins (e.g., human, rabbit, and and cynomolgus monkey FXI and / or FXIa), comprising 1, 2 or 3 having the amino acid sequence of any of the VL CDRs listed in Table 1 below. and providing an antibody comprising (or, alternatively, consisting of) three or more VL CDRs. do.

[0137] Other antibodies of the invention are mutated but still contain the amino acids listed in Table 1 within the CDR regions. The CDR regions depicted in the sequence shown and at least 60, 70, 80, 85, 90, or In some embodiments, the present invention comprises an amino acid sequence having 95 percent identity to a Other antibodies of the present invention have, within the CDR regions, the CDR regions depicted within the sequences set forth in Table 1. In comparison, one, two, three, four, or five or fewer amino acids were mutated. The amino acid sequence of the variant is included.

[0138] The present invention also relates to FXI and / or FXIa proteins (e.g., human, The VH, VL and full-length heavy chains of antibodies that specifically bind to rabbit and cynomolgus monkey FXIa Nucleic acid sequences encoding the full length light chain and the full length light chain are also provided. The expression of the antibodies of the present invention can be optimized in cells (e.g., Table 1 shows the weight of the antibodies of the present invention). Optimized nucleic acid sequences for the light and dark chains are shown.

[0139] [Table 1-1]

[0140] [Table 1-2]

[0141] [Table 1-3]

[0142] [Table 1-4]

[0143] [Table 1-5]

[0144] [Table 1-6]

[0145] Other antibodies of the invention have mutated amino acids or nucleic acids encoding amino acids. However, the sequences listed in Table 1 may be at least 60, 65, 70, 75, 80, 85, Some embodiments include antibodies having 90, 90, or 95 percent identity to the variable Within the region, a sequence depicted within the sequence set forth in Table 1 may be used while retaining substantially the same antigen binding activity. No more than one, two, three, four, or five amino acids when compared to the indicated variable region. The amino acid sequence of the mutant is mutated.

[0146] Each of these antibodies can bind to FXI and / or FXIa and therefore has the VH sequence , VL sequence, full-length light chain sequence, and full-length heavy chain sequence (amino acid sequence and coding amino acid sequence) and "mix and match" the nucleotide sequences (with the corresponding nucleotide sequences) to produce other FXI binding antibodies of the present invention. Such "mixed, "Matched" FXI-binding antibodies and / or FXIa-binding antibodies are known in the art. Using known binding assays (e.g., ELISA and other assays described in the Examples section), When these chains are mixed and matched, a particular VH / V The VH sequence derived from the L pairing is replaced with a structurally similar VH sequence. The full-length heavy chain sequence derived from a particular full-length heavy chain / full-length light chain pairing is then compared with a structurally similar full-length heavy chain sequence. Similarly, the VL sequence derived from a particular VH / VL pairing is A structurally similar VL sequence should be substituted. Similarly, a particular full-length heavy chain / full-length light chain The full-length light chain sequence derived from the pairing is replaced with a structurally similar full-length light chain sequence. .

[0147] Thus, in one aspect, the present invention relates to a method for the preparation of a nucleic acid sequence comprising the steps of: A heavy chain variable domain comprising the amino acid sequence SEQ ID NO: 19 and SEQ ID NO: 39. Isolated antibody having a light chain variable domain comprising a selected amino acid sequence or its antigen-binding activity In this case, the antibody is provided with a region that is specific for FXI and / or FXIa (e.g., human, mouse, It specifically binds to FXIa in humans (herons, egrets, and cynomolgus monkeys).

[0148] More specifically, in certain embodiments, the present invention provides SEQ ID NOs: 9 and 29; or 19 and and 39. A heavy chain variable domain and a light chain variable domain comprising an amino acid sequence selected from The present invention provides an isolated antibody or antigen-binding region thereof having a polypeptide comprising the polypeptide chain of interest.

[0149] In a specific embodiment, the present invention provides a method for the preparation of a method for the preparation of a human FXI antibody that specifically binds to human FXI and / or FXIa. The antibody or antigen-binding fragment thereof provided herein comprises the amino acid sequence of SEQ ID NO:9. It comprises a heavy chain variable region and a light chain variable region comprising the amino acid sequence of SEQ ID NO:19.

[0150] In a specific embodiment, the present invention provides a method for the preparation of a method for the preparation of a human FXI antibody that specifically binds to human FXI and / or FXIa. The antibody or antigen-binding fragment thereof provided herein comprises the amino acid sequence of SEQ ID NO:29. and a light chain variable region comprising the amino acid sequence of SEQ ID NO:39.

[0151] In another aspect, the present invention provides an amine analog optimized for expression in mammalian cells. The amino acid sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 11 or 31. The heavy chain is a full-length heavy chain containing the ribozyme A (RI) and an amino acid sequence optimized for expression in mammalian cells. and obtaining a full-length light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 21 or 41. or (ii) a functional protein comprising an antigen-binding portion thereof. More specifically, in certain embodiments, the present invention provides SEQ ID NOs: 11 and 31; or 19 and and 39, respectively. or an antigen-binding region thereof.

[0152] In a specific embodiment, the present invention provides a method for the preparation of a method for the preparation of a human FXI antibody that specifically binds to human FXI and / or FXIa. The antibody or antigen-binding fragment thereof provided herein comprises the amino acid sequence of SEQ ID NO:11. and a light chain comprising the amino acid sequence of SEQ ID NO:21.

[0153] In a specific embodiment, the present invention provides a method for the preparation of a method for the preparation of a human FXI antibody that specifically binds to human FXI and / or FXIa. The antibody or antigen-binding fragment thereof provided herein comprises the amino acid sequence of SEQ ID NO:31. and a light chain variable region comprising the amino acid sequence of SEQ ID NO:41.

[0154] As used herein, the terms "complementarity determining region" and "CDR" refer to a region that determines antigen specificity. and refers to the sequence of amino acids within the antibody variable region that confers antigen-binding affinity. Generally, there are three CDRs in each heavy chain variable region (HCDR1, HCDR2, HCDR3). Each light chain variable region (LCDR1, LCDR2, LCDR3) contains three CDRs. be.

[0155] The exact amino acid sequence boundaries of a given CDR can be determined by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National In Institutes of Health, Bethesda, MD ("Kabat" numbering scheme), Al-Lazikani et al., (1997) JMB 273, 927-948 ("Chothia" numbering scheme), Lefranc e t al., (2003) Dev. Comp. Immunol., 27, 55-77 ("IMGT" numbering scheme) Many schemes are known, including those described in, or "combined" systems. You can easily decide which one to use.

[0156] For example, according to Kabat, the antibody NOV109 The CDR amino acid residues of 0 are 31-35 (HCDR1), 50-66 (HCDR2), and and 99 to 111 (HCDR3), which are located in the light chain variable domain (VL). The CDR amino acid residues are 22 to 35 (LCDR1), 51 to 57 (LCDR2), and According to Chothia, the VH The CDR amino acids are 26-32 (HCDR1), 52-57 (HCDR2), and 99 ~111 (HCDR3), and the amino acid residues in VL are numbered 25 to 33 ( Numbered as LCDR1), 51-53 (LCDR2), and 92-99 (LCDR3) By combining both Kabat and Chothia CDR definitions, Therefore, the CDRs are the amino acid residues 26 to 35 (HCDR1), 50 to 66 (H CDR2), and 99-111 (HCDR3), and amino acid residues 2 in human VL 2-35 (LCDR1), 51-57 (LCDR2), and 90-100 (LCDR3 By combining both the Kabat and Chothia CDR definitions, Therefore, the "combined" CDRs are amino acid residues 26-35 (HCDR1), 50 ~66 (HCDR2), and 99–108 (HCDR3), as well as amines in human VL The acid residues 24-38 (LCDR1), 54-60 (LCDR2), and 93-101 ( As another example, according to IMGT, The CDR amino acid residues are 26-33 (HCDR1), 51-58 (HCDR2), and and 97–108 (HCDR3), which are located in the light chain variable domain (VL). The DR amino acid residues are 27-36 (LCDR1), 54-56 (LCDR2), and 9 Table 1 shows anti-FXI / FXIa antibodies, e.g. For example, for NOV1090 and NOV1401, Kabat, Chothia, Exemplary HCDR1, HCDR2, HCDR3, LCDR by combination and IMGT In another embodiment, the present invention provides a method for the preparation of a medicament for the treatment of a pulmonary artery disease comprising administering to a patient a therapeutically effective amount of a medicament for the treatment of a pulmonary artery disease, ... The heavy and light chain CDR1, CDR2, and CDR3, or a combination thereof, The amino acid sequence of the VH CDR1 of the antibody is represented by the sequence The amino acid sequences of the VH CDR2 of the antibody are shown in SEQ ID NOs: 4 and 23. The amino acid sequence of the VH CDR3 of the antibody is shown in SEQ ID NO:5 and SEQ ID NO:25. The amino acid sequences of the VL CDR1 of the antibody are shown in SEQ ID NOs: 13 and 33. The amino acid sequences of the VL CDR2 of the antibody are shown in SEQ ID NOs: 14 and 34. The amino acid sequences of the VL CDR3 of the antibody are shown in SEQ ID NOs: 15 and 35. These CDR regions are represented using the Kabat system.

[0157] Alternatively, the Chothia system (Al-Lazikani et al., (1997), JMB 273 927-948) The amino acid sequence of the VH CDR1 of the antibody is SEQ ID NO:6, as defined using the The amino acid sequence of the VH CDR2 of the antibody is shown in SEQ ID NO: 7 and SEQ ID NO: 27. The amino acid sequences of the VH CDR3 of the antibody are shown in SEQ ID NOs: 8 and 28. The amino acid sequences of the VL CDR1 of the antibody are shown in SEQ ID NOs: 16 and 36. The amino acid sequences of the VL CDR2 of the antibodies are shown in SEQ ID NOs: 17 and 37. The amino acid sequences of the VL CDR3 of the antibodies are shown in SEQ ID NOs:18 and 38.

[0158] Alternatively, the amino acid sequence of the VH CDR1 of the antibody may be determined using a combination system. The amino acid sequence of the VH CDR2 of the antibody is shown in SEQ ID NO: 46. The amino acid sequence of the VH CDR3 of the antibody is shown in SEQ ID NO:5. The amino acid sequence of the VL CDR1 of the antibody is shown in SEQ ID NO: 33. The amino acid sequence of the VL CDR2 is shown in SEQ ID NO: 14. The amino acid sequence is shown in SEQ ID NO:15.

[0159] Alternatively, the VH CDRs of an antibody as defined using the IMGT numbering scheme The amino acid sequence of antibody VH CDR2 is shown in SEQ ID NO: 43. The sequence is shown in SEQ ID NO: 44. The amino acid sequence of the VH CDR3 of the antibody is shown in SEQ ID NO: The amino acid sequence of the VL CDR1 of the antibody is shown in SEQ ID NO:47. The amino acid sequence of the VL CDR2 of the antibody is shown in SEQ ID NO: 37. The amino acid sequence of the L CDR3 is shown in SEQ ID NO:15.

[0160] Each of these antibodies is capable of binding to FXI and / or FXIa. The antigen-binding specificity is mainly determined by the CDR1, CDR2, and CDR3 regions. Given that each antibody is a FXI-binding molecule of the present invention, it is possible to use the FXI-binding molecule of the present invention in combination with other FXI-binding molecules and / or To create an FXIa binding molecule, VH CDR1, VH CDR2, and VH CDR3 are and VL CDR1, VL CDR2, and VL CDR3. and preferably, VH CDR1 sequence, VH CDR2 sequence, and VH CDR3 sequence and the VL CDR1 sequence, the VL CDR2 sequence, and the VL CDR3 sequence are referred to as " It is possible to "mix and match" (i.e., to mix and match CDRs from different antibodies) Such "mixed and matched" FXI-binding molecules The antibody and / or FXIa-binding antibody may be assayed using binding assays and procedures known in the art. Binding assays described in the Examples (e.g., ELISA, SET, BIACORE™ assays) When VH CDR sequences are mixed and matched, The CDR1, CDR2, and / or CDR3 sequences derived from a particular VH sequence are The VL CDR sequence is replaced with a structurally similar CDR sequence. When mixing and matching, the CDR1 and CDR2 sequences derived from a particular VL sequence are and / or CDR3 sequences are replaced with structurally similar CDR sequences. Those skilled in the art can easily derive novel VH and VL sequences by combining one or more VH CDR region sequences. The VL CDR region sequences are preferably selected from the group consisting of nucleotides, nucleotides, and / or VL CDR region sequences for the monoclonal antibodies of the present invention. Created by substituting structurally similar sequences derived from the CDR sequences shown in the subtitles. In addition to the above, in one embodiment, the The antigen-binding fragment of the antibody to be described comprises VH CDR1, VH CDR2, and VH CDR3. 3, or VL CDR1, VL CDR2, and VL CDR3. In this case, the fragment comprises a single variable domain in FXI and / or FXIa. and combine.

[0161] In certain embodiments of the invention, the antibodies or antigen-binding fragments thereof are those set forth in Table 1. More specifically, the antibody or its antigen may have the heavy and light chain sequences of Fab. The binding fragments can have the heavy and light chain sequences of NOV1090 and NOV1401.

[0162] In another embodiment of the invention, an antibody that specifically binds to FXI and / or FXIa Alternatively, the antigen-binding fragment may comprise a heavy chain variable fragment as defined by Kabat and set forth in Table 1. CDR1 of the heavy chain variable region, CDR2 of the heavy chain variable region, CDR3 of the light chain variable region The present invention further comprises CDR1, CDR2 of the light chain variable region, and CDR3 of the light chain variable region. In another embodiment, an antibody or antigen that specifically binds to FXI and / or FXIa is The binding fragments are those comprising the heavy chain variable region as defined by Chothia and listed in Table 1. CDR1 of the heavy chain variable region, CDR2 of the heavy chain variable region, CDR3 of the light chain variable region R1, CDR2 of the light chain variable region, and CDR3 of the light chain variable region. The antibodies or antigen-binding fragments that specifically bind to FXI and / or FXIa are The CDR1 of the heavy chain variable region is defined by the matching system and is listed in Table 1. CDR2 of the heavy chain variable region, CDR3 of the heavy chain variable region, CDR1 of the light chain variable region, In yet another embodiment of the present invention, the CDR2 of the light chain variable region and the CDR3 of the light chain variable region are included. Antibodies or antigen-binding fragments that specifically bind to FXI and / or FXIa are available from IM CDR1 of the heavy chain variable region defined by GT and listed in Table 1, CDR2 of the heavy chain variable region, CDR3 of the light chain variable region, CDR1 of the light chain variable region, R2, and CDR3 of the light chain variable region.

[0163] In a specific embodiment, the present invention provides antibodies that specifically bind to FXI and / or FXIa. An antibody comprising: CDR1 of a heavy chain variable region of SEQ ID NO: 3; CDR2 of a heavy chain variable region of SEQ ID NO: 4 R2; CDR3 of the heavy chain variable region of SEQ ID NO:5; CDR1 of the light chain variable region of SEQ ID NO:13; CDR2 of the light chain variable region of SEQ ID NO: 14; and CDR3 of the light chain variable region of SEQ ID NO: 15 The antibody comprises

[0164] In a specific embodiment, the present invention provides antibodies that specifically bind to FXI and / or FXIa. an antibody having a CDR1 of a heavy chain variable region of SEQ ID NO: 23, a heavy chain variable region of SEQ ID NO: 24, CDR2 of the heavy chain variable region of SEQ ID NO: 25; CDR3 of the light chain variable region of SEQ ID NO: 33 DR1, CDR2 of the light chain variable region of SEQ ID NO: 34, and CDR3 of the light chain variable region of SEQ ID NO: 35 Includes antibodies that contain CDR3.

[0165] In a specific embodiment, the present invention provides antibodies that specifically bind to FXI and / or FXIa. an antibody having a CDR1 of a heavy chain variable region of SEQ ID NO: 6, a CDR2 of a heavy chain variable region of SEQ ID NO: 7, DR2, CDR3 of the heavy chain variable region of SEQ ID NO: 8, CDR1 of the light chain variable region of SEQ ID NO: 16 , CDR2 of the light chain variable region of SEQ ID NO: 17, and CDR3 of the light chain variable region of SEQ ID NO: 18 3, including antibodies.

[0166] In a specific embodiment, the present invention provides antibodies that specifically bind to FXI and / or FXIa. an antibody having a CDR1 of a heavy chain variable region of SEQ ID NO: 26, a heavy chain variable region of SEQ ID NO: 27, CDR2 of the heavy chain variable region of SEQ ID NO: 28; CDR3 of the light chain variable region of SEQ ID NO: 36 DR1, CDR2 of the light chain variable region of SEQ ID NO: 37, and CDR3 of the light chain variable region of SEQ ID NO: 38 Includes antibodies that contain CDR3.

[0167] In specific embodiments herein, the compound specifically binds to FXI and / or FXIa. An antibody comprising: CDR1 of the heavy chain variable region of SEQ ID NO: 43; CDR2; CDR3 of the heavy chain variable region of SEQ ID NO: 45; CDR4 of the light chain variable region of SEQ ID NO: 47 R1; CDR2 of the light chain variable region of SEQ ID NO: 37; and CDR3 of the light chain variable region of SEQ ID NO: 15 Antibodies comprising DR3 are presented.

[0168] In specific embodiments herein, the compound specifically binds to FXI and / or FXIa. An antibody comprising: CDR1 of the heavy chain variable region of SEQ ID NO: 46; DR2; CDR3 of the heavy chain variable region of SEQ ID NO:5; CDR1 of the light chain variable region of SEQ ID NO:33 14; and the CDR2 of the light chain variable region of SEQ ID NO: 15. 3 is presented.

[0169] In certain embodiments, the present invention provides a method for the treatment of a pulmonary fibrosis (PF) comprising administering to a subject an antibody or antibody fragment thereof, ... an antibody or antibody fragment thereof, to a subject an antibody or antibody fragment thereof, In a preferred embodiment, the antibody or antigen-binding fragment specifically binds to FXIa. Antibodies or antigen-binding fragments that bind to FXIa and / or FXIa include NOV1090 and and NOV1401.

[0170] The variable region or full-length chain of the antibody uses human germline immunoglobulin genes As used herein, a human antibody refers to a "producer" of a particular germline sequence when derived from a human lineage. A heavy or light chain variable region or a full-length heavy or light chain variable region that is or is derived from Such a system includes transgenic mice carrying human immunoglobulin genes. A mouse model is immunized with an antigen of interest or displayed on a phage with the antigen of interest. The method includes screening a library of human immunoglobulin genes that are Human antibodies that are "the product of" or "derived from" immunoglobulin sequences of cell lines The amino acid sequence of the human antibody is compared to the amino acid sequence of human germline immunoglobulins. The human germline sequence that is most similar to the sequence of the human antibody (i.e., has the highest percent identity) By selecting immunoglobulin sequences of cell lineages, they can be identified as such. do.

[0171] "Product of" or "derived from" a specific human germline immunoglobulin sequence Human antibodies that are "human" include antibodies that have been engineered to be human, e.g., naturally occurring somatic mutations or site-specific mutations. The sequence may contain amino acid differences compared to the germline sequence due to the introduction of a different sequence. In the VH framework region or the VL framework region, the selected human antibody has The amino acid sequence is an amino acid sequence encoded by a human germline immunoglobulin gene. The sequences are at least 90% identical to those of the germline immunoglobulins of other species, making it possible to synthesize human antibodies. Identified as human when compared to a human amino acid sequence (e.g., mouse germline sequence) Typically, human antibodies contain amino acid residues that correspond to the amino acid sequence of the target protein. the amino acid sequence is an amino acid sequence encoded by a germline immunoglobulin gene, At least 60%, 70%, 80%, 90%, or at least 95%, or even less It may be at least 96%, 97%, 98%, or 99% identical.

[0172] Recombinant human antibodies may contain human amino acids within the VH or VL framework regions. A 10 amino acid sequence identical to the amino acid sequence encoded by the germline immunoglobulin gene. Typically, human antibodies exhibit the following differences: The amino acid sequence encoded by the immunoglobulin gene of the same series is 5 amino acids or less. Alternatively, they may display no more than 4, 3, 2, or 1 amino acid difference. Examples of immunoglobulin genes include the germline variable domain fragments described below, as well as , DP47 and DPK9.

[0173] homologous antibody In yet another embodiment, the present invention relates to a method for the preparation of a nucleic acid sequence comprising the steps of: 9, 31, 39, or 41) The antibodies provide fragments of FXI and / or FXIa proteins (e.g., For example, human FXIa, rabbit FXIa, and cynomolgus FXIa) and NOV1 The antibodies described in Table 1, such as 090 and NOV1401, retain the desired functional properties. In a specific embodiment, such a homologous antibody has the CDR amino acid sequence listed in Table 1. Acid sequences (e.g., Kabat CDR, Chothia CDR, IMGT CDR, or or combination CDR).

[0174] For example, the present invention provides an isolated antibody or antibody fragment thereof comprising a heavy chain variable domain and a light chain variable domain. wherein the heavy chain variable domain is selected from the group consisting of SEQ ID NO: 9 and 29, and at least 80%, at least 90%, or an amino acid sequence at least 95% identical; the light chain variable domain comprises an amino acid sequence of SEQ ID NO: 19 and 39, and at least 80%, at least 9 0%, or at least 95% identical amino acid sequence to FXI; to FXIa (e.g., human FXIa, rabbit FXIa, and cynomolgus FXIa) In one embodiment, the isolated antibody or functional antigen-binding fragment thereof specifically binds to The heavy chain variable domain comprises a light chain variable domain and a light chain variable domain, in which the heavy chain variable domain is 9 and at least 80%, at least 90%, or at least 95% the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 19 and at least one comprises an amino acid sequence that is at least 80%, at least 90%, or at least 95% identical; The antibody may be an antibody against FXI and / or FXIa (e.g., human FXIa, rabbit FXIa, and In one embodiment, the isolated antibody or its function is A capable antigen-binding fragment comprises a heavy chain variable domain and a light chain variable domain, where The heavy chain variable domain has at least 80%, at least 90%, or 0%, or at least 95% identical amino acid sequence; the light chain variable domain comprises No. 39 and at least 80%, at least 90%, or at least 95% identical % identical amino acid sequence; the antibody may be FXI and / or FXIa (e.g., human F The antibodies of the present invention specifically bind to the antibodies XIa, rabbit FXIa, and cynomolgus monkey FXIa. In certain embodiments, the heavy and light chain sequences are HCDR1 sequences as defined by Kabat. row, HCDR2 sequence, HCDR3 sequence, LCDR1 sequence, LCDR2 sequence, and LCD R3 sequences, e.g., SEQ ID NOs: 3, 4, 5, 13, 14, and 15, respectively. In certain other embodiments of the invention, the heavy and light chain sequences are Defined, HCDR1 sequence, HCDR2 sequence, HCDR3 sequence, LCDR1 sequence, LC DR2 sequences, and LCDR3 sequences, e.g., SEQ ID NOs: 6, 7, 8, 16, 1 In certain other embodiments, the heavy and light chain sequences are The HCDR1 sequence, HCDR2 sequence, HCDR3 sequence, and LC DR1, LCDR2, and LCDR3 sequences, e.g., SEQ ID NO: 46, respectively. In certain other embodiments, the heavy chain sequences and The light chain sequence is a sequence of HCDR1, HCDR2, HCDR3, HCDR4, HCDR5, HCDR6, HCDR7, HCDR8, HCDR9, HCDR10, HCDR11, HCDR12, HCDR13, HCDR14, HCDR15, HCDR16, HCDR17, HCDR18, HCDR19, HCDR111, HCDR192, 3 sequence, LCDR1 sequence, LCDR2 sequence, and LCDR3 sequence, for example Further including SEQ ID NOs: 43, 44, 45, 47, 37, and 15.

[0175] In other embodiments, the VH amino acid sequence and / or the VL amino acid sequence are selected from the group consisting of those shown in Table 1. Sequences that are 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, and 98% %, or 99% identical. In other embodiments, the VH amino acid sequence and / or The VL amino acid sequence may include amino acids at no more than 1, 2, 3, 4, or 5 amino acid positions. The VH and VL regions of the antibodies listed in Table 1 may be identical except for amino acid substitutions. Antibodies having VH and VL regions with high (i.e., 80% or more) identity are , SEQ ID NO: 10 or 30, and nucleic acids encoding SEQ ID NO: 20 and 40, respectively. Mutagenesis of the molecule (e.g., site-directed mutagenesis or PCR-mediated mutagenesis) The encoded modified antibodies are then assayed for functionality using the functional assays described herein. This can be obtained by examining retention.

[0176] In another embodiment, the full length heavy chain amino acid sequence and / or the full length light chain amino acid sequence are 1 and (e.g., SEQ ID NOs: 11 and / or 21, or 31 and / or Or 41), 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical. The full length of either SEQ ID NO: 11 or 31 heavy chain, and a full-length light chain of either SEQ ID NO:21 or SEQ ID NO:41 and a large (i.e. Antibodies having full-length heavy chains and full-length light chains with identical (80% or more) sequences to such polypeptides are Mutagenesis of a nucleic acid molecule encoding a peptide (e.g., site-directed mutagenesis or PCR-mediated mutagenesis) and functional assays as described herein were used to identify the coding region. The modified antibodies can be tested for retention of function.

[0177] In one aspect of the present specification, an isolated antibody comprising a heavy chain and a light chain or a functional antigen-binding domain thereof is provided. In one embodiment, the heavy chain is an amino acid sequence selected from the group consisting of SEQ ID NOs: 11 and 31. amino acid sequence at least 80%, at least 90%, or at least 95% identical to the amino acid sequence the light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 21 and 41; Amino acids that are at least 80%, at least 90%, or at least 95% identical to the sequence The antibody comprises a sequence encoding FXI and / or FXIa (e.g., human FXIa, rabbit F In one embodiment, the isolated antibody specifically binds to cynomolgus FXIa, XIa, and cynomolgus FXIa. or a functional antigen-binding fragment thereof, comprising a heavy chain and a light chain, wherein the heavy chain has the sequence 11 and at least 80%, at least 90%, or at least 9 the light chain comprises an amino acid sequence having at least 8.5% identity with the amino acid sequence of SEQ ID NO:21; 0%, at least 90%, or at least 95% identical amino acid sequence to FXI and / or FXIa (e.g., human FXIa, rabbit FXIa, and cyno In one embodiment, the isolated antibody or a functional antibody thereof specifically binds to human ovarian FXIa. The original binding fragment comprises a heavy chain and a light chain, wherein the heavy chain has the amino acid sequence of SEQ ID NO:31. amino acid sequence at least 80%, at least 90%, or at least 95% identical to the sequence the light chain comprises at least 80%, at least 90%, %, or at least 95% identical amino acid sequence to FXI; Specific for FXIa (e.g., human FXIa, rabbit FXIa, and cynomolgus FXIa) In certain embodiments of the invention, the heavy and light chain sequences are HCDR1 sequence, HCDR2 sequence, HCDR3 sequence, LCDR1 sequence, LCDR2 sequences, and LCDR3 sequences, e.g., SEQ ID NOs: 3, 4, 5, 13, respectively In certain other embodiments of the invention, the heavy chain sequences and the light chain sequences The sequences are the HCDR1 sequence, the HCDR2 sequence, the HCDR3 sequence, and the HCDR4 sequence as defined by Chothia. 3 sequence, LCDR1 sequence, LCDR2 sequence, and LCDR3 sequence, for example Further included are SEQ ID NOs: 6, 7, 8, 16, 17, and 18. In certain other embodiments, The chain and light chain sequences are defined by the combinatorial system. 2 sequence, HCDR3 sequence, LCDR1 sequence, LCDR2 sequence, and LCDR3 sequence, e.g. For example, further include SEQ ID NOs: 46, 4, 5, 33, 14, and 15, respectively. In another embodiment, the heavy and light chain sequences are selected from the HCDR1 sequences defined by IMGT. row, HCDR2 sequence, HCDR3 sequence, LCDR1 sequence, LCDR2 sequence, and LCD R3 sequences, e.g., SEQ ID NOs: 43, 44, 45, 47, 37, and 15, respectively. Including etc.

[0178] In another embodiment, the nucleotide sequence of the full length heavy chain and / or full length light chain is The sequences to be analyzed (e.g., SEQ ID NOs: 12 and / or 22, or 32 and / or 42) and 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99 % may be identical.

[0179] In other embodiments, the nucleotide sequence of the heavy chain variable region and / or the light chain variable region is The sequences shown in Table 1 (e.g., SEQ ID NOs: 10 and / or 20, or 30 and / or or 40) and 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical.

[0180] As used herein, the percent identity between two sequences refers to the best fit between the two sequences. Consider the number of gaps that need to be introduced for the alignment and the length of each gap. It is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical positions (number of positions / total number of positions × 100). Sequence comparison and percent identity between two sequences The determination of is accomplished using a mathematical algorithm, as described in the non-limiting examples below. It is possible.

[0181] Additionally or alternatively, the protein sequences of the present invention can be identified in the context of published databases. and performing a search using, for example, a "query sequence" to identify related sequences. For example, such searches can be performed using the methods described in Altschul et al., 1990 J. Mol. Biol. This was carried out using the BLAST program (version 2.0) according to 215:403-10. can be done.

[0182] Antibodies with conservative modifications In certain embodiments, an antibody of the invention comprises a CDR1 sequence, a CDR2 sequence, and a CDR A heavy chain variable region comprising three sequences, and a CDR1 sequence, a CDR2 sequence, and a CDR3 sequence wherein one or more of these CDR sequences comprises: The amino acid sequences designated based on the antibodies described herein or conservative modifications thereof are and the antibody retains the desired functional properties of the FXIa binding antibodies of the present invention.

[0183] Thus, the present invention provides a heavy chain IgG1A comprising a CDR1 sequence, a CDR2 sequence, and a CDR3 sequence. A light chain variable region comprising a variable region, a CDR1 sequence, a CDR2 sequence, and a CDR3 sequence. An isolated antibody or antigen-binding fragment thereof comprising a CDR1 amino acid sequence of a heavy chain variable region. The amino acid sequence is selected from the group consisting of SEQ ID NOs: 3 and 23, and conservative modifications thereof. The CDR2 amino acid sequence of the heavy chain variable region is set forth in SEQ ID NOs: 4 and 24, and their corresponding amino acid sequences. and the CDR3 amino acid sequence of the heavy chain variable region is selected from the group consisting of: and 25, and conservative modifications thereof, The R1 amino acid sequence is selected from the group consisting of SEQ ID NOs: 13 and 33, and conservative modifications thereof. and the CDR2 amino acid sequence of the light chain variable region is selected from SEQ ID NOs: 14 and 34; and conservative modifications thereof, is selected from the group consisting of SEQ ID NOs: 15 and 35, and conservative modifications thereof; L An antibody or antigen-binding fragment thereof that specifically binds to OX-1 is provided.

[0184] In one embodiment of the present disclosure, a heavy chain comprising a CDR1 sequence, a CDR2 sequence, and a CDR3 sequence A light chain variable region comprising a variable region, a CDR1 sequence, a CDR2 sequence, and a CDR3 sequence. An isolated antibody or antigen-binding fragment thereof comprising a CDR1 amino acid sequence of a heavy chain variable region. The amino acid sequence is selected from the group consisting of the amino acid sequences set forth in Table 1 and conservative modifications thereof. and the CDR2 amino acid sequence of the heavy chain variable region is the amino acid sequence shown in Table 1 and and conservative modifications thereof; the CDR3 amino acid sequence of the heavy chain variable region is selected from the group consisting of 1 and conservative modifications thereof; The CDR1 amino acid sequence of the variable region is the amino acid sequence shown in Table 1 and its conservative equivalents. the CDR2 amino acid sequence of the light chain variable region is selected from the group consisting of and conservative modifications thereof; The R3 amino acid sequence consists of the amino acid sequence set forth in Table 1 and conservative modifications thereof. the antibody or antigen-binding fragment thereof specifically binds to FXIa.

[0185] In other embodiments, the antibodies of the invention are optimized for expression in mammalian cells. and having a full-length heavy chain sequence and a full-length light chain sequence, one or more of which sequences are , an amino acid sequence designated based on an antibody described herein or a conservative modification thereof and the antibody retains the desired functional properties of the FXIa-binding antibodies of the present invention. The present invention provides a method for the expression of a full-length heavy chain and a full-length light chain in mammalian cells. An optimized isolated antibody, the full length heavy chain of which is selected from the group consisting of SEQ ID NO: 11 and SEQ ID NO: 31, and their derivatives. and the full length light chain has an amino acid sequence selected from the group of SEQ ID NO: 21 or 4, 1, and conservative modifications thereof, and / or specific for FXIa (e.g., human, rabbit, and cynomolgus monkey FXIa) The present invention provides an antibody that binds to

[0186] Antibodies that bind to the same epitope The present invention relates to FXI-binding antibodies and / or FXIa-binding antibodies as described in Table 1. The present invention provides antibodies that bind to the same epitope as FXI and / or FX. Ia binding assays (such as the FXI and / or FXIa binding assays described in the Examples section) competes with other antibodies of the invention (e.g., inhibits the binding of other antibodies of the invention at the same Statistically significant competitive inhibition by binding to epitopes or overlapping epitopes Further antibodies can be identified based on their ability to inhibit the expression of the antibodies of the present invention. the ability of the test antibody to inhibit binding to the FXI protein and / or the FXIa protein; The test antibody competes with the antibody for binding to FXI and / or FXIa. Such antibodies may bind to the FXI protein, according to one non-limiting theory. on the protein and / or FXIa protein, which is the same as or related to the competing antibody can bind to related (e.g., structurally similar or spatially proximate) epitopes In certain embodiments, the antibodies of the present invention may be used in combination with FXI and / or The antibody that binds to an epitope on FXIa is a human monoclonal antibody. Human monoclonal antibodies can be prepared and isolated as described herein. Cut.

[0187] As used herein, in the presence of an equimolar concentration of a competing antibody, the competing antibody is an antibody that binds to the agonist of the present invention. The same FX as the antibody or antigen-binding fragment (e.g., NOV1401 or NOV1090) I epitope and / or FXIa epitope, The binding of the active fragment to FXI and / or FXIa is increased by more than 50% (e.g., 80% , 85%, 90%, 95%, 98%, or 99%), the antibody is considered to be inhibiting binding. This can be done, for example, by any of the methods known to those of skill in the art. The amount of the β-amyloid in the β-amyloid can be determined in a combination assay.

[0188] As used herein, an antibody or antigen-binding fragment thereof refers to a competing antibody or an antigen-binding fragment thereof. The binding fragment may bind to the same FXI epitope and / or antigen as the antibody or antigen-binding fragment of the present invention. or FXIa epitopes or overlapping FXI and / or FX epitopes The FXI antibody and / or FXI of the present invention may be used in the absence of binding to the Ia epitope. a) "competing" with an antibody or antigen-binding fragment (e.g., NOV1401 or NOV1090) As used herein, a competing antibody or antigen-binding fragment thereof refers to an antibody or antigen-binding fragment thereof that: Sterically block (e.g., block) an antibody or antigen-binding fragment from binding to its target. The competing antibodies are adjacent to non-overlapping FXI and / or FXIa epitopes. and physically prevent the antibody or antigen-binding fragment of the invention from binding to its target. and / or (ii) different, non-overlapping FXI epitopes and / or The FXIa epitope is bound to the protein by the FXI antibody and / or The FXIa antibody or antigen-binding fragment is capable of inhibiting the FXIa antibody or antigen-binding fragment from undergoing the conformational change in the absence of the conformational change. The conformational change of the FXI protein and / or does not include a competing antibody or antigen-binding fragment thereof directed against the FXIa protein.

[0189] Engineered and modified antibodies As a starting material for engineering modified antibodies with altered properties from the starting antibody, The present invention provides a method for the detection of HIV-1-associated HIV-1-related ... The antibodies can further be prepared by isolating one or both of the variable regions (i.e. , VH and / or VL), e.g., within one or more CDR regions, and / or or by modifying one or more residues in one or more framework regions. Additionally, or alternatively, the antibody can be engineered by modifying residues within the constant region. For example, the effector functions of the antibody can also be modified. .

[0190] One type of variable region engineering that can be performed is CDR grafting. , primarily through amino acid residues located within the six heavy and light chain complementarity determining regions (CDRs). For this reason, the amino acid sequences within the CDRs are highly consistent between individual antibodies. The diversity of CDR sequences is greater than that of sequences outside the CDRs. CDR sequences are responsible for most antibody-antigen interactions. This contributes to the use of the nucleotide sequence, which is then grouped into framework sequences from different antibodies with different properties. Constructing an expression vector containing the CDR sequences derived from a specific naturally occurring antibody that has been rafted By combining these techniques, it is possible to express recombinant antibodies that mimic the properties of specific naturally occurring antibodies. (e.g., Riechmann, L. et al., 1998 Nature 332:323-327; Jones, P. et al., 1986 Nature 321:522-525; Queen, C. et al., 1989 Proc. Natl. Acad. USA 86:10029-10033; Win No. 5,225,539 to Queen et al. Patent No. 5,530,101; Patent No. 5,585,089; Patent No. 5,693 ,762; and 6,180,370).

[0191] Thus, another embodiment of the present invention is a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 3 and 23. and CDR1 sequences having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4 and 24. A CDR2 sequence having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 and 25. and a heavy chain variable region comprising each of the CDR3 sequences having the amino acid sequence of SEQ ID NO: 13 and 33, a CDR1 sequence having an amino acid sequence selected from the group consisting of SEQ ID NO: 14, and 34, and SEQ ID NO:1. Each of the CDR3 sequences is selected from the group consisting of an amino acid sequence of 5 and 35. and a light chain variable region having the amino acid sequence of Such antibodies include those that contain the VH and VL CDR sequences of a monoclonal antibody. The antibodies may have the same framework sequences as those described above, but may contain different framework sequences from these antibodies.

[0192] Such framework sequences are based on published D-RNA sequences, including germline antibody gene sequences. The sequences can be obtained from the NA database or published references. For example, human heavy chains and Germline DNA sequences of the human and light chain variable region genes were obtained from the human germline sequence database. The VBase database (available on the internet at mrc-cpe.cam.ac.uk / vbase) , as well as Kaba, the contents of each of which are expressly incorporated herein by reference. t, EA et al., 1991 Sequences of Proteins of Immunological Interest, 5th ed., US Department of Biology. rtment of Health and Human Services, NIH Publication No. 91-3242; Tomlinson, I. M. .et al., 1992 J. Mol. Biol. 227:776-798; and Cox, J.P.L. et al., 1994 Eur. J Immunol . 24:827-836.

[0193] Exemplary framework sequences for use in the antibodies of the invention include those of selected antibodies of the invention. The framework sequences used by the antibody of the present invention, for example, The consensus sequence and / or framework sequence used in the present study are structurally similar to the VH CDR1 sequence, VH CDR2 sequence, and VH CDR3 sequence. The sequence, and the VL CDR1 sequence, the VL CDR2 sequence, and the VL CDR3 sequence are The framework sequences are derived from the sequences found in the germline immunoglobulin genes. Alternatively, the CDR sequences can be grafted into framework regions having the same sequence as the CDR sequences. , a framework region that contains one or more mutations compared to the germline sequence For example, in certain cases, the amino acid sequence of It is believed that it is beneficial to mutate residues to maintain or enhance the antigen-binding ability of the antibody. (e.g., U.S. Pat. No. 5,530,101 to Queen et al.; Nos. 5,585,089; 5,693,762; and 6,18 (See US Pat. No. 5,370,370). Antibodies and antigen-binding fragments described herein The frameworks that can be used as a scaffolding on which to build the VH1A, VH1B, and VH1C are These include, but are not limited to, H3, Vk1, Vl2, and Vk2. Further frameworks are known, for example available on the Internet at vbase.mrc-cpe.cam. It can be found in the vBase database at ac.uk / index.php?&MMN_position=1:1 can.

[0194] Thus, an embodiment of the present invention relates to an antigen-binding domain selected from the group consisting of SEQ ID NOs: 9 and 29. amino acid sequence, or within the framework regions of such a sequence, Contains an amino acid sequence with 5 amino acid substitutions, deletions, or additions. an amino acid sequence selected from the group consisting of SEQ ID NO: 19 or 39, comprising a heavy chain variable region comprising or 1, 2, 3, 4, or 5 amino acids within the framework regions of such sequences. A light chain having an amino acid sequence with amino acid substitutions, deletions, or additions. The invention relates to an isolated FXIa-binding antibody or antigen-binding fragment thereof, which further comprises a variable region.

[0195] Another type of variable region modification is known as "affinity maturation", which involves the modification of the VH CDR1 region. within the VH CDR2 region, and / or within the VH CDR3 region, and / or within the VL CDR1 region, the VL CDR2 region, and / or the VL CDR3 region mutating amino acid residues within the The aim of this study is to improve the affinity (e.g. affinity) of the target gene by site-directed mutagenesis or P CR-mediated mutagenesis can be performed to introduce mutations and is described herein. In vitro or in vivo assays, as also provided in the Examples section, In one embodiment, the effect on antibody binding or other functional properties of interest can be assessed. Conservative modifications (discussed above) can be introduced. Mutations can be in the form of amino acid substitutions. In addition, there may be additions or deletions within the CDR regions. No more than one, two, three, four, or five residues are altered.

[0196] Thus, in another embodiment, the present invention provides a method for the preparation of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 3 and 23. 1, 2, 3, 4 or 5 as compared to the amino acid sequence of SEQ ID NO: 3 and SEQ ID NO: 23. is an amino acid sequence that has five amino acid substitutions, deletions, or additions. a VH CDR1 region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4 and 24; 1, 2, 3, 4, or 5 amino acid substitutions compared to SEQ ID NOs: 4 and 24. VH CD having an amino acid sequence with amino acid substitutions, deletions, or additions R2 region, an amino acid sequence selected from the group consisting of SEQ ID NO: 5 and 25, or SEQ ID NO: 1, 2, 3, 4, or 5 amino acid substitutions compared to Nos. 5 and 25; VH CDR3 region having an amino acid sequence with deletion or addition of amino acids, SEQ ID NO: 13 and 33, or SEQ ID NO: 13 and 3 1, 2, 3, 4, or 5 amino acid substitutions, deletions, or deletions compared to 3 is a VL CDR1 region having an amino acid sequence with an amino acid addition, SEQ ID NO: 14, and 34, or compared to SEQ ID NOs: 14 and 34. , 1, 2, 3, 4, or 5 amino acid substitutions, amino acid deletions, or amino acid additions and a VL CDR2 region having an amino acid sequence having the amino acid sequence of SEQ ID NO: 15 and SEQ ID NO: 35. or compared to SEQ ID NOs: 15 and 35, , 2, 3, 4, or 5 amino acid substitutions, deletions, or additions An isolated FX comprising a heavy chain variable region having a VL CDR3 region having an amino acid sequence Ia binding antibodies or antigen-binding fragments thereof are provided.

[0197] Thus, in another embodiment, the present invention provides a method for the preparation of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 6 and 26. 1, 2, 3, 4 or 5 as compared to the amino acid sequence of SEQ ID NO: 6 and SEQ ID NO: 26. is an amino acid sequence that has five amino acid substitutions, deletions, or additions. a VH CDR1 region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 7 and 27; 1, 2, 3, 4, or 5 amino acid substitutions compared to the sequence of SEQ ID NO: 7 and SEQ ID NO: 27. VH CD having an amino acid sequence with amino acid substitutions, deletions, or additions R2 region, and an amino acid sequence selected from the group consisting of SEQ ID NOs: 8 and 28, has 1, 2, 3, 4, or 5 amino acid substitutions compared to SEQ ID NOs: 8 and 28; VH CDR3 region having an amino acid sequence with amino acid deletion or addition and a heavy chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 16 and 36. 1, 2, 3, 4, or 5 amino acids compared to SEQ ID NOs: 16 and 36. VLC having an amino acid sequence with amino acid substitution, deletion, or addition DR1 region, an amino acid sequence selected from the group consisting of SEQ ID NOs: 17 and 37, or a sequence Compared with columns 17 and 37, 1, 2, 3, 4, or 5 amino acid substitutions, a VL CDR2 region having an amino acid sequence with an amino acid deletion or addition; and an amino acid sequence selected from the group consisting of SEQ ID NOs: 18 and 38, or SEQ ID NOs: Compared with Nos. 18 and 38, 1, 2, 3, 4, or 5 amino acid substitutions, The VL CDR3 region has an amino acid sequence with amino acid deletion or addition. and a light chain variable region that binds FXIa, or an antigen-binding fragment thereof. do.

[0198] Grafting of antigen-binding domains onto alternative frameworks or scaffolds The resulting polypeptide has at least one bond that specifically binds to FXIa. A wide variety of antibody / immunoglobulin framework or Such frameworks or scaffolds can be used to identify human immunoglobulins. The five major idiotypes of phosphodiesterase or fragments thereof, preferably with humanized aspects. In this respect, the immunoglobulins identified in camelids include those of other animal species that have Of particular interest are single heavy chain antibodies, such as single heavy chain antibodies. New frameworks, scaffolds, and fragments continue to be discovered and developed.

[0199] In one aspect, the present invention provides a method for the preparation of antibodies using a non-immunoglobulin scaffold onto which the CDRs of the present invention can be grafted. The aim of this study is to generate non-immunoglobulin-based antibodies that target FXI. As long as it contains a binding domain specific for the protein and / or FXIa protein , utilizing known or future non-immunoglobulin frameworks and non-immunoglobulin scaffolds Known non-immunoglobulin frameworks and non-immunoglobulin scaffolds Fibronectin (Compound Therapeutics, Inc., Wa ltham, MA), ankyrin (Molecular Partners AG, Zu rich, Switzerland), domain antibody (Domantis, Ltd., C ambridge, MA; and Ablynx nv, Zwijnaarde, Belgium ium), lipocalin (Pieris Proteolab AG, Freising, Germany), Small molecule modular immunopharmaceuticals (Trubion Pharmaceut icals Inc., Seattle, WA), Maxibody (Avidia, Inc. ., Mountain View, CA), protein A (Affibody AG, S weden), and affilin (gamma-crystallin or ubiquitin) (Scil Proteins GmbH, Halle, Germany I can't.

[0200] The fibronectin scaffold may comprise a type III fibronectin domain (e.g., type III fibronectin domain). Based on the 10th module of fibronectin (10 Fn3 domain). The ronectin domains pack against each other to form the core of the protein. It also contains loops that connect the beta strands to each other and are exposed to the solvent (CDRs and similar), having seven or eight beta strands distributed between two beta sheets There are at least three such loops on each edge of the beta-sheet sandwich. , edges are protein boundaries perpendicular to the direction of the beta strands (US6,818, The overall fold is consistent with antigen recognition in camel and llama IgG. It is closely related to the heavy chain variable region fold, which is the smallest functional antibody fragment containing the entire unit. However, these fibronectin-based scaffolds are not immunoglobulins. Therefore, non-immunoglobulin antibodies have properties and affinities that are different from those of antibodies. These scaffolds mimic the antigen-binding properties of antibodies similar to those of antibodies in vivo. Randomization of loops in vitro, similar to the affinity maturation process in vivo These fibronectin can be used in the synthesis and shuffling strategies. The cDNA-based molecules can be cloned using standard cloning techniques to clone the loop regions of the molecule into the CDNA of the present invention. It can be used as a scaffold that can be replaced by DR.

[0201] Ankyrin technology is a method to synthesize proteins with ankyrin-derived repeat modules into heterologous The method is based on using a scaffold that carries variable regions that can be used to bind to different targets. A kyrin repeat module consists of two antiparallel α-helices and a β-tandem repeat. It is a 33 amino acid polypeptide consisting of a ribosome-specific domain. The use of sprays provides a large degree of optimization.

[0202] Avimers are derived from naturally occurring A domain-containing proteins, such as LRP-1. Domains are primarily used for protein-protein interactions, and in humans there are over 250 proteins. The proteins are structurally based on the A domain. Avimers are linked via amino acid linkers. It consists of multiple (2-10) different "A domain" monomers that can bind to target antigens. Avimers are described, for example, in U.S. Patent Application Publication No. 20040175756; No. 50053973; No. 20050048512; and No. 2006 These can be created using the methods described in US Pat. No. 5,999,343.

[0203] Affibodies, which are affinity ligands, are the IgG-binding domains of Protein A. A small, simple protein consisting of a three-helix bundle based on the scaffold of one of the Protein A is a protein found in the bacterium Staphylococcus aureus. These scaffolding domains are surface proteins derived from the IL-11 domains, 13 of which are involved in multiple linkages. A randomized 58-nucleotide sequence was used to generate an affibody library with mutant variants. (See, e.g., US 5,831,012). Affibody Molecules It mimics an antibody and has a molecular weight of 6 kDa compared to the molecular weight of an antibody, which is 150 kDa. Despite their small size, the binding site of an affibody molecule is identical to that of an antibody. It seems that.

[0204] Anticalins are synthetic peptides developed by Pieris ProteoLab AG. Anticalins are generally used to bind chemically sensitive or insoluble compounds to the physiological Lipoproteins are a diverse group of small, robust proteins involved in metabolic transport or storage. Several naturally occurring lipocalins occur in human tissues or in human body fluids. The protein architecture involves hypervariable loops on top of a rigid framework Reminiscent of immunoglobulins. However, in contrast to antibodies or their recombinant fragments, Pocrine kinase is a 160-180 amino acid sequence barely larger than a single immunoglobulin domain. It consists of a single polypeptide chain with four loops that form a binding pocket. The set of α-amino acids exhibits remarkable structural plasticity and tolerates a variety of side chains. binding sites to recognize a defined target molecule with high affinity and specificity can be remodeled in a unique way. By mutagenizing a set of four loops, To develop anticalins, a protein from the lipocalin family, , used by bilin-binding protein (BBP) of Pieris brassicae One example of a patent application describing anticalins is PCT Publication WO 2005 / 023363. Found in brochure no. 199916873.

[0205] Affilin molecules are molecules that bind to proteins and small molecules due to their specific affinity. The new affilin molecule is a small non-immunoglobulin protein designed to Each of them was highly enriched from two libraries based on different human-derived scaffold proteins. Affilin molecules can be rapidly selected for specific binding to immunoglobulin proteins. There are currently two affilin scaffolds in use, which do not show any structural homology. One of them is gamma crystallin, a structural protein of the human lens, and the other is , a "ubiquitin" superfamily protein. Both human scaffolds are very small. It is highly thermostable and nearly resistant to pH changes and denaturing agents. The stability is mainly due to the unfolding of the beta-sheet structure of the protein. Examples of proteins derived from ubiquitin are described in WO200104144 and are referred to as "ubiquitin-binding proteins". Examples of "tin-like" proteins are described in WO2004106368.

[0206] Protein epitope mimics (PEMs) are key molecules involved in protein-protein interactions. A medium-sized secondary structure that mimics the beta-hairpin secondary structure of proteins. It is a cyclic peptide-like molecule (molecular weight: 1-2 kDa).

[0207] The present invention provides fully human antibodies that specifically bind to the FXIa protein. In comparison to human or humanized antibodies, the human FXIa-binding antibodies of the present invention are The antigenicity is further reduced when

[0208] Camelid antibodies Llama species (alpacas (Lama paccos), llamas (Lama glama), and vicuñas (Lama vi Camels and dromedaries (Fraxonidae), including New World members such as Camelidae (Brachyidae) and Dromedaries (Brachyidae) bactrian camel (Camelus bactrianus) and dromedary (Calelus dromaderius) Antibody proteins derived from members of the family vary in size, structural complexity, and heterodimerization. The naturally occurring members of this family have been characterized for their antigenicity to target subjects. Certain IgG antibodies derived from mammals lack light chains and therefore are different from those derived from other animals. The typical four-chain quaternary structure of an antibody is two heavy chains and two light chains. are structurally different. PCT / EP93 / 02214 (published March 3, 1994) See WO 94 / 04678, filed on October 1, 2006.

[0209] The regions of camelid antibodies that are small single variable domains identified as VHHs This results in small proteins with high affinity for the target, making it a promising candidate for the Resulting in low molecular weight antibody-derived proteins known as "cudidae nanobodies" It can be obtained by genetic engineering. U.S. Patent No. 5,741,293 issued on June 2, 1998. 59,808. Also see Stijlemans, B. et al., 2004 J Biol Chem 279:1256 ~1261; Dumoulin, M. et al., 2003 Nature 424:783~788; Pleschberger, M. et al., 2003 Bioco njugate Chem 14:440~448; Cortez-Retamozo, V. et al. 2002 Int J Cancer 89:456~62; and Lauwereys, M. et al., 1998 EMBO J 17:3512-3520. Camelid Antibodies and engineered libraries of antibody fragments are available from, for example, Ablynx, Ghent, Belgium. As with other antibodies of non-human origin, the amino acid sequence of camelid antibodies is The sequence can be modified by recombinant techniques to obtain a sequence that more closely resembles the human sequence. Thus, nanobodies can be "humanized" and thus administered to humans. The naturally low antigenicity of cucurbit antibodies can be further reduced.

[0210] The molecular weight of camelid nanobodies is approximately one-tenth that of human IgG molecules. Proteins have a physical diameter of only a few nanometers. One consequence of their small size is , camelid natto binds to antigenic sites that are functionally invisible to the larger antibody protein. The ability of camelid nanobodies, i.e., to circumvent classical immunological techniques, They are useful as reagents for detecting antigens that would otherwise remain hidden, and may be Thus, a further consequence of their small size is that they are useful as therapeutic agents. The nematode nanobody targets specific sites within grooves or narrow clefts of target proteins. As a result of binding to the site, it is possible to inhibit the target protein, and thus In their ability to more closely resemble the functions of classical small molecular weight drugs than those of classical antibodies It can be used.

[0211] The low molecular weight and compact size also give it exceptional thermal stability and resistance to extremes of pH and The Camelidae Nanobody is stable to proteolytic digestion and has low antigenicity. Another consequence is that camelid nanobodies are more easily transported from the circulation to tissues. It travels easily, can even cross the blood-brain barrier, and can treat disorders that affect nervous tissue. Nanobodies may also facilitate drug transport across the blood-brain barrier. See U.S. Patent Application No. 20040161738, published August 19th. These features, combined with low antigenicity to humans, give rise to Moreover, these molecules have been shown to be useful in the treatment of prokaryotic cells, such as E. coli. It can be expressed entirely intracellularly and is expressed as a fusion protein with a bacteriophage. It is expressive and functional.

[0212] Thus, a feature of the present invention is the inclusion of a compound having high affinity for FXI and / or FXIa. Certain of the above-mentioned specific antibodies and nanobodies are also provided herein. In an embodiment, the camelid antibody or camelid nanobody is naturally derived from a camelid. Produced in animals, i.e., using the techniques described herein for other antibodies. immunization with FXI and / or FXIa or peptide fragments thereof, Alternatively, FXI and / or FXIa binding camelids are produced. Nanobodies are engineered, i.e., as described in the examples herein. The disclosed FXI and / or FXIa as targets, and / or Using a panning procedure involving domains and / or peptide fragments, appropriately mutated Selection of phage libraries displaying induced camelid nanobody proteins Engineered nanobodies are generated by further genetic engineering to select recipient The half-life in the target subject can be customized to range from 45 minutes to 2 weeks. In specific embodiments, the camelid antibody or camelid nanobody is, for example, As described in PCT / EP93 / 02214, the heavy chain or Grating the CDR sequences of the light or dark chains into nanobody or single domain antibody framework sequences Obtained by rafting.

[0213] Bispecific molecules and multivalent antibodies In another aspect, the present invention relates to a FXI-binding antibody and / or a FXIa-binding antibody of the present invention. The present invention also features bispecific or multispecific molecules comprising the antibody or fragments thereof. or its antigen-binding region binds to at least two different binding sites or target molecules. Alternatively, the antibody can be derivatized to create a bispecific molecule that can bind to another functional molecule, e.g. linked to a peptide or protein of interest (e.g., another antibody or ligand for the receptor) The antibodies of the invention may in fact have three or more distinct binding sites and / or They can also be derivatized to create multispecific molecules that bind to a target molecule and two or more other Such multispecific molecules can also be linked to the above functional molecules, and such multispecific molecules are also used herein. These are also intended to be encompassed by the term "bispecific molecule" as used herein. To create an isomeric molecule, the antibodies of the invention can be combined with one another to form a bispecific molecule, such that a bispecific molecule results. one or more other binding molecules, such as another antibody, an antibody fragment, a peptide, or a binding mimetic; Operatively link to a molecule (e.g., by chemical coupling, genetic fusion, non-covalent association) This may be achieved by any of the following means:

[0214] Thus, the present invention provides at least one target molecule for FXI and / or FXIa. A bispecific molecule comprising one binding specificity and a second binding specificity for a second target epitope. For example, the second target epitope may be a different epitope than the first target epitope, such as FXI or and / or another epitope of FXIa.

[0215] In addition, in the present invention where the bispecific molecule is multispecific, the molecule may comprise a first target epitope and and the second target epitope, it may further comprise a third binding specificity.

[0216] In one embodiment, the bispecific molecules of the invention have as binding specificities, e.g., Fab, Fa At least one antibody or a combination thereof, including F(ab'), F(ab')2, Fv, or single chain Fv. Antibodies also include antibody fragments. Antibodies may also be dimers of light or heavy chains, or the antibody fragments described in Ladner et al., US Pat. Fv or single chain constructs, such as those described in U.S. Pat. No. 4,946,778. or any smallest fragment thereof.

[0217] Diabodies are peptides that are too short to allow pairing between the two domains on the same chain. The VH and VL domains are expressed on a single polypeptide chain, connected by an anchor. The VH and VL domains are expressed as counterparts of different chains. The complementary domains pair together, thereby creating two antigen-binding sites (see, e.g., Hollis et al., J. Am. Soc. 1999, 143:1311-1323). Iger et al., 1993 Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak et al., 1994 Structure 2:1121-1123). The diabodies are VHA-VLB and VHB-VLA. structure (VH-VL configuration), or VLA-VHB and VLB-VHA structures (VL- by expressing two polypeptide chains with the same VH configuration in the same cell Most diabodies can be expressed in soluble form in bacteria. Single-chain diabodies (scDbs) are composed of two diabody-forming polypeptide chains, each of which is approximately 1 The 5-amino acid linker is used to connect the 5-amino acid residues (Holliger and Winter, 1997). Cancer Immunol. Immunother., 45(3~4):128~30; Wu et al., 1996 Immunotechnology, 2 (1):21-36). The scDb is expressed in a soluble, active, monomeric form in bacteria. (Holliger and Winter, 1997 Cancer Immunol. Immunother., 45( 34):128-30; Wu et al., 1996 Immunotechnology, 2(1):21-36; Pluckthun and Pack, 1 997 Immunotechnology, 3(2):83~105; Ridgway et al., 1996 Protein Eng., 9(7):617~ 21). Diabodies can be fused to Fc to create "didiabodies." (See Lu et al., 2004 J. Biol. Chem., 279(4):2856-65).

[0218] Other antibodies that may be incorporated within the bispecific molecules of the invention include murine monoclonal antibodies, chimeric monoclonal antibodies, and humanized monoclonal antibodies.

[0219] Bispecific molecules can be prepared by covalently binding the constituent binding specificities using methods known in the art. For example, each binding specificity of a bispecific molecule can be conjugated to a corresponding The isomers can be generated separately and then conjugated to one another. When the target substance is a protein or peptide, various coupling or cross-linking agents can be used. Examples of cross-linking agents include protein A, protein B, and protein C. Rubodiimide, N-Succinimidyl-S-acetyl-thioacetate (SATA), 5 ,5'-Dithiobis(2-nitrobenzoic acid) (DTNB), o-phenylenedimaleimide (oPDM), N-succinimidyl-3-(2-pyridyldithio)propionate (S PDP), and sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane 1-carboxylate (sulfo-SMCC) (e.g., Karpovsky et al., 1984 J. E. xp. Med. 160:1686; Liu, MA et al., 1985 Proc. Natl. Acad. Sci. USA 82:8648. Other methods are described in Paulus, 1985 Behring Ins. Mitt. 78, 118-132; Brennan et al., 1985 985 Science 229:81-83; and Glennie et al., 1987 J. Immunol. 139:2367-2375. The conjugating agents are SATA and sulfo-SMCC. Both are manufactured by Pierce Chemical Co. (Rockford, IL). Available from:

[0220] When the binding specificity is an antibody, they are linked by sulfhydryl bonds to the C-terminal hinge regions of the two heavy chains. In certain embodiments, the conjugation can be by a drill bond. Prior to conjugation, an odd number of sulfhydryl residues, e.g., one sulfhydryl The hinge region is modified to contain the residues:

[0221] Alternatively, both binding specificities can be encoded in the same vector and expressed in the same host cell. This method allows the bispecific molecule to be expressed and assembled in a mAb x mAb Fusion proteins, mAb x Fab fusion proteins, Fab x F(ab')2 fusion proteins The present invention is particularly useful when the antibody is a ligand x Fab fusion protein. The specificity molecule may be a single chain molecule containing one single chain antibody and a binding determinant, and two binding Bispecific molecules may also be single-chain bispecific molecules that contain a determinant. Methods for preparing bispecific molecules are described, for example, in U.S. Pat. No. 5,455,030; U.S. Pat. No. 4,881, 175; U.S. Pat. No. 5,132,405; U.S. Pat. No. 5,091,51 No. 3; U.S. Patent No. 5,476,786; U.S. Patent No. 5,013,653 No. 5,258,498; and U.S. Pat. No. 5,482,858. This is described in the specification.

[0222] The binding of the bispecific molecules to their specific targets can be determined, for example, by enzyme immunoassays. (ELISA), radioimmunoassay (REA), FACS analysis, bioassay (e.g. This can be confirmed by a growth inhibition assay or a Western blot assay. Each of these assays generally involves the use of a labeled reagent ( For example, by using a protein-antibody complex, the presence of a protein-antibody complex of particular interest can be detected. is detected.

[0223] In another aspect, the present invention provides at least two identical antibodies of the present invention that bind to FXIa. or different antigen-binding moieties. The antigen-binding moiety is , linked together via protein fusion or covalent or non-covalent linkage. Alternatively, linking methods for bispecific molecules have also been described. The compound can be, for example, a combination of an antibody of the invention and an antibody that binds to the constant region of the antibody of the invention, e.g., F This can be obtained by cross-linking with the c region or the hinge region.

[0224] Trimerization domains are described, for example, in the Borean patent EP10122. The pentamerization module is described in, for example, PCT / E P97 / 05897.

[0225] Antibodies with extended half-lives The present invention provides a method for the production of FXIa protein specific antibodies that have an extended half-life in vivo. A binding antibody is provided.

[0226] Many factors can affect the half-life of a protein in vivo. For example, filtration in the kidneys, metabolism in the liver, and degradation by proteolytic enzymes (proteases) degradation by the immune system, and immunogenic responses (e.g., neutralization of proteins by antibodies and macrophage activation). Various strategies can be used to extend the half-life of the antibodies of the invention. For example, polyethylene glycol (PEG), reCODE PEG , antibody scaffold, polysialic acid (PSA), hydroxyethyl starch (HES), albumin Chemical linkage to albumin, IgG, and carbohydrate shields It has been shown to have similar ancestry to proteins that bind to serum proteins such as FcRn and transferrin. Gene fusions allow the synthesis of nanobodies, Fabs, DARPins, avimers, affibodies, and It can be coupled to other binding moieties, such as anticalins, that bind to serum proteins (gene By combining rPEG, albumin, albumin domains, albumin By genetic fusion with amine-binding proteins and Fc, or by nanocarriers, sustained release formulations, Alternatively, the half-life of the antibody of the present invention can be extended by incorporation into a medical device. .

[0227] To prolong the serum circulation of antibodies in vivo, we have developed a method to use unsaturated fatty acids such as high molecular weight PEG. The active polymer molecule is site-specifically conjugated to the N- or C-terminus of the antibody via PEG. via gating or via the epsilon-amino group present on the lysine residues. to antibodies or fragments thereof, with or without functional linkers To PEGylate an antibody, the antibody or fragment thereof can be attached to a polyethylene glycol. PEG, such as a reactive ester or aldehyde derivative of PEG, Typically, the PEG-binding domains are reacted under conditions that result in multiple PEG groups being attached to the antibody or antibody fragment. PEGylation is the process of reacting a compound with a reactive PEG molecule (or an analogous reactive water-soluble polymer). This can be carried out by an acylation reaction or an alkylation reaction. The term "polyethylene glycol" refers to mono(C1-C10)alkoxy-polyethylene Polyethylene glycol or aryloxy-polyethylene glycol or polyethylene glycol PEG, which has been used to derivatize other proteins, such as lysine-maleimide. In certain embodiments, P The antibody to be EG is an aglycosylated antibody. Linear or branched polymer Derivatizations that result in minimal loss of biological activity are used. The degree of conjugation will be closely examined by SDS-PAGE and mass spectrometry. Conjugation of PEG molecules to antibodies can be monitored periodically to ensure proper conjugation. Unreacted PEG can be purified by size exclusion or ion exchange chromatography. The PEG conjugate can be separated from the antibody by chromatography. Derivatized antibodies can be prepared using methods well known to those of skill in the art, for example, by immunoprecipitation using the methods described herein. Assays can be used to assess binding activity and in vivo efficacy. Methods for PEGylating proteins are known in the art and can be used to PEGylate the antibodies of the invention. For example, EP0154316 by Nishimura et al. and and EP0401384 by Ishikawa et al.

[0228] Another modified PEGylation technique uses a reconstituted system containing tRNA synthetase and tRNA. Direct reconstitution of chemically defined side chains into biosynthetic proteins via reconstituting chemically orthogonal directed engineering ( The technology includes ReCODE PEG, a novel method for the synthesis of over 30 new amino acids in Escherichia coli ( Incorporation into biosynthetic proteins in E. coli, yeast, and mammalian cells tRNA can then transfer the unnatural amino acid to any position where an amber codon is located. and a chemically specified amino acid incorporation signal is generated from the termination amber codon. It is converted into a codon that transmits the signal.

[0229] Recombinant PEGylation technology (rPEG) can also be used to extend serum half-life. This technology combines unstructured protein tails of 300-600 amino acids with existing pharmaceutical tails. This involves genetically fusing the unstructured protein chains into the The molecular weight is approximately 15 times its actual molecular weight, so the serum half-life of the protein is greatly reduced. In contrast to traditional PEGylation, which requires chemical conjugation and repurification Furthermore, the manufacturing process is greatly simplified and the product is homogeneous.

[0230] Polysialylation is the process of using a natural polymer, polysialic acid (PSA), to enhance the activity of peptides. Another technology that extends the life and improves the stability of therapeutic peptides and proteins. PSA is a polymer of sialic acid (a sugar). When used for drug delivery, upon conjugation, polysialic acid creates a protective microenvironment This extends the active life of the therapeutic protein in the circulation, where it is detected by the immune system. PSA polymers are found naturally in the human body. SA are a type of bacteria that have evolved over millions of years to coat their walls with PSA. These naturally polysialylated bacteria were then molecularly Mimicry makes it possible to disable the body's defenses. Nature's ultimate stealth technique PSA, which is a protease inhibitor, can be easily isolated from such bacteria in large quantities and with certain physical characteristics. Bacterial PSA is chemically identical to PSA in humans, so , yet is completely non-immunogenic when coupled to proteins.

[0231] Another technique involves the use of hydroxyethyl starch ("HES") derivatives linked to antibodies. HES is a modified natural polymer derived from waxy maize starch. HES solutions are usually used to compensate for blood volume deficiencies and improve blood circulation. The hydroxysalicylic acid derivatives of antibodies are administered to improve their biological properties. In addition, the reduction of renal clearance also allows for an extension of the circulating half-life. This results in increased biological activity. A wide range of HES antibody conjugates can be customized by modifying can.

[0232] Antibodies with increased in vivo half-lives also have one or more amino acid modifications. (i.e., substitutions, insertions, or deletions) to the IgG constant domain or its FcRn binding It may also be introduced into a functional fragment (preferably an Fc domain fragment or a hinge Fc domain fragment). For example, International Patent Publication No. 98 / 23289, International Patent Publication No. 97 / 34631; and U.S. Pat. No. 6,277,375. Please refer to the book.

[0233] In addition, the antibody or antibody fragment may be rendered more stable in vivo or To increase the half-life in vivo, the antibody can be covalently coupled to albumin (e.g., human serum albumin). Alternatively, the antibody may be conjugated to serum albumin (HSA). are well known, and are described, for example, in International Patent Publication Nos. 93 / 15199 and 93 / 1 Nos. 5200 and 01 / 77137; and European Patent Nos. See, for example, US Pat. No. 413,622. In addition, in the context of bispecific antibodies as described above, So, the specificity of the antibody is such that one binding domain of the antibody binds to FXIa, whereas The second binding domain of the antibody is adapted to bind to serum albumin, preferably HSA. You can also design it.

[0234] Strategies for extending half-life include those in which extending half-life in vivo is desired. Nanobodies, fibronectin-based binders, and other antibodies or proteins This is particularly useful.

[0235] Antibody conjugates The present invention relates to the use of heterologous proteins or polypeptides to create fusion proteins. to (or a fragment thereof, preferably at least 10, at least 20, at least 30 , at least 40, at least 50, at least 60, at least 70, at least 80 , or a polypeptide of at least 90, or at least 100 amino acids, fused or chemically conjugated (covalent conjugation and (including both covalent and non-covalent conjugation) specifically binds to the FXIa protein. In particular, the present invention provides antibodies or fragments thereof that bind to the antibodies described herein. Antigen-binding fragments of (e.g., Fab fragments, Fd fragments, Fv fragments, F(ab)2 fragments, VH domain, VH CDR, VL domain, or VL CDR) and a heterologous protein, a heterologous The present invention provides fusion proteins comprising a heterologous polypeptide or a heterologous peptide. The present invention relates to a method for the preparation of a protein, polypeptide, or peptide that is fused or conjugated to an antibody or antibody fragment. For example, a method for conjugating a cyclic alkyl group is known. Specification No. 5,622,929, Specification No. 5,359,046, No. 5,34 Nos. 9,053, 5,447,851, and 5,112,946 No. 307,434 and EP367,166; International Patent Publication No. 96 / 04388 and International Patent Publication No. 91 / 06570 Ashkenazi et al., 1991, Proc. Natl. Acad. Sci. USA 88:10535-10539; Zheng et al., 1992, Proc. 95, J. Immunol. 154:5590-5600; and Vil et al., 1992, Proc. Natl. Acad. Sci. USA 89 Please refer to 11337~11341.

[0236] Further fusion proteins have been developed using gene shuffling, motif shuffling, and exon shuffling. shuffling, and / or codon shuffling (collectively referred to as "DNA shuffling") The present invention can be produced by using the technique of DNA shuffling. modifying the activity of the antibody or fragment thereof (e.g., increasing affinity, decreasing dissociation rate, etc.) Generally, U.S. Patent No. 5,605,737, and ... Specification No. 93, Specification No. 5,811,238, Specification No. 5,830,721, Specification No. 5,830,721, Nos. 5,834,252 and 5,837,458; Patten et al., 19 97, Curr. Opinion Biotechnol. 8:724~33; Harayama, 1998, Trends Biotechnol. 16( 2):76-82; Hansson et al., 1999, J. Mol. Biol. 287:265-76; and Lorenzo and Bla sco, 1998, Biotechniques 24(2):308-313 (each of these patents and publications is incorporated herein by reference). (which are incorporated herein by reference in their entirety). The fragments, or the encoded antibodies or fragments thereof, may be modified to contain errors prior to recombination. Random mutagenesis by prone PCR, random nucleotide insertion, or other methods The antibody that specifically binds to the FXIa protein can be modified by subjecting it to a method. The polynucleotide encoding the polypeptide or a fragment thereof may be incorporated into one or more of the heterologous molecules. or multiple components, motifs, segments, parts, domains, fragments, etc. .

[0237] Additionally, antibodies or fragments thereof may be linked to marker sequences, such as peptides, to facilitate purification. In a preferred embodiment, the amino acid sequence of the marker can be fused to Many of these vectors are commercially available, including pQE vectors (QIAGEN, Inc. , 9259 Eton Avenue, Chatsworth, CA, 91311 A hexahistidine peptide such as the tag provided in Gent (SEQ ID NO: 48). As described in, e.g., Zhang et al., 1989, Proc. Natl. Acad. Sci. USA 86:821-824, For example, hexa-histidine (SEQ ID NO:48) provides for convenient purification of the fusion protein. Another peptide tag useful for purification is derived from the influenza hemagglutinin protein. epitope (Wilson et al., 1984, Cell 37:767). "Flag" tags, and "Flag" tags.

[0238] In other embodiments, the antibodies of the invention or fragments thereof can be coupled to diagnostic or detectable agents. Such antibodies are useful in preventing and controlling the onset, development, progression, and progression of a disease or disorder. and / or severity as part of a clinical examination procedure, such as to determine the effectiveness of a particular treatment. Such diagnosis and detection may be useful for monitoring or prognostic diagnosis. The antibodies were stained with horseradish peroxidase, alkaline phosphatase, beta-galactosidase, and Various enzymes, such as, but not limited to, acetylcholinesterase, acetylcholinesterase, or acetylcholinesterase such as, but not limited to, streptavidin / biotin and avidin / biotin. Unknown prosthetic group: Umbelliferone, fluorescein, fluorescein isothiocyanate fluorescein, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride, are fluorescent materials such as, but not limited to, phycoerythrin; luminol, etc. Luminescent materials, including but not limited to luciferase, luciferin, and aequorin. Bioluminescent materials such as, but not limited to, iodine (I, I, I , and 121I), carbon (14C), sulfur (35S), tritium (3H), indium In (115In, 113In, 112In, and 111In), Technetium (99T c), thallium (201Tl), gallium (68Ga, 67Ga), palladium (103 Pd), molybdenum (99Mo), xenon (133Xe), fluorine (18F), 153 Sm, 177Lu, 159Gd, 149Pm, 140La, 175Yb, 166Ho, 9 0Y, 47Sc, 186Re, 188Re, 142Pr, 105Rh, 97Ru, 68G e, 57Co, 65Zn, 85Sr, 32P, 153Gd, 169Yb, 51Cr, 54 Radioactive materials such as, but not limited to, Mn, 75Se, 113Sn, and 117Tin. radioactive materials; and positron-emitting metals and non-radioactive materials using a variety of positron emission tomography techniques. and coupling to a detectable substance, including but not limited to a reactive paramagnetic metal ion. This can be achieved by:

[0239] The present invention further relates to the use of antibodies or fragments thereof conjugated to a therapeutic moiety. The antibody or fragment thereof may be a cytotoxin, e.g., a cytostatic or cytocidal agent. , conjugation to a therapeutic moiety such as a therapeutic agent or a radioactive metal ion, e.g., an alpha emitter. A cytotoxin or cytotoxic agent is any agent that is detrimental to cells. include.

[0240] Additionally, antibodies or fragments thereof can be used as therapeutic moieties or drugs that modify a given biological response. The therapeutic or drug moiety can also be conjugated to a moiety using classical chemistry. For example, the drug moiety may be a therapeutic agent that is capable of inducing a desired biological effect. The target protein may be a protein, peptide, or polypeptide that possesses a therapeutic activity. Proteins include, for example, abrin, ricin A, Pseudomonas exotoxin, cholera toxin, and toxins such as diphtheria toxin; tumor necrosis factor, α-interferon, β-interferon ron, nerve growth factor, platelet-derived growth factor, tissue plasminogen activator, apoptosis or proteins such as biological response modifiers, e.g., lymphokines. It may include quality.

[0241] Additionally, the antibodies can be used with radioactive metal ions, such as alpha emitters such as 213Bi, 131I Radiation including but not limited to n, 131LU, 131Y, 131Ho, 131Sm Macrocyclic chelating agents useful for conjugating reactive metal ions to polypeptides It can be conjugated to any therapeutic moiety. In certain embodiments, macrocyclic The chelator may be attached to the antibody via a linker molecule, such as 1,4,7,10-tetrahydrofuran. The compound is azacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA). Such linker molecules are generally known in the art, and each is incorporated herein by reference. Incorporated in their entirety, Denardo et al., 1998, Clin Cancer Res. 4(10):2483-90; Peterson et al., 1999, Bioconjug. Chem. 10(4):553-7; and Zimmerman et al., 1999, Nucl. . Med. Biol. 26(8):943-50.

[0242] Techniques for conjugating therapeutic moieties to antibodies are well known and are described, for example, in Arno n et al., “Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy”, M Onoclonal Antibodies and Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Li ss, Inc. 1985); Hellstrom et al., “Antibodies For Drug Delivery,” Controlled Drug Delivery (2nd ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe , “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review”, Monoclo nal Antibodies 84: Biological And Clinical Applications, Pinchera et al. (eds.), 475~ 506 pages (1985); “Analysis, Results, And Future Prospective Of The Therapeutic Us e Of Radiolabeled Antibodies In Cancer Therapy”, Monoclonal Antibodies For Cancer Detection and Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985); and and Thorpe et al., 1982, Immunol. Rev. 62:119-58.

[0243] Antibodies can also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include glass, cellulose, polyacrylamide, and the like. including, but not limited to, polyethylene, nylon, polystyrene, polyvinyl chloride, or polypropylene. Not limited.

[0244] How to make antibodies Nucleic acid encoding the antibody The present invention relates to a polypeptide comprising a segment or domain of the FXIa-binding antibody chain described above. The present invention provides a substantially purified nucleic acid molecule encoding a polypeptide. The nucleotide sequence encoding the heavy chain variable region shown in SEQ ID NO: 10 or 30 is and / or a nucleotide sequence encoding the light chain variable region set forth in SEQ ID NO: 20 or 40. In a specific embodiment, the nucleic acid molecule comprises a nucleic acid molecule identified in Table 1. Certain other nucleic acid molecules of the present invention are nucleotide equivalents of the nucleic acid molecules identified in Table 1. Substantially (e.g., at least 65, 80%, 95%, or 99%) identical to the octide sequence When expressed from an appropriate expression vector, these polynucleotides The polypeptide encoded by the peptide is capable of binding to the FXI and / or FXIa antigens. It is possible to present the Noh.

[0245] The present invention also provides at least one antibody derived from the heavy chain or light chain of the FXIa-binding antibody shown above. A polynucleotide encoding at least one CDR region, and usually all three CDR regions, is Several other polynucleotides are also provided that bind to the FXIa-binding antibodies set forth above. The nucleic acid sequence encoding the heavy and / or light chain variable regions of the nucleic acid sequence of the present invention is substantially the same as that of the nucleic acid sequence of the present invention. Due to the degeneracy of the nucleic acid sequences, a variety of nucleic acid sequences can be used to encode each of the immunoglobulin amino acid sequences. It will be.

[0246] The nucleic acid molecules of the invention can encode both the variable and constant regions of an antibody. Some of the nucleic acid sequences have a substantially similar sequence to the heavy chain sequence shown in SEQ ID NO: 11 or 31. For example, nucleic acids encoding heavy chain sequences at least 80%, 90%, or 99%) identical to each other. Some other nucleic acid sequences include the light chain sequences shown in SEQ ID NO: 21 or 41. and encoding a light chain sequence substantially (e.g., at least 80%, 90%, or 99%) identical to It contains nucleotides that modulate the nucleotide sequence.

[0247] The polynucleotide sequences can be synthesized by de novo solid phase DNA synthesis or by the synthesis of FXIa-binding antibodies or to an existing sequence encoding the binding fragment (e.g., a sequence described in the Examples below). Direct chemical synthesis of nucleic acids can be achieved by PCR-based mutagenesis. , Narang et al., 1979, Meth. Enzymol. 68:90; the phosphotriester method by Brown et al., Meth. Enzymol. 68:109, 1979; phosphodiester method by Beaucage et al., Tetra. Lett., 22:185 9, 1981; and U.S. Pat. No. 4,458,066. This can be achieved by methods known in the art, such as solid support methods as described herein. Introduction of mutations into a polynucleotide sequence by PCR can be achieved, for example, by PCR Technology. In: Principles and Applications for DNA Amplification, HA Erlich (ed.), Freeman. Press, NY, NY, 1992; PCR Protocols: A Guide to Methods and Applications, Innis et al. (eds.), Academic Press, San Diego, CA, 1990; Mattila et al., Nucleic Acids Res. 19:96 7, 1991; and Eckert et al., PCR Methods and Applications 1:17, 1991. The provisions of the present invention may be implemented as described above.

[0248] The present invention also provides the above-described FXI-binding antibody and / or FXIa-binding antibody. Expression vectors and host cells for producing the organism are also provided. The present invention relates to a method for expressing a polynucleotide encoding an FXIa-binding antibody chain or binding fragment. Both viral and non-viral expression vectors can be used. Any of these vectors can be used to produce antibodies in mammalian host cells. Transfected and non-viral systems use plasmids, typically expressing proteins or RNA. and human artificial chromosomes (e.g. (See, Harrington et al., Nat Genet 15:345, 1997). For example, mammals (e.g. FXIa-binding polynucleotide and LOX-1-binding polypeptide in human cells Non-viral vectors useful for expression of ThioHis include pThioHis A, pThioHis B, and pThioHis C, pcDNA3.1 / His, pEBVHis A, pEB VHis B, and pEBVHis C (Invitrogen, San Diego, CA) , CA), MPSV vectors, as well as methods in the art for expressing other proteins. Useful viral vectors include retroviruses, adenomyomatous viruses, and numerous other vectors known in the art. Vectors based on SV40, adenovirus, and herpesvirus Vectors, papillomavirus, HBP Epstein-Barr virus, vaccinia virus and Semliki Forest virus (SFV). Brent et al., supra; Smith, Annu. Rev. Microbiol. 49:807, 1995; and Rosenfeld et al., Cell 68:143, 1992. I want to.

[0249] The choice of expression vector will depend on the intended host cell in which the vector will be expressed. The expression vector can carry a polynucleotide encoding an FXIa-binding antibody chain or fragment. Contains an operably linked promoter and other regulatory sequences (e.g., enhancers). In some embodiments, except under inducing conditions, the inserted sequence To prevent expression of the gene, an inducible promoter is used. , arabinose, lacZ, metallothionein promoter, or heat shock promoter Cultures of transformed organisms contain vectors that express their products better in host cells. They can be grown under non-inducing conditions without biasing the population of permissive coding sequences. In addition to the promoter, other regulatory elements may also be involved in the expression of the FXIa-binding antibody chain or These elements may be required or desired for efficient expression of the fragment. Typically includes a TG initiation codon and adjacent ribosome binding site or other sequences. The efficiency of expression can be increased by incorporating enhancers appropriate for the cell line being used. (See, e.g., Scharf et al., Results Probl. Cell Differ. 20:125, 1994; (See, for example, SV40 enzyme. or CMV enhancer to increase expression in mammalian host cells. It is possible.

[0250] The expression vector also contains the polypeptide encoded by the inserted FXIa-binding antibody sequence. The position of a secretory signal sequence may also be provided to form a fusion protein with the insert. The inserted FXI-binding antibody sequence and / or FXIa-binding antibody sequence are FXI-binding antibodies and / or or sequences encoding the light chain variable domain and the heavy chain variable domain of a FXIa-binding antibody. The vectors used to receive the vectors optionally also contain constant regions or portions thereof. Such vectors also encode the variable region as a fusion protein with the constant region. Expression is permitted, resulting in the production of an intact antibody or a fragment thereof. Typically, such constant regions are human constant regions.

[0251] The antibody has an FXI-binding antibody chain and / or an FXIa-binding antibody chain and expresses the same. Host cells for the production of the vectors can be either prokaryotic or eukaryotic. ) is one prokaryotic organism useful for cloning and expressing the polynucleotides of the present invention. Other microbial hosts suitable for use are bacillus bacteria such as Bacillus subtilis. Bacteria, and Salmonella spp., Serratia spp., and various Schizosaccharomyces cerevisiae. These prokaryotic hosts include other Enterobacteriaceae, such as Pseudomonas species. The vector also typically contains expression control sequences compatible with the host cell (e.g., an origin of replication). In addition, expression vectors using the lactose promoter system, tryptophan, The trp promoter system, the beta-lactamase promoter system, or the f There are also any number of different well-known promoters, such as the promoter system derived from dilambda. Typically, the promoter optionally controls expression through an operator sequence. ribosome binding site sequences for initiating and terminating transcription and translation, etc. Other microorganisms, such as yeast, may also be used to express the FXIa-binding polypeptides of the present invention. The method can also be used in combination with a baculovirus vector. Cells may also be used.

[0252] In some preferred embodiments, the FXI binding polypeptides and / or uses mammalian host cells to express and produce FXIa-binding polypeptides The mammalian host cell may be any normal non-immortalized animal cell or any normal immortalized animal cell or Non-normal immortalized animal or human cells, e.g., CHO cell lines, various Cos cells Intact immunoglobulins, including IgG1, HeLa cells, myeloma cell lines, and transformed B cells, A number of suitable host cell lines capable of secreting purine have been developed. For the use of mammalian tissue cell cultures to express Discussed generally in ROM GENES TO CLONES, VCH Publishers, NY, NY, 1987. Expression vectors for mammalian host cells include an origin of replication, a promoter, and an enhancer. Expression control sequences such as sensors (see, e.g., Queen et al., Immunol. Rev. 89:49-68, 1986) (referred to as "ribosome binding sites", "RNA splice sites", "polyadenylation sites") , and may contain necessary processing information sites, such as a transcription terminator sequence.

[0253] These expression vectors typically contain promoters derived from mammalian genes or Suitable promoters include constitutive promoters, including promoters derived from viruses. -, cell type specific promoters, stage specific promoters, and / or modulating Useful promoters can be regulatable or regulatable promoters. tarothionine promoter, constitutive adenovirus major late promoter, dexamethasone Zone-inducible MMTV promoter, SV40 promoter, MRP polIII promoter promoter, constitutive MPSV promoter, tetracycline-inducible CMV promoter (Human (e.g., immediate early CMV promoter), constitutive CMV promoter, and those known in the art. These include, but are not limited to, known promoter-enhancer combinations.

[0254] Methods for introducing an expression vector containing a polynucleotide sequence of interest include the use of a cellular host species. For example, calcium chloride transfection is commonly used in prokaryotic cells. whereas calcium phosphate treatment or electroporation can be used for other cellular hosts. (See generally, Sambrook et al., supra). Other methods include, for example, electrochemical Perforation, calcium phosphate treatment, liposome-mediated transformation, injection and microinjection , gene gun method, virosomes, immunoliposomes, polycation:nucleic acid conjugates Gates, naked DNA, artificial virions, and herpesvirus structural proteins, VPs 22 (Elliot and O'Hare, Cell 88:223, 1997), which is a fusion with Long-term high-level delivery of recombinant proteins For yield production, stable expression is often desired. For example, FXIa-binding antibodies Cell lines that stably express the chains or binding fragments can be constructed using viral origins of replication or endogenous expression. The expression vector of the present invention contains a gene encoding a nucleotide sequence and a selectable marker gene. After the vector is introduced, the cells are cultured in enriched medium for 1-2 days. After growth, the cells can be switched to selective media. The purpose of the selectable marker is to allow Its presence allows the cells to grow, thereby The goal is to successfully express the sequence in selective medium. The transplanted cells can be grown using tissue culture methods appropriate for the cell type.

[0255] Framework or Fc operations Engineered antibodies of the invention may, for example, be modified in the VH and / or VL sequences to improve the properties of the antibody. Such framework modifications include engineered antibodies in which modifications have been made to framework residues within the Modifications are typically performed to reduce the immunogenicity of the antibody. For example, one approach The present invention provides a method for “reverting” one or more framework residues to the corresponding germline sequence. More specifically, antibodies that have undergone somatic mutations are mutated to the same extent as the antibodies from which they are derived. These residues may contain framework residues that differ from the germline sequence of the antibody. The framework sequences are identified by comparison to the germline sequences from which the antibody is derived. To revert the framework region sequences to their germline configuration, For example, somatic mutations can be converted to germline sequences by site-directed mutagenesis. Such "backmutated" antibodies can also be are intended to be encompassed by the present invention.

[0256] Another type of framework modification is to modify residues within one or more framework regions, Alternatively, residues within one or more CDR regions may be mutated to generate T cell epitopes. This approach involves removing the cleavage sites, thereby reducing the potential immunogenicity of the antibody. Also referred to as "deimmunization," Carr et al., U.S. Patent Publication No. 20030153043 This is described in further detail in the specification.

[0257] In addition to, or as an alternative to, modifications made within the framework or CDR regions The antibodies of the invention may contain modifications within the Fc region to typically improve serum half-life, complement fixation, Fc c Receptor binding, and / or antigen-dependent cellular cytotoxicity, Additionally, the antibodies of the present invention can be chemically engineered to modify their functional properties. Alternatively, the antibody can be modified (e.g., one or more chemical moieties can be attached to the antibody). and modifying its glycosylation, again to improve one or more functional characteristics of the antibody. Each of these embodiments is described below. The numbering of residues in the Fc region is based on the EU index according to Kabat. It is cus.

[0258] In one embodiment, the number of cysteine ​​residues in the hinge region is altered, e.g., increased or The hinge region of CH1 is modified to reduce the cleavage of the nucleosome. This technique was previously described by Bodmer et al. Further described in U.S. Patent No. 5,677,425. CH1 Hinge The number of cysteine ​​residues in a region determines, for example, whether it facilitates assembly of the light and heavy chains. , or modified to increase or decrease the stability of the antibody.

[0259] In another embodiment, the Fc hinge region of the antibody is mutated to increase the biological half-life of the antibody. More specifically, the binding of antibodies to Staphylococcus aureus protein A (SpA) is one or more of the Fc-hinge domains are disrupted in binding to SpA, such that binding to SpA is impaired compared to that of the native Fc-hinge domain. Amino acid mutations in the CH2-CH3 domain interface region of the Fc-hinge fragment This method is described in U.S. Pat. No. 6,165,745 by Ward et al. Further details are provided in the following.

[0260] In another embodiment, the antibody is modified to increase its biological half-life. For example, in U.S. Pat. No. 6,277,375 to Ward, One or more of the mutations described above can be used. To extend biological half-life, antibodies can be synthesized using methods such as those described in U.S. Patent No. 5,869 by Presta et al. ,046; and 6,121,022, Salvage receptor binding properties taken from two loops of the CH2 domain of the Fc region of glucagon It can also be modified within the CH1 or CL region to contain the epitope.

[0261] In yet another embodiment, at least one amino acid residue is modified to enhance the effector function of the antibody. The Fc region is modified by replacing the following with a different amino acid residue that modifies the Fc region. For example, The antibody has altered affinity for an effector ligand but not the antigen of the parent antibody. One or more amino acids are replaced with different amino acid residues so that binding ability is maintained. The effector ligand that modifies the affinity for it can be, for example, For example, the Fc receptor or the C1 component of complement. This approach was previously described by Winter et al. Nos. 5,624,821 and 5,648,260 to This is described in further detail in

[0262] In another embodiment, the antibody alters binding to C1q and / or complement dependent cytotoxicity. One or more amino acid residues selected from the group consisting of 1 to 5 are selected so as to reduce or eliminate the adverse drug reaction (CDC) effect. One or more amino acids can be replaced with different amino acid residues. As further described in U.S. Patent No. 6,194,551 to Dusogie et al. It is listed.

[0263] In another embodiment, one or more amino acid residues are modified to provide a polypeptide that binds complement. This technique is described in PCT Publication WO 2005 / 023363 by Bodmer et al. This is further described in US Pat. No. 94 / 29351.

[0264] In specific embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NO The antibody (containing the VL and VH CDRs of V1401) binds to any surface-associated FXI. The two amino acids are inserted to reduce the possibility of ADCC or CDC caused by A human IgG (e.g., IgG1) Fc domain containing the substitutions D265A and P329A. These alanine substitutions have been shown to reduce ADCC and CDC. (e.g., Idosugie et al., J. Immunol. 164:4178-4184, 2000; Shields et al., J. (see Biol. Chem. 276:6591-6604, 2001).

[0265] In yet another embodiment, the antibody-dependent Increase the ability of the antibody to mediate anti-cellular cell-mediated cytotoxicity (ADCC) and / or inhibit Fcγ receptors The Fc region is modified to increase the affinity of the antibody for the receptor. Presta in PCT Publication WO 00 / 42072 It has been further described. Furthermore, FcγRI, FcγRII, Fcγ The binding sites for RIII and FcRn have also been mapped, and mutations that improve binding have been identified. Variants have also been described (see Shields, RL et al., 2001 J. Biol. Chen. 276:6591-6604). (I want to be).

[0266] In yet another embodiment, the glycosylation of the antibody is modified. For example, aglycosylated antibody The antibody can be made to be glycosylated (i.e., the antibody lacks glycosylation). For example, the antibody may be modified to increase its affinity for an "antigen." Such carbohydrate modifications can include, for example, one or more glycosylation sites within the antibody sequence. This can be achieved by modifying one or more variable region fragments. One or more amino acids resulting in the loss of a framework glycosylation site Substitutions can be made to eliminate glycosylation at that site. Such deglycosylation can increase the affinity of the antibody for the antigen. Such an approach is described in U.S. Patent No. 5,714,350 to Co et al.; and more fully described in US Pat. No. 6,350,861.

[0267] Additionally or alternatively, a hypofucosylated antibody or a bi-branched antibody having a reduced amount of fucosyl residues. To generate antibodies with altered glycosylation types, such as antibodies with increased GlcNac structures, Such modification of the glycosylation pattern can increase the ADCC ability of the antibody. Such carbohydrate modifications, for example, have been shown to enhance the glycosylation machinery. This can be achieved by expressing the antibody in a modified host cell. describes cells with modified glycosylation machinery, capable of expressing recombinant antibodies of the invention. This allows the use of the host cells for producing antibodies with modified glycosylation. For example, EP 1,176,195 by Hang et al. The antibody expressed in the recombinant human fucosyltransferase was engineered to exhibit low fucosylation. Presta describes a cell line with a functional disruption of the FUT8 gene, which regulates The PCT publication WO 03 / 035835 brochure states that fucose is replaced by Asn( 297) Reduces the ability of a polypeptide to attach to linked carbohydrates and is expressed in its host cell A mutant CHO cell line, Lecl, which also results in hypofucosylation of the antibody 3 cells (see also Shields, RL et al., 2002 J. Biol. Chem. 277:26733 See also PCT Publication WO 99 / 54342 by Umana et al. The brochure shows that antibodies expressed in engineered cell lines result in increased ADCC activity of the antibodies. Glycoproteins were modified to display increased bisecting GlcNac structures as a Glycosyltransferases that convert beta(1,4)-N-acetylglucosamine Cell lines engineered to express GnTIII (see also Umana et al., 1999 Nat. Biotech. 17:176-180). stomach).

[0268] Methods for Engineering Engineered Antibodies As discussed above, the VH and VL sequences or full length heavy chains and A FXIa-binding antibody having a full-length light chain sequence may be a FXIa-binding antibody having a full-length heavy chain sequence and / or a full-length light chain sequence. The VH and / or VL sequences, or the constant regions attached thereto, may be modified. This can be used to generate new FXIa-binding antibodies. Thus, in another aspect of the invention, the structural features of the FXIa-binding antibodies of the invention can be used to identify human Binding to FXIa and also inhibiting one or more functional properties of FXIa (e.g., For example, it inhibits the binding of FXIa to the FXIa receptor and inhibits FXIa-dependent cell proliferation. Structurally related FX that retain at least one functional property of the antibodies of the invention, such as Ia-binding antibodies are created.

[0269] For example, one or more CDR regions of the antibody of the invention or mutations thereof may be recombinantly Thus, recombinant CDRs can be combined with known framework regions and / or other CDRs. The present invention provides further FXIa-binding antibodies, as discussed above, which are engineered to Other types of modifications include those described in the previous section. Starting Materials for the Procedure The material may comprise one or more of the VH and / or VL sequences presented herein. The engineered antibodies may be generated by using a number of CDR regions, or one or more CDR regions thereof. one or more of the VH and / or VL sequences presented in the specification, and The method actually prepares an antibody having one or more of those CDR regions (i.e., It is not necessary that the sequence be expressed as a protein. The information is used as starting material to create "second generation" sequences derived from the original sequence. The "second generation" sequence is then prepared and expressed as a protein.

[0270] Thus, in another embodiment, the present invention provides a method for the preparation of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 3 and 23. a CDR1 sequence selected from the group consisting of SEQ ID NOs: 4 and 24; and / or a CDR3 sequence selected from the group consisting of SEQ ID NOs: 5 and 25. an antibody sequence of the chain variable region; and a CDR1 sequence selected from the group consisting of SEQ ID NOs: 13 and 33; SEQ ID NO: 14 and 34, and / or A light chain variable region having a CDR3 sequence selected from the group consisting of SEQ ID NOs: 15 and 35. and an antibody sequence for binding to FXIa; by modifying at least one amino acid residue in the antibody sequence of the light chain variable region to form at least Creating a modified antibody sequence; and methods for expressing the modified antibody sequence as a protein to provide.

[0271] Thus, in another embodiment, the present invention provides a method for the preparation of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 6 and 26. a CDR1 sequence selected from the group consisting of SEQ ID NOs: 7 and 27; and / or a CDR3 sequence selected from the group consisting of SEQ ID NOs: 8 and 28. an antibody sequence of the chain variable region; and a CDR1 sequence selected from the group consisting of SEQ ID NOs: 16 and 36; SEQ ID NO: 17 and 37, and / or A light chain variable region having a CDR3 sequence selected from the group consisting of SEQ ID NOs: 18 and 38. and an antibody sequence for binding to FXIa; by modifying at least one amino acid residue in the antibody sequence of the light chain variable region to form at least Creating a modified antibody sequence; and methods for expressing the modified antibody sequence as a protein to provide.

[0272] Thus, in another embodiment, the present invention provides a method for the production of a polypeptide optimized for expression in mammalian cells. A FXIa-binding antibody having a sequence selected from the group consisting of SEQ ID NO: 11 or 31. and a full-length heavy chain antibody sequence having a sequence selected from the group of SEQ ID NO: 21 or 41. and a FXIa-binding antibody comprising a full-length heavy chain antibody sequence and / or a long light chain antibody sequence. At least one amino acid residue in the full-length light chain antibody sequence is modified to produce at least one modified To provide methods for creating variant antibody sequences and expressing the variant antibody sequences as proteins. In one embodiment, the heavy or light chain modification is within the framework regions of the heavy or light chain. It is.

[0273] The modified antibody sequence may also be the CDR3 sequence, or the sequence described in US2005 / 0255552. The minimal essential binding determinants are fixed and the CDR1 and CDR2 sequences are Alternatively, antibodies can be prepared by screening a diverse antibody library. Screening can be performed by using techniques such as phage display technology to screen antibodies from antibody libraries. This may be done according to any screening technique appropriate for screening from the can.

[0274] Standard molecular biology techniques can be used to prepare and express the modified antibody sequences. The antibodies encoded by the modified antibody sequences may be human, cynomolgus monkey, rat and / or specifically binds to mouse FXIa; and the antibody binds to F36E cell proliferation assay and / or FXIa-dependent cell proliferation in Ba / F3-FXIaR cell proliferation assays. The FXIa binding proteins described herein include, but are not limited to, inhibiting cell proliferation. An antibody that retains one, some, or all of the functional properties of the recombinant antibody.

[0275] In certain embodiments of the methods of engineering an antibody of the invention, the FXIa-binding antibody coding sequence Mutations can be introduced randomly or selectively along all or part of the sequence. and the resulting modified FXIa-binding antibodies are assayed for binding activity and and / or other functional properties. Mutational methods have been described, for example, in PCT Publication No. WO 02 / 024444 by Short. No. 92780 provides information on saturation mutagenesis, synthetic ligation assembly, and or combinations thereof to create and screen antibody mutations. Alternatively, Lazar et al., PCT Publication No. WO 03 / 033664, discloses a method for the preparation of a medicament for use in a pharmaceutical composition comprising the steps of: The 74679 pamphlet uses computer-based screening methods to identify antibodies Methods for optimizing physiochemical properties are described.

[0276] In certain embodiments of the invention, the antibody is engineered to remove deamidation sites. Deamidation induces structural and functional changes in a peptide or protein. It is known that deamidation can cause not only a decrease in biological activity but also the formation of cytoplasmic amino acids in protein pharmaceuticals. This may also result in alterations in the pharmacokinetics and antigenicity of the drug (Anal Chem. 2005 March 1;77 (5):1432~9).

[0277] In certain embodiments of the invention, the antibodies have an increased pI and improved drug-like properties. The pI of a protein is key to the overall biophysical properties of the molecule. Antibodies with a small pI are less soluble, less stable, and less prone to aggregation. Furthermore, purification of antibodies with small pI is particularly useful for clinical use. Scaling up for practical use of the present invention can be difficult and problematic. Increasing the pI of anti-FXI and / or anti-FXIa antibodies or Fabs This improves their solubility and allows the antibodies to be formulated at high concentrations (>100 mg / ml). By formulating antibodies at high concentrations (e.g., >100 mg / ml), This offers the advantage that high doses of the antibody can be administered, which reduces the risk of thrombosis. The present invention is of particular interest for treating chronic diseases, including sexual and / or thromboembolic disorders. Increasing the pI also improves the IgG version of the antibody, allowing for less frequent dosing. It also increases the FcRn-mediated recycling of the drug, which allows the drug to be released for a long period of time. It may also be possible for the drug to remain in the body, reducing the number of injections required. Due to the increased stability of the antibody, the overall stability of the antibody is significantly improved, resulting in a longer shelf life. and prolonged in vivo biological activity. pI is 8.2 or higher. It is preferable that:

[0278] The functional properties of the modified antibodies can be evaluated using assays such as those shown in the Examples (e.g., ELISA). Standard applications available in the art and / or described herein, such as The effect can be assessed using an assay.

[0279] Prophylactic and Therapeutic Uses Antibodies that bind to FXI and / or FXIa as described herein (e.g., NO Table 1, including anti-FXI / FXIa antibodies containing the VL and VH CDRs of V1401 The antibody or antigen-binding fragment of the present invention may be administered in an amount of about 100 mg / kg / day or more. The administration of the compound to a subject in need thereof can be used to treat a thromboembolic disease or disorder (e.g., Thrombotic stroke, Atrial fibrillation, Prevention of Stroke in Atrial Fibrillation (SPAF), Deep vein thrombosis , venous thromboembolism, pulmonary embolism, acute coronary syndrome (ACS), ischemic stroke, acute lower limb ischemia It is therapeutically useful for treating chronic pulmonary hypertension, chronic thromboembolic pulmonary hypertension, or systemic embolism. The present invention provides an effective amount of the antibody of the present invention to a subject in need thereof. and administering to a subject a composition comprising the compound of formula (I) or (II) to treat a thromboembolic disorder (e.g., a thrombotic disorder). The present invention provides a method for administering an effective amount of an antibody of the present invention to a subject in need thereof. This may reduce the risk of thromboembolic disorders (e.g., thrombotic stroke, atrial fibrillation, and cerebral Prevention of stroke (SPAF), deep vein thrombosis, venous thromboembolism, pulmonary embolism, acute coronary syndrome group (ACS), ischemic stroke, acute limb ischemia, chronic thromboembolic pulmonary hypertension, or systemic The present invention provides a method for treating chronic vascular embolism.

[0280] The antibodies described herein (e.g., NOV1401, or the VL of NOV1401) Antibodies that include the anti-FXI / FXIa CDRs and VH CDRs described in Table 1. The term "body mediated immunity" refers to, among other things, thrombotic disorders, including, but not limited to, thrombotic disorders, as described in more detail herein. The present invention relates to a method for treating, preventing, and ameliorating thromboembolic conditions or disorders, including, but not limited to, It can be used.

[0281] The antibodies provided herein (e.g., the VL CDRs and VH CDRs of NOV1401) Antibodies such as anti-FXI / FXIa antibodies, including those listed in Table 1, have also been shown to be effective in preventing thromboembolic It may also be used in combination with other drugs to prevent, treat, or ameliorate a disorder. For example, statin therapy is used to treat patients with thrombotic and / or thromboembolic disorders. and in combination with the FXIa antibodies and antigen-binding fragments of the present invention to detect can be done.

[0282] In specific embodiments herein, a method for treating or preventing stroke in patients with atrial fibrillation is provided. The method includes administering an effective amount of an anti-FXI / FXIa antibody described herein, e.g., , NOV1401, or an anti-F comprising the VL CDR and VH CDR of NOV1401 If necessary, use an anti-FXI / FXIa antibody listed in Table 1, such as the XI / FXIa antibody. A method is presented comprising administering to a patient a

[0283] In specific embodiments herein, the present invention provides a method for preventing embolic stroke and total cardiomyopathy in patients with atrial fibrillation. To manage or prevent the risks or conditions associated with atrial fibrillation (AF), such as systemic embolism The method includes administering to the patient an effective amount of an anti-FXI / FXIa antibody described herein, e.g., NOV 1401, or an anti-FXI / F antibody containing the VL and VH CDRs of NOV1401 Anti-FXI / FXIa antibodies, such as XIa antibodies, listed in Table 1, should be administered to patients in need of them. A method is presented comprising administering to a subject.

[0284] In specific embodiments herein, the present invention provides a method for preventing embolic stroke and total cardiomyopathy in patients with atrial fibrillation. In a method for treating, managing, or preventing atrial fibrillation (AF) and associated conditions, such as systemic embolism an effective amount of an anti-FXI / FXIa antibody described herein, e.g., NOV14 01, or anti-FXI / FXI containing the VL and VH CDRs of NOV1401 Provide anti-FXI / FXIa antibodies, such as those listed in Table 1, to patients in need of them. In certain embodiments, the AF patient is treated with High risk.

[0285] In specific embodiments herein, a subject (e.g., a patient suffering from or suffering from deep vein thrombosis) is To treat deep vein thrombosis or related conditions in subjects at risk of developing deep vein thrombosis. The present invention relates to a method for treating, managing, or preventing a patient with a vascular endothelial disorder, the method comprising administering to the patient an effective amount of an anti-FXI / F antibody as described herein. XIa antibody, e.g., NOV1401, or the VL CDR and VH of NOV1401 Anti-FXI / FXIa antibodies containing the CDRs, such as those listed in Table 1 A method is presented that includes administering the antibody to a subject in need thereof.

[0286] In specific embodiments herein, a subject (e.g., a patient suffering from or suffering from venous thromboembolism) is Venous thromboembolism (VTE) or related events in subjects at risk of developing VTE The method of treating, managing, or preventing a condition comprising administering an effective amount of an anti-inflammatory agent as described herein. FXI / FXIa antibodies, such as NOV1401, or the VL CDRs of NOV1401 and anti-FXI / FXIa antibodies comprising the VH CDRs as described in Table 1. / A method is presented that includes administering an antibody to a subject in need thereof. In certain embodiments, subjects treated with the anti-FXI / FXIa antibodies provided herein 1) First-time spontaneous VTE with low bleeding risk, including in cancer patients; 2) Idiopathic VTE or 3) have experienced a VTE associated with a thrombophilia.

[0287] In specific embodiments herein, a subject (e.g., a subject suffering from or suffering from pulmonary embolism) is (c) to treat, manage, or administer pulmonary embolism or related conditions in subjects at risk of developing pulmonary embolism; A method for preventing or preventing inflammatory bowel disease comprising administering to a subject an effective amount of an anti-FXI / FXIa antibody as described herein, For example, NOV1401, or a sequence that includes the VL and VH CDRs of NOV1401 Anti-FXI / FXIa antibodies, such as those listed in Table 1, to a subject in need thereof.

[0288] In specific embodiments herein, a method for treating acute coronary syndrome (ACS) or its associated cardiovascular disease in a subject is provided. A method for treating, managing, or preventing a condition associated therewith, comprising administering to a subject an effective amount of a compound as described herein. The anti-FXI / FXIa antibody described herein, for example, NOV1401, or a variant of NOV1401, Anti-FXI / FXIa antibodies containing the L CDR and VH CDR are listed in Table 1. The method includes administering to a subject in need thereof an anti-FXI / FXIa antibody. is presented.

[0289] In specific embodiments herein, a subject (e.g., a subject suffering from or having an ischemic stroke) is Methods for Treating, Managing, or Preventing Ischemic Stroke in a Subject at Risk for Developing an Ischemic Stroke an effective amount of an anti-FXI / FXIa antibody described herein, e.g., NOV1 401, or anti-FXI / FX containing the VL and VH CDRs of NOV1401 Anti-FXI / FXIa antibodies, such as those listed in Table 1, can be administered to patients in need of such antibodies. A method is presented comprising administering to

[0290] In specific embodiments herein, the present invention relates to a method for treating, managing, or administering acute lower limb ischemia in a subject. A method of preventing, comprising administering to a subject an effective amount of an anti-FXI / FXIa antibody described herein, e.g. For example, NOV1401 or an antibody containing the VL and VH CDRs of NOV1401. Anti-FXI / FXIa antibodies, such as those listed in Table 1, may be used if necessary. A method is presented comprising administering to a subject in need thereof.

[0291] In specific embodiments herein, a method for treating and regulating chronic thromboembolic pulmonary hypertension in a subject is provided. A method for treating or preventing FXI / FXIa-related inflammatory disease comprising administering to a subject an effective amount of an anti-FXI / FXIa antibody as described herein. An antibody, such as NOV1401, or the VL CDR and VH CDR of NOV1401 Anti-FXI / FXIa antibodies listed in Table 1, including R-containing anti-FXI / FXIa antibodies and administering the same to a subject in need thereof.

[0292] In specific embodiments herein, a subject (e.g., a patient suffering from or suffering from a systemic embolism) is Methods for Treating, Managing, or Preventing Systemic Embolism in Subjects at Risk for Developing a Systemic Embolism an effective amount of an anti-FXI / FXIa antibody described herein, e.g., NOV1 401, or anti-FXI / FX containing the VL and VH CDRs of NOV1401 Anti-FXI / FXIa antibodies, such as those listed in Table 1, can be administered to patients in need of such antibodies. A method is presented comprising administering to

[0293] In certain embodiments herein, the catheter is a thrombosed catheter (e.g., Hickman catheter in cancer patients) related condition or tubing causing blood clots Treating, managing, or preventing thromboembolic conditions that may develop with extracorporeal membrane oxygenation (ECMO) The method includes administering an effective amount of an anti-FXI / FXIa antibody described herein, e.g., , NOV1401, or an anti-F comprising the VL CDR and VH CDR of NOV1401 If necessary, use an anti-FXI / FXIa antibody listed in Table 1, such as the XI / FXIa antibody. A method is presented comprising administering to a subject

[0294] In certain embodiments, the anti-FXI / FXIa antibodies described herein, e.g., NOV 1401, or an anti-FXI / F antibody containing the VL and VH CDRs of NOV1401 Requires treatment with an anti-FXI / FXIa antibody, such as an XIa antibody, as described in Table 1 The target is: - Patients with indications for chronic anticoagulation therapy (e.g., AF, left ventricular thrombosis, previous cardioembolic stroke) Target; Subjects at moderate to high risk of major bleeding; Dual antiplatelet therapy (aspirin and P2Y1) to prevent stent thrombosis Elective percutaneous coronary intervention with stent placement, which may require administration of a stent-based anticoagulant (PTCA) or a stent-based anticoagulant (PTCA) Subjects undergoing percutaneous coronary intervention (PCI) or direct PCI may include.

[0295] In certain embodiments, the following conditions: Paroxysmal atrial fibrillation or flutter, persistent atrial fibrillation or flutter, or suspected or confirmed cardiac arrhythmias, such as permanent atrial fibrillation or permanent atrial flutter Thromboembolism in subjects who have been A subpopulation of subjects with stroke prevention in atrial fibrillation (SPAF) Subjects with AF undergoing percutaneous coronary intervention (PCI); Treatment of acute venous thromboembolic events (VTE) in patients at high risk for bleeding, and and prevention of long-term secondary VTE; In secondary prevention after a transient ischemic attack (TIA) or non-disability-inducing stroke In the prevention of cerebral and cardiovascular events, as well as thromboembolic events in heart failure with sinus rhythm cerebral and cardiovascular events in - Left atrium clot formation and thrombosis in subjects undergoing cardiac defibrillation for cardiac arrhythmias Thrombosis; · Thrombosis before, during, and after ablation procedures for cardiac arrhythmias; Venous thrombosis, which can be deep vein thrombosis or superficial vein thrombosis in the legs or upper extremities. thrombosis of the abdominal and thoracic veins, venous sinus thrombosis and jugular vein thrombosis including but not limited to treatment and secondary prevention; Thrombosis on any artificial surfaces within a vein, such as catheters or pacemaker leads; Pulmonary embolism in patients with or without venous thrombosis; ·Chronic Thromboembolic Pulmonary Hypertension (CTEPH); Arterial thrombosis on ruptured atherosclerotic plaques, on prostheses or catheters in arteries Thrombosis in the thrombosis of the ventricles and in apparently normal arteries, which may be associated with acute coronary syndrome. group, ST elevation myocardial infarction, non-ST elevation myocardial infarction, unstable angina, stent thrombosis, arterial Thrombosis of any artificial surface in the system, and in subjects with or without pulmonary hypertension including but not limited to pulmonary artery thrombosis; Thrombosis and thrombosis in patients undergoing percutaneous coronary intervention (PCI) Embolism; Cardioembolic and cryptogenic stroke; Thrombosis in patients with invasive and non-invasive cancer malignancies; Thrombosis across the indwelling catheter; Thrombosis and thromboembolism in critically ill patients; Cardiac thrombosis and thromboembolism, which are cardiothrombosis after myocardial infarction, Conditions such as aneurysms, myocardial fibrosis, cardiac hypertrophy and dysfunction, myocarditis, and artificial surfaces within the heart. including, but not limited to, cardiothrombotic events associated with pulmonary embolism; · Thromboembolism in patients with valvular heart disease, with or without atrial fibrillation; · Thromboembolism involving mechanical or biological prostheses for heart valves; - After cardiac repair surgery for simple or complex cardiac anomalies, natural or artificial cardiac pads injury or trauma in patients with arterial or venous conduits; Knee replacement, hip replacement, and orthopedic, thoracic or abdominal surgery venous thrombosis and thromboembolism after; Following neurosurgery, including intracranial and spinal interventions arterial or venous thrombosis; Factor V Leiden, Mutation of Prothrombin, Antithrombin III, Prothrombin Factor C deficiency and protein S deficiency, factor XIII mutations, familial fibrinogen deficiency Plasminogenemia, congenital plasminogen deficiency, elevated factor XI levels, sickle cell disease, Antiphospholipid syndrome, autoimmune diseases, chronic intestinal diseases, nephrotic syndrome, hemolytic uremia, bone marrow Proliferative disorders, disseminated intravascular coagulation, paroxysmal nocturnal hemoglobinuria, and heparin-induced hematopoietic disorders congenital or acquired thrombophilia, including but not limited to thrombocytopenia; Thrombosis and thromboembolism in chronic kidney disease; and - Thrombosis and pulmonary embolism in patients undergoing hemodialysis and extracorporeal membrane oxygenation Thromboembolism or an anti-FXI / FXIa antibody described herein, e.g., NOV140. 1, or anti-FXI / FXIa containing the VL and VH CDRs of NOV1401 The patient may be treated or administered with an anti-FXI / FXIa antibody, such as those listed in Table 1. Cut.

[0296] In specific embodiments herein, the anti-FXI / FXIa antibodies provided herein (e.g. , an anti-FXI / FXIa antibody comprising the VL CDR and VH CDR of NOV1401, etc. Bleeding in patients treated with or administered A method for managing bleeding associated with, for example, trauma, surgery, menstruation, or postpartum, comprising administering an anticoagulant A method involving reversal of the solid effect is presented. FXI deficiency has been associated with spontaneous bleeding episodes. In particular embodiments, bleeding is associated with trauma, surgery, menstruation, or postpartum. Prolonged bleeding is most typically seen after major trauma or in the oral mucosa, nasal mucosa, May occur after surgery involving organs with areas of high fibrinolysis, such as the genital or urinary mucosa Tooth extractions, tonsillectomies, and uterine or prostate ablations carry a significant risk of bleeding. People with disabilities are also prone to developing nosebleeds and ecchymoses. FXI deficiency is associated with a high tendency to develop urinary or intestinal bleeding, although this is rare. The frequency of spontaneous muscle or joint bleeding and intracranial bleeding is not increased in patients with idiopathic pulmonary edema. Pulse puncture is not usually associated with prolonged bleeding. Other gene mutations associated with FXI deficiency This may contribute to the heterogeneous and unexpected bleeding tendency in patients with severe FXI deficiency. The concomitant use of platelet agents, other anticoagulants, and fibrinolytic agents may increase the risk of bleeding.

[0297] In certain embodiments herein, the anti-FXI / FXIa antibodies provided herein (e.g., For example, an anti-FXI / FXIa antibody containing the VL CDR and VH CDR of NOV1401. 1. A method for managing bleeding in a patient treated with an antibody (such as an antibody listed in Table 1). A method is presented that involves reversal of the primary anticoagulant effect for a period of time sufficient to control bleeding. In a specific embodiment, the step of reversing the anticoagulant effect comprises (i) administering a colloid, crystalline Fluid replacement using plasma, human plasma, or plasma proteins such as albumin; or (ii) transfusion with packed red blood cells or whole blood. In certain embodiments, e.g. In severe emergency cases, a therapeutic agent for reversing the effects of anticoagulants is fresh frozen plasma (FFP). FP), prothrombin complex concentrate (PCC), and activated PCC [(APCC); For example, factor VIII inhibitor bypass activity (FEIBA)] and recombination activity Hemostatic pro-blood components, including, but not limited to, recombinant factor VII (rFVIIa) In one embodiment, administration of rFVIIa at a dose of 30 μg / kg is followed by administration of 6 hourly for 5-7 days, plus 1 g of tranexamic acid every 2-4 hours, plus 15 A regimen involving administration of rFVIIa at a dose of ~30 μg / kg over 24 to 48 hours undergoing major surgery, anti-FXI / FXIa antibodies presented herein (e.g., NOV 1401 or NOV1401 VL CDR and VH CDR) and restoring hemostasis in subjects with ongoing bleeding and inaccessible sites of bleeding, For example, Riddelle et al. We reported our experience in four patients undergoing surgery with severe FXI deficiency. Riddell et al., 2011, Thromb. Haemost.; 106: 521-527), patients received 30 μg / kg rFVIIa and 1 g of tranexamic acid were administered intravenously at the time of induction of anesthesia. , bolus administration of 15-30 μg / kg rFVIIa was used in Rotational Th As indicated by the results of romboelastometry (ROTEM), Patients were treated with the above doses of rFVIIa for 24–48 hours. Tranexamic acid, 1 g every 6 hours, was continued for 5 days. In small series, low doses of 15–30 μg / kg in combination with tranexamic acid rFVIIa was shown to be a reliable treatment for correcting the hemostatic abnormalities in severe FXI deficiency in this study. The results were safe and effective. has severe FXI deficiency with autologous FXI neutralizing antibodies acquired after administration of blood products. In another study involving four patients who underwent five surgeries, the authors (Livnat et al., 2009, T hromb. Haemost.; 102: 487-492) applied the following protocol: 2 hours before surgery. Oral tranexamic acid 1 g in the 10-mg dose, then immediately before the intervention, the patient was given The rats were administered 1 g of iv tranexamic acid. FVIIa was infused at the completion of surgery, followed by oral tranexamic acid 1 g for 6 h. Fibrin glue was applied for at least 7 days after removal of the graft in one patient. This protocol was used in patients with severe FXI deficiency with inhibitors. Normal hemostasis was ensured in patients with pulmonary embolism.

[0298] In one embodiment, fibrin glue is used to improve dental prosthesis in patients with FXI deficiency. It can restore local hemostasis during surgery (Bolton-Maggs (2000) Haemophilia; 6 (S1): 100-9). The anti-FXI / FXIa antibodies presented herein (e.g., NOV1401) In certain embodiments of the method for managing bleeding in a treated patient, The use of tranexamic acid, 1 g every 6 hours for 5 to 7 days, was associated with The regimen is intended for subjects undergoing minor surgery and for bleeding events in the oral and nasal cavity. may be used to establish local hemostasis in subjects where the bleeding site is accessible. do.

[0299] Pharmaceutical Compositions The present invention relates to a FXIa-binding antibody (interacting antibody) formulated together with a pharma- ceutical acceptable carrier. The compositions are additionally provided as pharmaceutical compositions comprising the agonist, agonist or binding fragment thereof, e.g., One or more other therapies suitable for the treatment or prevention of an embolic disorder (e.g., a thrombotic disorder). The pharma- ceutically acceptable carrier may also contain an agent that enhances or stabilizes the composition. Alternatively, it may be used to facilitate preparation of the composition. The carrier may contain physiologically compatible solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic These include agents that delay absorption and agents that delay absorption.

[0300] The pharmaceutical compositions of the present invention can be administered by a variety of methods known in the art. The route and / or mode of administration will vary depending on the desired results. Intravenous (iv), intramuscular (im), intraperitoneal (ip), or subcutaneous administration (sc) or in close proximity to the target site. Acceptable carriers include those for intravenous, intramuscular, subcutaneous, parenteral, spinal, or epidermal administration. It should be suitable for administration (e.g., by injection or infusion). Depending on the route of administration, activation Antibodies that are combinations, i.e., bispecific and multispecific molecules, can bind compounds and block compounds. It can be coated with a material that protects it from the action of activating acids and other natural conditions. Cut.

[0301] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NOV14 01, or an antibody containing the LCDR and HCDR of NOV1401, as described in Table 1. Approximately 75 mg to 1 mL of antibody (antibody) is added to a fluid vial for subcutaneous injection. In certain embodiments, the pharmaceutical composition is formulated in a concentration of about 200 mg per 100 mg of the active ingredient. or pharmaceutical excipients, such as sucrose and polysorbate 20. In the present invention, the pharmaceutical composition comprises L-histidine and / or histidine HCl monohydrate. In certain embodiments, the pharmaceutical composition has a pH of about 4-7 or 5-6.

[0302] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NOV14 01, or an antibody containing the LCDR and HCDR of NOV1401, as described in Table 1. The antibody (which is being tested) is prepared in a fluid vial for subcutaneous injection at a concentration of 150 mg per mL. In one embodiment, the 150 mg / mL fluid formulation is formulated at pH=5.5±0.5. 150mg of anti-FXI / FXIa antibody, L-histidine, histidine HCl monohydrate , sucrose, and polysorbate 20. The composition is sterile and flowable. The proper fluidity can be achieved by using a coating such as lecithin. In the case of a dispersion, the required particle size can be maintained by This can be achieved by using surfactants. In many cases, an isotonic agent, For example, sugars, polyhydric alcohols such as mannitol or sorbitol, and sodium chloride. It is preferable that the composition contains a compound that delays absorption in order to prolong the absorption of the injectable composition. By incorporating agents such as aluminum monostearate or gelatin. can bring about.

[0303] The pharmaceutical compositions of the present invention can be prepared by any method known and routinely practiced in the art. For example, the compound can be prepared according to the method described in Remington: The Science and Practice of Pharmacy. acy, Mack Publishing Co., 20th edition, 2000; and Sustained and Controlled Release Dru See, for example, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978. The pharmaceutical composition of the present invention is preferably manufactured under GMP conditions. Herein, a therapeutically effective dose or therapeutically effective dose of a FXIa-binding antibody is used. Typically, FXIa-binding antibodies can be produced as pharmaceuticals by conventional methods known to those of skill in the art. The dosage regimen is adjusted to provide the optimal desired response (e.g., therapeutic efficacy). For example, a single bolus can be administered, or multiple Several divided doses may be administered over a period of time, as indicated by the requirements of the therapeutic situation. Doses may also be proportionally reduced or increased as indicated. It is preferred that parenteral compositions be formulated in dosage unit form for ease and uniformity of dosage. As used herein, a dosage unit form is a unit that is administered to a subject to be treated. Each unit is a physically discrete unit suitable as a unit dosage for the desired pharmaceutical agent. It contains a predetermined amount of active compound calculated to produce a desired therapeutic effect in association with a carrier. Yes.

[0304] The practical dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be adjusted to any level, particularly without causing toxicity to the patient. An effective amount of the active ingredient is used to achieve the therapeutic response desired for a given patient, composition, and mode of administration. The dosage level selected can be varied according to the method described in the incorporated application. The specific compositions of the invention, their activity, route of administration, timing of administration, and excretion of the specific compounds incorporated therein. the release rate, duration of treatment, other drugs used in combination with the particular composition employed, the compound and / or material, the age, sex, weight, condition and general health of the patient to be treated; The dosage depends on various pharmacokinetic factors, including factors such as the dosage and medical history.

[0305] A physician may administer the antibodies of the invention, incorporated in a pharmaceutical composition, to achieve the desired therapeutic effect. Start at levels below those required to achieve optimal efficacy and gradually increase the dosage until the desired effect is achieved. Generally, the thrombotic and / or thromboembolic The dosage of the compositions of the invention that is effective to treat a disorder will depend on the means of administration, the target site, the physiological state of the patient, and the dosage regimen. the clinical condition, other medications being administered, and whether the treatment is prophylactic or therapeutic Treatment dosages vary depending on many different factors. For systemic administration of antibodies, the dose should be adjusted to 100 mg / kg of host body weight. For antibody administration (e.g., subcutaneous administration), the dose is in the range of about 0.01 to 15 mg. can be in the range of 0.1 mg to 5 mg or 1 mg to 600 mg. The anti-FXI / FXIa antibody described in is administered at 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4mg / kg, 0.5mg / kg, 0.6mg / kg, 0.7mg / k g, 0.8mg / kg, 0.9mg / kg, 1.0mg / kg, 1.1mg / kg, 1. 2mg / kg, 1.3mg / kg, 1.4mg / kg, 1.5mg / kg, 1.6mg / kg, 1.7mg / kg, 1.8mg / kg, 1.9mg / kg, 2.0mg / kg, 2 .1mg / kg, 2.2mg / kg, 2.3mg / kg, 2.4mg / kg, 2.5mg / kg, 2.6mg / kg, 2.7mg / kg, 2.8mg / kg, 2.9mg / kg, 3.0mg / kg, 3.1mg / kg, 3.2mg / kg, 3.3mg / kg, 3.4m g / kg, 3.5mg / kg, 3.6mg / kg, 3.7mg / kg, 3.8mg / kg , 3.9mg / kg, 4.0mg / kg, 4.1mg / kg, 4.2mg / kg, 4.3 mg / kg, 4.4mg / kg, 4.5mg / kg, 4.6mg / kg, 4.7mg / k The drug was administered at doses of 4.8 mg / kg, 4.9 mg / kg, or 5.0 mg / kg. Exemplary treatment regimes include once every two weeks, or once a month, or once every 3 to 6 days. It involves systemic administration once per month. An exemplary treatment regimen involves administration once per week, once every two weeks , once every 3 weeks, once every month, or once every 3-6 months, or as needed ( This involves systemic administration of prothrombin time (PRN).

[0306] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NO V1401, or an antibody comprising the VL CDR and VH CDR of NOV1401. Antibodies listed in Table 1) at 3 mg / kg, for example, by iv or sc The dose is administered.

[0307] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NO V1401, or an antibody comprising the VL CDR and VH CDR of NOV1401. Antibodies listed in Table 1) at 10 mg / kg, for example, by iv or sc Administer at a dose of g.

[0308] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NO V1401, or an antibody comprising the VL CDR and VH CDR of NOV1401. Antibodies listed in Table 1) at 30 mg / kg, for example, by iv or sc Administer at a dose of g.

[0309] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NO V1401, or an antibody comprising the VL CDR and VH CDR of NOV1401. Antibodies listed in Table 1) at 50 mg / kg, for example, by iv or sc Administer at a dose of g.

[0310] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NO V1401, or an antibody comprising the VL CDR and VH CDR of NOV1401. Antibodies listed in Table 1) at 100 mg / mL, for example, by iv or sc Administer in kg doses.

[0311] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NO V1401, or an antibody comprising the VL CDR and VH CDR of NOV1401. Antibodies listed in Table 1) are administered intravenously, for example, by the iv or sc route, for 5 min. Administer in doses ranging from 1000g to 600mg.

[0312] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NO V1401, or an antibody comprising the VL CDR and VH CDR of NOV1401. 1) for about 5 minutes by iv or sc route. mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg, 90 mg, 100mg, 120mg, 150mg, 180mg, 200mg, 210mg, 2 40mg, 250mg, 270mg, 300mg, 330mg, 350mg, 360mg , 390mg, 400mg, 420mg, 450mg, 480mg, 500mg, 510 It is administered in doses of 500 mg, 540 mg, 550 mg, 570 mg, or 600 mg.

[0313] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NO V1401, or an antibody comprising the VL CDR and VH CDR of NOV1401. 1) at a dose of 5 mg, for example, by the sc route. .

[0314] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NO V1401, or an antibody comprising the VL CDR and VH CDR of NOV1401. 1) administered at a dose of 15 mg, for example, by the sc route. do.

[0315] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NO V1401, or an antibody comprising the VL CDR and VH CDR of NOV1401. 1) administered at a dose of 50 mg, for example, by the sc route. do.

[0316] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NO V1401, or an antibody comprising the VL CDR and VH CDR of NOV1401. 1) administered at a dose of 150 mg, for example, by the sc route. do.

[0317] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NO V1401, or an antibody comprising the VL CDR and VH CDR of NOV1401. 1) administered at a dose of 300 mg, for example, by the sc route. do.

[0318] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NO V1401, or an antibody comprising the VL CDR and VH CDR of NOV1401. 1) administered at a dose of 600 mg, for example, by the sc route. do.

[0319] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NO V1401, or an antibody comprising the VL CDR and VH CDR of NOV1401. Antibodies listed in Table 1) can be administered, for example, by the iv or sc route, to The mean duration of TT was extended by more than 2 times for 30 days, 35 days, 36 days, and 37 days. 38 days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, or administered in a dose sufficient to achieve this for a period not to exceed 50 days.

[0320] In certain embodiments, the anti-FXI / FXIa antibodies described herein (e.g., NO V1401, or an antibody comprising the VL CDR and VH CDR of NOV1401. Antibodies listed in Table 1) can be administered, for example, by the iv or sc route, to Achieved a 2-fold increase in the mean duration of TT for a period not exceeding 42 days Administer in a dose sufficient to

[0321] The antibody is typically administered multiple times. The interval between single doses may be weekly, biweekly, monthly, or annually. The interval may also be years. It may also be irregular, as indicated by measuring blood levels of combined antibodies. In addition, your doctor may determine an alternative dosing interval, such as monthly or as needed to be effective. In some methods of systemic administration, the dose is administered at intervals that result in a plasma concentration of antibody of 1 to 1 Adjust to achieve 1,000 μg / mL or 1 to 1,200 μg / mL in some cases. The antibody is adjusted to achieve a concentration of 25-500 μg / mL. Alternatively, the antibody can be administered in a sustained release formulation. It can also be administered as an excipient, in which case less frequent administration is required. The frequency and frequency of antibody responses vary depending on the half-life of the antibody and its target in the patient. and humanized antibodies have a longer half-life in humans than chimeric and non-human antibodies. The dosage and frequency of administration will vary depending on whether the treatment is prophylactic or therapeutic. In prophylactic applications, relatively low dosages are administered at relatively infrequent intervals over a long period of time. Some patients continue to receive treatment for the rest of their lives. Thus, relatively high doses are required at relatively short intervals until disease progression is attenuated or terminated. and preferably until the patient shows partial or complete improvement of the symptoms of the disease. Thereafter, the patient can be administered a prophylactic regimen. EXAMPLES

[0322] The following examples are presented to further illustrate the present invention, but are not intended to limit its scope. Other variations of the invention will be readily apparent to those skilled in the art. and is encompassed by the appended claims.

[0323] Example 1 Panning with human Fab phage library To select antibodies that recognize human factor XI, multiple panning strategies were utilized. Different mutants of the catalytic domain proteins of human factor XI and rabbit factor XIa The therapeutic antibodies were generated using a commercially available phase display library, Mo Using the rphosys HuCAL PLATINUM® library, The phage mide library was generated by selecting clones that bound to factor XI. Lee has developed the HuCAL® concept (Knap et al., 2003) to display Fabs on the phage surface. pik et al., 2000, J Mol Biol 296: 57-86), CysDisplay™ The present invention relates to a method for the detection of anti-factor XI antibodies. To isolate the body phase, a panning strategy was employed.

[0324] Cross-reactivity analysis The purified Fab was subjected to ELISA to detect human factor XI (factor XI, factor XIa, and and the catalytic domain of factor XIa) and the biotinylated catalytic domain of rabbit factor XIa. The binding of the lysed protein to different mutants was investigated. p™ (Nunc) 384-well plates were incubated at 4° C. with 10 ug / ml Ne in PBS. The antigen was coated with NeutrAvidin overnight. Top, capture was performed via biotin at room temperature (RT) for 30 min. Binding was confirmed using the Attophos fluorescent substrate (Roche: product number 11681982001). was used to conjugate to alkaline phosphatase (diluted 1:5000). and detection with F(ab)2-specific goat anti-human IgG. Fluorescence emission at 535 nm was , recorded with excitation at 430 nm.

[0325] IgG conversion and expression To express full-length IgG in CAP-T cells, the variable domain (VH) of the heavy chain was truncated. The Fab and light chain variable domain (VL) fragments were synthesized from the expression vector of human IgG1 The two sites were subcloned into the appropriate pMorph®_hIg vector. The amino acid substitutions D265A and P329A were introduced into the Fc portion to allow for arbitrary surface association. These antibodies reduced the possibility of ADCC or CDC caused by FXI. Ranine substitutions have been shown to reduce ADCC and CDC (e.g., Idosugie et al., J. Immunol. 164:4178-4184, 2000; Shields et al., J. Biol. Chem. 276:659 (See, e.g., J. Immunol. 2001, 1-6604). Seven days after transfection, cell culture supernatants were harvested. After sterile filtration, the solution was transferred to the process using a liquid handling station. The samples were subjected to tein A affinity chromatography. The product was eluted in 40 nM NaOH, the pH was neutralized with 1 M Tris buffer, and sterile filtered ( Protein concentration was determined by UV spectrophotometry at 280 nm. The purity of the IgG was analyzed under denaturing and reducing conditions in SDS-PAGE.

[0326] Example 2 Combined Data Surface plasmon resonance (SPR) analysis of FXI catalytic domain SPR measurements were performed using the surface plasmon resonance-based optical biosensor BIACORE (Trademark) T200 (BIACORE (Trademark), GE Healthcare, Uppsa The experiment was carried out on a 100-well plate (100-well plate) using a Series S sensor chip (CM5), immobilization kit, and and regeneration buffer were purchased from GE Healthcare (Uppsala). Depending on the ligand format of the Fab, two different assay setups were performed: First, N-hydroxysuccinimide (NHS) and N-(3-dimethylamine) were used. The surface was activated with N-ethyl-N-propylcarbodiimide hydrochloride (EDC). The standard amine coupling method (GE Healthcare, Uppsala, India) was used. a) NOV1401-Fab was bound to activated dextran matrices on a CM5 chip. The NOV1401-IgG was covalently attached to the antibody. Goat anti-human IgG-Fc antibody (JIR) was immobilized on the chip at 14,000 RU. The remaining active surface groups were deactivated with ethanolamine (EA). Prepare uncultured reference cells and inoculate the system with 1x HBS-EP+ buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% P20, pH 7 The mixture was equilibrated with 1.4 ml of 1000 mM NaCl (Teknova H8022).

[0327] All binding experiments were performed using HBS-EP+ buffer at 25°C with a flow rate of 50 μL / min. For the capture assay, NOV1401-IgG was diluted to a level of 80 RU. For kinetic studies, the antibody was captured in the range of 0–200 nM in HBS-EP+ buffer. A dilution series of FXI catalytic domain was used at a concentration of 0.01 mg / mL. The association time was 120 seconds. The dissociation time was 180 seconds. The surface was washed with a single injection of 10 mM glycine, pH 1.5 ( The data was regenerated by 60 seconds of contact time and 120 seconds of stabilization time. Processing and k on、 k off , and K D The decision was made by the T200 BiaEvaluat This was achieved using the ion software version 1.0. A correction factor (subtraction of the injection of 100 μg / cm2) was applied to correct for bulk effects and other systematic artifacts. The 1:1 binding model (R max By applying The sargram was applied.

[0328] Equilibrium titration in solution (SET) for FXI and FXIa Twenty-two serial 1.6 n dilutions of antigen were diluted in sample buffer (0.5% Prepared in PBS (pH 7.4, containing BSA and 0.02% Tween 20) Then, a fixed concentration of NOV1401-Fab (for huFXI, 200 pM; for huFXI, 200 pM) was used. For FXIa, the concentration was 500 pM) or NOV1401 antibody (huFXI and For huFXIa, 10 pM was added to each antigen concentration. Antigen dilution series The starting concentration of was 100 nM for huFXIa and 20 The concentration was 60 nM (Fab assay) or 1 nM (IgG assay) per well. Aliquots of the diluted mix were dispensed in duplicate into 384-well polypropylene MTPs. Sample buffer was used as a negative control, and a sample containing no antigen was used as a positive control (Bmax). The plates were sealed and insulated overnight at room temperature on a shaker. A standard 384-well MSD array MTP was incubated with 100 µg / mL of diluted 100 µg / mL PBS. 1 well of 0.1 μg / ml huFXIa (for huFXIa and huFXI) Coat with 30 μl per well, seal and incubate overnight at 4 °C. I did.

[0329] Incubation and TBST (TBS containing 0.05% Tween 20) After washing three times with 100 mM NaCl, the antigen-coated MSD plate was placed in one well of the plate. Block with 50 μl of blocking buffer (PBS containing 5% BSA) per well. The plate was then incubated at room temperature for 1 hour on a shaker. The washing step was then repeated. 30 μl of Fab-antigen preparation / IgG-antigen preparation per well was added to polypropionate Transfer the plate from the Renn MTP to the antigen-coated MSD plate and incubate at room temperature on a shaker. After a further washing step, the plate was diluted in sample buffer and incubated for 20 min. Diluted with 0.5 μg / ml of ECL-labeled goat anti-human IgG / Fab detection antibody (MSD 30 μl of the mixture was added to each well and incubated at room temperature for 30 minutes with shaking. The plate was washed again three times and then 35 μl of read buffer (M SD) was added to each well. Electrochemiluminescence (ECL) signal was generated and MSD Detection was performed using a Sector Imager 6000.

[0330] The mean ECL signal was calculated from duplicate measurements within each assay. The data points were adjusted for baseline by subtracting the lowest value from the baseline and then plotted against the corresponding antigen concentration. and plotted. D The value is to split the plot into 1:1 (for Fab) or 1: 2 (for IgG) using a fitting model (following Piehler et al. 1997). This was decided as follows.

[0331] result The results are summarized in Tables 3 and 4. The mat also contains the FXI catalytic domain as determined by BIACORE™. For the α-aminobutyric acid, the K D The values ​​obtained were: Fab, activated FXI and zymogen F The affinity for both XIs is in the pM range, and the affinity for the catalytic domain is Based on their high affinity, These interactions were measured by SET assay. Zymogen FXI (62 pM) vs. activated FXI (305 pM) The interaction may be influenced by avidity effects. Therefore, we investigated the mechanism of action of NOV1401-IgG in the dimeric zymogen FXI and the activated form The affinity of FXI for either D The value is recorded as

[0332] To confirm that NOV2401 also binds to cynomolgus monkey FXI, we performed SET Experiments were performed on cynomolgus monkey activated FXI and cynomolgus monkey zymogen FXI The results were 12.5±6.6pM (N=2) and 5.0±0.7pM, respectively. (N=2) apparent K D Therefore, the results showed that NOV1401 inhibited the cynomolgus FXI The affinity for the protein (active form and zymogen) was determined by binding to human FXI. The affinity for the binding is equivalent to that for the binding (Table 3).

[0333] [Table 2]

[0334] [Table 3]

[0335] Example 3 Biochemical assay: Inhibition of FXIa in activity assays using fluorescent peptides as substrates harm Human FXIa (Kordia Life Science NL: Model No. HFXIa 1 The activity of 111a) was determined by the sequence D-Leu-Pro-Arg*Rh110-D-Pro (product No.: BS-2494; Biosyntan GmbH, Berlin, Germany The cleavage of a fluorescently labeled peptide with In the substrate sequences shown, * is the scissile bond, D-Leu: D-leucine, Pro: Proline, Arg: arginine, Rh110: rhodamine 110, D-Pro: D-proline FXIa-mediated cleavage of the scissile bond of a peptide substrate is , rhodamine when using excitation and emission wavelengths of 485 nm and 535 nm. This results in an increase in fluorescence intensity of 110. The fluorescence intensity was measured at room temperature (RT) using a microtiter plate. Rate reader Safire2 (TECAN, Maennedorf, Switzerland) and) are used in series. The assay buffer is 50 mM HE2 at pH 7.4. PES, 125 mM NaCl, 5 mM CaCl2, and 0.05% (w / v) C The final activity assay contained human FXIa and the substrate BS- 2494 have assay concentrations of 0.1 nM and 0.5 μM, respectively. Under these conditions, the increase in fluorescence intensity over time was linear for at least 60 minutes. do.

[0336] To examine the inhibitory activity of the antibody, BS buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, Prepare a dilution series of the antibody in 1.8 mM KH2PO4. Add 2 μL of antibody solution to 1 Preincubated with 100 μL of FXIa solution (in assay buffer) at room temperature for 60 min. After the preincubation step, 10 μL of the substrate BS-2 494 (diluted in assay buffer) was added and the enzymatic reaction was allowed to proceed for 60 min. The fluorescence intensity is then measured. The signal from the control reaction (uninhibited reaction) is 0%. The signal from reactions containing no enzyme is equivalent to 100% inhibition. ) and the following formula for transferring the values: y=100%-[FI(x)-FI(min)] / [FI(max)-FI(min)] [where y is the % inhibition when the antibody concentration is x, and FI(x) is the inhibition percentage when the antibody concentration is x. FI(min) is the fluorescence intensity measured when the antibody is not present in the control reaction. FI(max) is the fluorescence intensity measured in the uninhibited control reaction; FI(max) is the fluorescence intensity measured in the uninhibited control reaction. The fluorescence intensity values ​​were calculated as the percentage inhibition by using the The data was converted to a graph using the Origin 7.5SR6 program (OriginLa b Analyzed using the ELISA Kit (Citroenza, Inc., USA). IC50 based on average data The value is the logistic function: y = A2 + (A1 - A2) / (1 + (x / IC50) p ) [wherein y is the inhibition % when the antibody concentration is x, A1 is the minimum inhibition value, A2 is the maximum inhibition value. The exponent p is the Hill coefficient.

[0337] FIG. 6A shows the inhibitory effect of antibody NOV1401 on the enzymatic activity of full-length human FXIa. Representative composite response curves for human full-length FXIa are shown. The enzyme activity was inhibited in a concentration-dependent manner (Figure 6A). A linear fit gave an IC of approximately 160 pM. 50 Brings value.

[0338] Example 4 Anticoagulant activity of anti-FXIa Ab Activated partial thromboplastin time (aPTT) assay and thrombin generation assay By using TGA, the antibodies NOV1401 and NOV1090 The antithrombotic activity was examined.

[0339] aPTT Assay: Lyophilized normal human plasma "Coagulation Control N" (reference number: 5020050) was purchased from Techno The clotting control N was purchased from Clone GmbH (Vienna, Austria). The citrated plasma from selected healthy donors was pooled. Clotting time reflects the normal concentrations of clotting factors involved in blood clotting. Freeze-dried plasma is stored at 4°C. Before its use, the vial was carefully rotated and then incubated at room temperature for 10 min. The plasma was resuspended in 1 mL of distilled water by retention.

[0340] The intrinsic pathway induction reagent "aPTT-s" (Reference No.: TE0350) is The buffer (sodium chloride) was purchased from med (Lemgo, Germany). , polyethylene glycol 20000; sucrose, sodium azide) in phospholipids The solution was stored at 4°C.

[0341] Calcium chloride (Reference number: C1016-500G; Sigma-Aldrich C hemie GmbH, Steinheim, Germany) in double-distilled water for 25 Prepared at a stock concentration of 1 mM.

[0342] UltraPure Tris / HCl buffer at pH 7.5 (Reference number: 15567-02 7;Life Technologies Corporation, NY, USA) and and phosphate-buffered saline (PBS; ref. no. P4417-100TAB; Sigma -Aldrich Chemie GmbH, Steinheim, Germany) , was used as a composite diluent.

[0343] 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate drate (CHAPS; Reference Number: C3023-25G) and anhydrous dimethylsulfoxide DMSO (Ref: 276855-100ML) was purchased from Sigma-Aldrich It was purchased from Chemie GmbH (Steinheim, Germany).

[0344] The clotting time was measured using a semi-automatic mechanical clot detection system, Amelung ba ll coagulometer model KC4A(SYCOmed, Lemgo The system was equipped with a stainless steel ball (Ref. AI5000; SYCOmed) in a specially made cuvette (Ref. A Utilize I4000;SYCOmed).

[0345] The sample is added to the cuvette. After a suitable incubation period, the cuvette is Then, place it in the measurement well of the Amelung ball coagulometer. The well is slowly rotated, forcing the cuvette to rotate about its long axis. Because it is placed at a slight angle, gravity and inertia forces always push the ball to the lowest position in the cuvette. The magnetic sensor is located opposite the ball. After adding the inducer, A timer is started. As clotting occurs, fibrin strands are formed in the reaction mixture. The fibrin strands pull the ball away from its inertial position, which causes it to move into the magnetic sensor. , triggers an impulse that electrically stops the timer. The feeding scheme was as follows (Table 4a):

[0346] [Table 4]

[0347] The samples were incubated in duplicate in an Amelung ball coagulometer at 37°C. Measured in degrees.

[0348] FIG. 6B shows the results of a concentration-dependent increase in aPTT clotting time for the antibody NOV1401. Representative composite response curves are shown. Results show that NOV1401 inhibits the aPTT clotting time in human plasma. These results suggest that the aPTT clotting time was increased at a concentration of approximately 14 nM. IC 50 The value is about 13 nM. It was calculated that there was.

[0349] Thrombin Generation Assay (TGA): TGA lyophilized normal human plasma (clotting control N) was purchased from Technoclone GmbH ( Reference number: 5020040, Lot number: 1P37B00) and indicated by the manufacturer. Reconstitute in distilled water in the suggested volume.

[0350] Technoclone GmbH (Reference number: 5006230, Lot number: 8F4 The fluorescent substrate Z-Gly-Gly-Arg-AMC (manufactured by 1B00) was used to detect the substrate The solution was prepared. Aliquots of the lyophilized substrate were kept at 4°C. 20 min prior to use, freshly dissolve the substrate in the volume of distilled water indicated on the vial. The substrate solution contained 1 mM of fluorescent peptide and 15 mM of CaCl2. Contains.

[0351] Two different reagents, "T "GA RD" (Reference number: 500622) and "TGA RC Low" (Reference number: (5006213) is a subsidiary of Technoclone GmbH, Vienna, Austria. The induction reagent, PPP (platelet poor plasma) - Reagent Low " is a Thrombinoscope (TS31.00, lot number: PPL1409 / PPP-Reagent was purchased from Eppendorf (Frankfurt, Germany) and reconstituted in distilled water as indicated on the vial. "t Low" contains a mixture of phospholipids and tissue factor at very low concentrations. Immediately prior to use, resuspend the solution in 80 mM Tris / HCl, pH 7.4, 0.05% (w / v) CHAP The solution was diluted 8-fold in S.

[0352] Samples were plated in a 96-well black clear bottom plate purchased from Costar (product number: 3603). For automated transfer, samples were transferred to a V-bottom 96-well plate and measured in aliquots. The wells were placed in a well plate (Costar, 3894) and then analyzed using a CyBio automated system (Anal The transfer was performed using a ytik Jena US (Woburn, MA, USA).

[0353] reconstituted human plasma, the induction reagent "PPP-Reagent Low" and The substrate was preheated in a water bath at 37° C. for 10 minutes. Antibody was diluted 1:3 in PBS. A dilution series was prepared in a 96-well plate at 5 μM (5x the final highest concentration of 1 μM). A total of eight dilutions were prepared starting with NOV1401 concentration. The drug was mixed with 1108 μl of substrate solution to create a 10+50 induction reagent substrate mix. For subsequent transfer using an automated system, 80 μl was added per well in a V-shaped The plates were kept at 37°C. The reagents were as shown in Table 4b. The addition was performed according to the scheme shown in the figure.

[0354] [Table 5]

[0355] Automation was used to transfer the inducer / substrate mixture. After adding the mixture, the Syner gy Neo instrument(BioTek Instrument Inc. , Winooski, VT, USA) at 360 nm and 460 nm, respectively. The excitation and emission of the sample were recorded immediately. The samples were incubated in a plate reader at 37°C. , in duplicate with 55 second intervals, over a period of 90 minutes.

[0356] To generate the peaks, the TGA evaluation software provided by Technoclone was used. The thrombin concentration data was processed using the software file. To generate a graph, use GraphPad software to plot thrombin concentration versus antibody concentration. The concentration data were fitted using the GraphPad Prism5 software. GraphPad Software Inc., La Jolla, CA, USA SA) were fitted to a nonlinear regression model. 50 The value is a 4-parameter built-in type. Dose-response curve equation (variable slope): y=Bottom+(Top-Bottom) / (1 +10 (Log IC50-x)×HillSlope ) [wherein y is the inhibitor concentration The maximum thrombin concentration formed when the concentration is x, and Top and Bottom are , the inhibitor-free thrombin concentration and the maximum inhibitor concentration, respectively. The thrombin concentration was determined using the following formula:

[0357] FIG. 6C shows the concentration-dependent inhibition of thrombin generation in TGA by the antibody NO. A representative composite response curve for V1401 is shown. IC of 24 nM 50 Value and 159 Residual thrombin concentrations in nM (dotted line) were calculated for this composite response curve.

[0358] Example 5 Protein expression, complex formation, and binding of NOV1401(Fab)-FXI(catalytic domain) Crystallization and structure determination Antibody NOV1 obtained by papain cleavage in a complex with the factor XI catalytic domain The structure of the Fab portion of 401 was obtained by cocrystallization at 2.04 Å resolution.

[0359] Protein Expression: The expression construct for the FXI catalytic domain contained an unpaired cysteine ​​mutated to a cysteine. Amino acid residues 388 to 625 (Swissprot P0395 1), which is composed of the amino acid MGSS (SEQ ID NO: 49), an octahistidine tag (sequence No. 50), a PreScission™ cleavage site followed by an enterokinase cleavage site The construct was assembled by gene synthesis and plasmid pE E. coli was cloned into the T24a expression vector and grown in LB medium. The inclusion bodies were expressed in 50 mM Tris / HCl pH 8.0, 6.0 M guanidinium chloride, 50 mM DTT for 2 hours The recombinant protein was completely denatured by solubilizing it over a period of 10 min. Buffer (0.5 M Tris pH 8.0, 0.9 M arginine HCl, 5 mM GSH , 0.5 mM GSSG, 1 mM EDTA into the IB solution, final protein concentration 50 The mixture was immediately added to 100 μg / ml and incubated at 4°C for 5 days. Bonding and disulfide bridge formation were performed in buffer A (50 mM Tris This was achieved by dialysis with 0.0% sodium hypochlorite (pH 8.0).

[0360] The refolded protein was equilibrated and washed with buffer A on a Q-Sep Anion exchange containing harose® FF (GE Healthcare) The unbound recombinant protein was loaded onto the chromatography column. Enterokinase (Enterokinase: Recombinant Protein) was collected from the flow-through and wash fractions. (protein ratio 1:100, incubation time 2.5 h) The p53A was purified by dialysis with 50 mM Tris, pH 7.4, before removing the N-terminal tag sequence. The H was adjusted to 7.4. The cleavage reaction was carried out by diluting the sample in buffer B (50 mM Tris(III) at pH 7.4). Benzamidine Separation Contains harose 4 FF (high sub) (GE Healthcare) The eluate was terminated by loading onto a benzamidine affinity column containing 100 mM trisodium fumarate (PBS) and then eluted with Buffer C ( Elution was performed with buffer B containing 50 mM benzamidine. Active FXI catalytic domain was equilibrated with 20 mM Na acetate, 75 mM NaCl, pH 5.3, XK 26 / 600 Superdex 75 size exclusion column (GE Healthcare) The final protein concentration was 1.07 mg / ml.

[0361] The Fab portion of NOV1401 was obtained by papain cleavage of IgG. The final Fab concentration was The digest was added to the antibody at a ratio of 1:100 (w / w). Papain (Roche Diagnostics: 108 014; 10 mg / ml) and in the presence of 1 mM cysteine ​​(added to the original IgG solution). Digestion was carried out overnight at 37° C. The digestion was performed in the presence of 50 μM of specific papain inhibitor E64 (N-[N-(L-3-trans-carboxylane-2-carbonyl)-L- The antibody was stopped by adding glycerol ([glyceryl]-agmatine) and digested with glycerol to remove the Fc portion. The product was passed through a small Protein A column (5 mL). Fab was in the flow-through. The solution is then harvested at 100° C., dialyzed against PBS, concentrated to its final concentration by ultrafiltration, and sterile filtered. (0.22 μm).

[0362] Complexation, crystallization, and structure resolution: FXI catalytic domain and Fab were mixed in an equimolar ratio to a final concentration of approximately 9 mg / ml. Concentrated.

[0363] The crystals used for data collection were placed in 0.3 μL of reservoir solution (0.2 M ammonium chloride). monium, 20% PEG 3350), 0.2 μL of Fab-FXI complex, and 0.1 μL of crystal seeds derived from crystals obtained in the first round of crystal screening The results were obtained at 277K using the sitting drop vapor diffusion method.

[0364] For data collection, crystals were flash frozen directly in liquid nitrogen. K, using the Pilatus pixel detector (Dectris), and The data were collected at the Swiss Light Source beamline X10SA at wavelengths of 100 nm and 100 nm. Data processing and scaling were performed with XDS and XSCALE (Kabsch , W. (2010) Acta Cryst. D66, 125-132). The crystals consist of one complex per asymmetric unit. The dimensions of the unit cell are a=191.27, b=53.22, and c=65.164. and alpha = 90.0, beta = 94.56, gamma = 90.0 (C2 space group). , diffracted to 2.04 Å resolution.

[0365] The structure of the complex was determined using P...

Claims

1. 1. A method for producing an antibody or antigen-binding fragment thereof that binds human factor XI (FXI) and / or factor XIa (FXIa), comprising: (a) growing a host cell comprising an expression vector encoding a heavy chain variable domain (VH) and a light chain variable domain (VL) under conditions where said host cell expresses one or more polypeptides comprising said VH and VL, thereby producing said antibody or antigen-binding fragment thereof; Where: i. the VH comprises a CDR1 amino acid sequence of SEQ ID NO:23; a CDR2 amino acid sequence of SEQ ID NO:24; and a CDR3 amino acid sequence of SEQ ID NO:25; and the VL comprises a CDR1 amino acid sequence of SEQ ID NO:33; a CDR2 amino acid sequence of SEQ ID NO:34; and a CDR3 amino acid sequence of SEQ ID NO:35; ii. the VH comprises a CDR1 amino acid sequence of SEQ ID NO:26; a CDR2 amino acid sequence of SEQ ID NO:27; and a CDR3 amino acid sequence of SEQ ID NO:28; and the VL comprises a CDR1 amino acid sequence of SEQ ID NO:36; a CDR2 amino acid sequence of SEQ ID NO:37; and a CDR3 amino acid sequence of SEQ ID NO:38; iii. the VH comprises a CDR1 amino acid sequence of SEQ ID NO: 43; a CDR2 amino acid sequence of SEQ ID NO: 44; and a CDR3 amino acid sequence of SEQ ID NO: 45; and the VL comprises a CDR1 amino acid sequence of SEQ ID NO: 47; a CDR2 amino acid sequence of SEQ ID NO: 37; and a CDR3 amino acid sequence of SEQ ID NO: 15; or iv. the VH comprises a CDR1 amino acid sequence of SEQ ID NO: 46; a CDR2 amino acid sequence of SEQ ID NO: 4; and a CDR3 amino acid sequence of SEQ ID NO: 5; and the VL comprises a CDR1 amino acid sequence of SEQ ID NO: 33; a CDR2 amino acid sequence of SEQ ID NO: 14; and a CDR3 amino acid sequence of SEQ ID NO: 15; (b) purifying the antibody or antigen-binding fragment thereof; The method includes:

2. the antibody or antigen-binding fragment thereof (i) an antibody or fragment comprising a variable region heavy chain sequence of SEQ ID NO: 9 and a variable region light chain sequence of SEQ ID NO: 19, or (ii) an antibody or fragment comprising a variable region heavy chain sequence of SEQ ID NO: 29 and a variable region light chain sequence of SEQ ID NO: 39, or The antibody comprises: (iii) an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 and a light chain comprising the amino acid sequence of SEQ ID NO: 41; or (iv) an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 11 and a light chain comprising the amino acid sequence of SEQ ID NO:

21. The method of claim 1.

3. The method of claim 1 or 2, wherein the antibody comprises an Fc domain comprising a D265A substitution and a P329A substitution.

4. The method of any one of claims 1 to 3, wherein the antibody is a human or humanized monoclonal antibody.

5. The method of any one of claims 1 to 4, wherein the antibody is of the human IgG1 isotype.

6. The method according to any one of claims 1 to 5, wherein the host cell is a eukaryotic cell.

7. The method according to any one of claims 1 to 6, wherein the host cell is a mammalian cell.

8. The method of any one of claims 1 to 7, wherein the host cell is selected from the group consisting of a CHO cell, a HeLa cell, a myeloma cell, and a transformed B cell.

9. The method of any one of claims 1 to 8, wherein the host cell is a CHO cell.

Citation Information

Patent Citations

  • Anti-factor XI monoclonal antibody and method of use thereof

    JP2011504371A

  • Antibodies capable of binding to coagulation factor XI and / or its activated form, factor XIA, and their applications

    JP2015517305A